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ABSTRACT 
 
 
Huntington’s disease (HD) is a neurodegenerative disorder caused by a 
polyglutamine expansion in the huntingtin protein. There are currently no effective 
therapeutics available to treat this disorder despite intense research in the field. Recently, 
however, the flavoenzyme kynurenine 3-monooxygenase (KMO) emerged as a promising 
candidate therapeutic target for HD. KMO is an FAD-dependent outer mitochondrial 
membrane protein which catalyses the conversion of L-kynurenine (L-KYN) to 3-
hydroxykynurenine (3-HK). It has been shown that inhibition of KMO activity is 
protective in yeast, fruit fly, and mouse models of HD [1–5]. Additionally, it has been 
also implicated in the pathophysiology of several other neurological conditions such as 
Alzheimer’s and Parkinson’s Disease, AIDS-dementia complex, amyotrophic lateral 
sclerosis, depression and schizophrenia [6, 7]. 
Despite major interest in pharmacological targeting of KMO, only a few potent 
inhibitors are currently available, and none are known to appreciably penetrate the blood-
brain barrier in adult animals [3, 8]. Furthermore, the molecular basis of KMO inhibition 
by available lead compounds has remained unknown and for that reason KMO crystal 
structures in complex with tight binding inhibitors would be of undeniable interest for the 
future design of new small molecule inhibitors that can penetrate the blood-brain barrier 
and could ultimately have major therapeutic value.  
The aim of this thesis was to produce high levels of KMO protein for structural, 
functional, and mechanistic studies, with the final goal of developing novel inhibitors that 
possess the selectivity and affinity to open up new opportunities for therapeutic 
intervention and inform the development of brain-penetrant KMO inhibitors.  
Several constructs, including both full length and truncated forms of human KMO 
(HsKMO), were efficiently overexpressed and purified and kinetic analysis of pure 
recombinant KMO showed a Km value for L-kynurenine of 22.62± 4 M which is very 
similar to that observed for the rat liver mitochondria preparations (16 M) [9] and 
human liver enzyme (13.0 ± 3.3 M) [10]. The tight-binding substrate-like inhibitor UPF 
648 was found to bind recombinant KMO tightly (Ki 56.7 nM). The poor stability and low 
expression yield of human KMO however prevented crystallisation. We thus turned our 
attention to Saccharomyces cerevisiae KMO (ScKMO), which is highly related to human 
KMO (38 % identity and 51 % similarity). The biochemical characterisation of ScKMO 
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was carried out by using a combination of UV/Visible absorbance spectroscopy, 
fluorescence spectroscopy, HPLC-based assays and stopped-flow analyses and revealed 
that Sc enzyme was active as a flavin-dependent monooxygenases, generated 
authentic 3-HK in HPLC-based assays and was inhibited by UPF 648 (Ki 74 nM) with 
potency similar to that with HsKMO. 
The structure of ScKMO was determined using selenomethionine single anomalous 
diffraction and subsequent crystal structures were solved to 1.85 Å resolution. We were 
unable to obtain a complex with the kynurenine substrate but succeeded in co-
crystallising the enzyme with UPF 648, a tight-binding substrate-like inhibitor. UPF 648 
binds close to the FAD cofactor and perturbs the local active-site structure, preventing 
productive binding of the substrate kynurenine. 
Functional assays and targeted mutagenesis revealed that the active-site architecture 
and UPF 648 binding are essentially identical in human KMO, validating the ScKMO–
UPF 648 structure as a template for structure-based drug design. This will inform the 
search for new KMO inhibitors that are able to cross the blood–brain barrier in targeted 
therapies against HD and other neurological diseases.  
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RESUMO 
 
 
A doença de Huntington é uma doença neurodegenerativa causada por uma 
mutação no gene que codifica a proteína huntingtina. Apesar do grande desenvolvimento 
cientifico no campo das neurociências não existe actualmente nenhum tratamento capaz 
de tratar ou retardar o progresso desta doença. A enzima quinurenina mono oxigenase 
(KMO) surgiu recentemente como importante alvo terapêutico para a doença de 
Huntington. KMO é uma flavoproteína mitocondrial que catalisa a conversão do substrato 
quinorinina em 3-hidroxiquinorinina. Vários estudos mostraram que a inibição da 
actividade da KMO é neuroprotectora em modelos animais de Huntington, incluindo 
modelos de levedura, de Drosophila e de rato [1–5]. Esta enzima está igualmente 
relacionada com outras doenças neurológicas como por exemplo Alzheimer, Parkinson, 
complexo AIDS demência, esclerose lateral amiotrófica, depressão e esquizofrenia [6, 7]. 
Apesar do grande interesse terapêutico da KMO, até à data foram desenvolvidos 
poucos inibidores especificos para esta enzima, e nenhum deles comprovou ser  eficiente 
a atravessar a barreira hemoto-encefálica em modelos animais.  
O conhecimento da estrutura molecular da KMO em complexo com substratos ou 
potenciais inibidores é desta forma fundamental para o desenvolvimento de novas 
moléculas capazes de penetrar a barreira hemoto-encefálica.  O objectivo principal da 
presente tese é produzir quantidades significativas da proteína KMO para o 
desenvolvimentos de estudos estruturais, funcionais e mecanisticos com o objectivo 
futuro de desenvolver novos fármacos que possuam a selectividade e afinidade 
necessárias para intervenções terapêuticas. 
A proteina humana KMO foi eficientemente expressa e purificada, e estudos 
cinéticos da respectiva proteina revelaram um valor de Km para  quinorinina (22.62± 4 
M) bastante semelhante ao valor calculado para preparações mitocondriais de fígado de 
rato (16 M) [9] e humano (13.0 ± 3.3 M) [10]. Estudos de inibição enzimática com o 
inibidor forte da KMO (substrato análogo) UPF 648, revelaram também que este se liga 
com uma afinidade nanomolar (Ki 56.7 nM). Os baixos niveis de expressão proteica em 
conjunto com a instabilidade da proteina impossibilitaram o processo de crsitalização e 
futuros estudos estruturais.  Consequentemente, o projecto foi direccionado para a 
proteína homologa KMO de Saccharomyces cerevisiae (ScKMO), que apresenta 38 % de 
identidade e 51 % de similaridade com a proteina humana.  
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A caracterização bioquimica da proteina Sc foi realizada utilizando uma 
combinação de várias técnicas biofisicas, como espectroscopia de UV-visivel e de 
fluorescência, HPLC e ensaios de stopped-flow, mostrando que o mecanismo enzimático 
da ScKMO se assemelha a  maioria das flavoproteinas, e mostrando que esta enzima é 
inibida pela molécula UPF 648 de modo semelhante a homóloga humana (Ki 74 nM). 
A estrutura da ScKMO foi inicialmente determinada usando o método da dispersão 
anómala a um unico comprimento de onda e estruturas subsequentes foram determinadas 
com uma resolução de 1.85 Å. Foi igualmente determinada a estrutura da ScKMO em 
complexo com a molécula UPF 648. Este inibidor liga-se na proximidade do cofactor 
FAD e perturba a estrutura do sitio activo, impossibilitando a ligação do substrato 
quinorinina. 
Estudos de mutagenese  sitio-dirigida em aminoácidos do sitio activo e respectivos 
ensaios enzimáticos revelaram que a arquitectura do sitio activo é identico à proteina 
humana, validando a estrutura ScKMO–UPF 648 como base para o futuro 
desenvolvimento de moléculas baseadas na estrutura da proteina, e consequentemente a 
pesquisa de novos farmacos capazes de atravessar a barreira hemato-encefalica e com 
potencial terapêutico para a doença de Huntington e outras doenças neurológicas. 
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1. INTRODUCTION 
 
 
1.1. HUNTINGTON’S DISEASE 
 
 
1.1.1. Historical background 
 
"Of its hereditary nature. When either or both the parents have shown manifestations of 
the disease ..., one or more of the offspring almost invariably suffer from the disease ... 
But if by any chance these children go through life without it, the thread is broken and the 
grandchildren and great-grandchildren of the original shakers may rest assured that they 
are free from the disease”[11] 
 
Originally called simply 'chorea', ‘hereditary chorea’ or ‘chronic progressive 
chorea’, Huntington’s disease (HD) has been recognised as a disorder since the Middle 
Age. However it was just in 1872 that George Huntington gave an accurate definition of 
the disease in  his first paper [11]. He described a disease affecting several generations of 
a family presenting similar symptoms including chorea, presence of dance-like 
movements, the major motor abnormality occurring in HD, cognitive and psychiatric 
impairment and gradual deterioration finally leading to death. Huntington also reported 
the autosomal-dominant hereditary nature of the disease. 
The disorder has been extensively studied throughout the 20th century as an 
example of autosomal dominant inheritance. In 1983, a study conducted by the US–
Venezuela Huntington's Disease Collaborative Research Project in a small town along the 
Lake Maracaibo in Venezuela, where there was the largest known concentration of HD in 
one family [12], linked the HD gene to a polymorphic DNA marker. It was only ten years 
later that the mutation in the gene responsible for HD was finally identified [13]. Briefly, 
the polymorphic DNA marker consists of an abnormal expansion of the CAG triplet in 
the coding region of the HD IT15 (Interesting Transcript 15) gene on the short arm of
14 
 
chromosome 4 (4p16.3), which encodes for a polyglutamine tract at the N-terminal of the 
huntingtin protein (HTT) [14]. Since then, several new models and approaches were 
developed in order to unveil the molecular pathology of HD and testing possible 
intervention strategies. The first mouse model of HD was created 1996 [15] and one year 
later the aggregation of mutant huntingtin in intranuclear inclusions was discovered in the 
brain of HD mice and related to the pathogenic mechanism in HD [16]. Similar findings 
were also made in the brains of HD patients [17]. Since then, intense research focused on 
the elucidation of the molecular mechanisms of the disease in order to discover potential 
drug targets. Several animal and cell models have been developed, potential genetic 
modifiers have been discovered and many aspects of neuronal dysfunction have been 
explored. Post-translational modifications of huntingtin protein have also been subject to 
several studies. The details of the genetic aspects of HD and the formation of inclusion 
bodies will be described throughout this Chapter as well as some of the most promising 
therapeutic approaches.  
 
 
1.1.2. Epidemiology 
 
The worldwide prevalence of HD is ~5-10 cases per 100,000 individuals, but 
varies to a great extent and can reach up to 700 cases per 100,000 individuals in some 
isolated regions of Venezuela [18, 19]. The age of onset is typically between 35 and 50, 
15% of the cases can occur before 20 (juvenile HD), and as a progressive disorder the life 
expectancy is typically 15-20 years from onset of symptoms until death [19, 20]. 
 
 
1.1.3. The disease: Clinical presentation 
 
HD is characterised by three distinct clinical features: movement disorder, 
cognitive dysfunction and psychiatric disorder [19, 21]. Chorea, the most common 
remarkable manifestation of HD, is a hyperkinetic movement recognisable by the 
involuntary, abnormal and irregular movements that can affect many parts of the body, 
particularly the limbs, trunk and face [22, 21]. As the disease gradually worsens, chorea 
often stabilises giving way to bradikynesia and rigidity [23], which is very common in 
other neurodegenerative pathologies such as Parkinson’s disease.  Gait disturbances often 
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affect individuals in the last stages of HD, when they lose mobility and falls are more 
frequent. The very last stage of the disease is characterised by the inability to swallow and 
ultimately the incapability of oral nutrition [21, 23]. 
In terms of cognitive dysfunction in HD, dementia is present in the majority of 
cases, starting from what it is called subcortical dementia where individuals are not able 
to learn new motor skills and visuospatial memory is also affected, and progresses to a 
certain level where all aspects of cognition are affected [22, 21, 23]. 
Finally, the psychiatric disturbances of HD are variable but the most common are 
irritability, apathy, anxiety, depression and impulsivity [24]. Suicide is also prevalent 
among HD patients [25, 26]. 
 
 
1.1.4. Genetic aspects and neuropathology of HD 
 
As previously mentioned, HD is an autosomal-dominant neurodegenerative 
disorder caused by an abnormal expansion of the CAG triplet near the end of  the 5’ 
region of the HD gene which codes for the protein HTT [13, 27]. HTT is expressed 
throughout the body with the highest levels found in the testis and brain. Within the brain, 
it is more predominant in the neocortex, cerebellar cortex, striatum and hippocampus 
[28]. In cells the HTT protein is present mainly in the cytoplasm [29]. Although its exact 
function is not fully understood, HTT interacts with several proteins involved in 
intracellular transport and signalling, axonal trafficking of vesicles  and gene expression 
and it also plays important roles in  morphogenesis and apoptosis [30, 31]. 
In non-pathological conditions, the trinucleotide repeat present in the coding 
region of the HD gene varies in length from 6 to a maximum of 36 repeats and this DNA 
sequence is translated into a polyglutamine tract [20]. When the polyglutamine length 
reaches this threshold the HTT protein has different characteristics (named mHTT), with 
a gain of toxic function, which leads to the progressive loss of medium spiny neurons in 
the striatum and it is also related to cerebral cortex dysfunction [32, 33]. Interestingly, the 
age of onset of HD is inversely related to CAG size expansion [34, 35]. However, it is 
important to emphasise that just ~60 % of the variance of the age at onset is explained by 
the length of the CAG expansion, the remaining is related to modified genes and 
environment [20, 34]. 
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The pathology of HD is restricted to the brain with atrophy and cell loss mostly 
marked in the striatum, more specifically in the caudate and putamen, and in the later 
stages cortex is also affected [19, 36, 37]. The neurons mostly affected in HD are 
medium-sized spiny neurons that primarily innervate the substantia nigra and globus 
pallidus although the mechanism of mHTT toxicity is not clearly understood [37]. The 
fact that the striatum is the most affected brain region in HD is in agreement with the fact 
that chorea is one of the main symptoms in early stages of HD, since this part of the brain 
plays an important role in the motor circuit and behavioral control [20]. 
HD is also characterised by the presence of neuritic, cytoplasmic and nuclear 
inclusions [38], although their role in neurodegeneration is controversial [39]. Initially 
thought as pathological [30], recent studies carried out in mouse and cell models of HD 
have shown that inclusion bodies seem to appear only after symptoms begin and cells 
with these aggregates seem to survive longer than those without them [20, 39, 40]. 
Studies in human brain tissues with different grades of HD have shown that inclusion 
bodies were more prevalent in cortex than in the striatum, even if striatum is the most 
affected region in HD [41, 42]. Furthermore, they also found that aggregates tend to 
increase in size in more advanced stages, which seems to suggest that they are relatively 
benign and persist in neurons that survive longer [41, 42]. Several other studies also 
confirm the hypotheses that aggregate formation might be one of the mechanisms 
activated by misfolded Htt to protect against toxic forms of mHtt and reduce cell death 
[30, 43, 44]. 
 
 
1.1.5. Diagnosis of HD 
 
Diagnosis of the onset of HD is usually straightforward based on the appearance 
of physical symptoms specific to the disease. As previously described, the motor 
symptoms are the clinical features firstly diagnosed, specifically abrupt, excessive and 
random timing of involuntary movement [19, 20]. There is also a genetic test for HD that 
consists of a simple blood examination to confirm the number of trinucleotide repeats in 
the HTT gene, although a positive result is not considered a differential diagnosis because 
it could be obtained before the onset of symptoms. This genetic test is important to rule 
out the disease but it is also extremely important because it can dramatically influence 
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personal and family planning decisions. Since HD is an autosomal dominantly 
transmitted disorder, there is a 50 % chance of children from an affected individual 
inheriting the disease [19, 45]. 
Prenatal testing can also be performed using non-invasive techniques to determine 
the carrier status of a fetus.  
The progression of the disease can be measured based on the unified Huntington's 
disease rating scale (UHDRS) that characterises the relevant clinical features of HD [46]. 
Medical functional imaging, such as fMRI and PET, can also help in the early detection 
of HD since they can show changes in the brain activity before symptom onset as well as 
to monitor the disease progression [47, 48]. 
 
 
1.1.6. Treatment of HD 
 
Unfortunately, at present there is no effective treatment to slow or stop disease 
progression. The only therapies available so far act on the symptoms of HD with the 
intention of improving the patient’s quality of life. These therapies are mainly focused 
treating movement disorders such as chorea and dystonia, as well as gait, speech, 
swallowing and fine motor tasks [49]. 
The only drug currently approved by the US Food and Drug Administration 
(FDA) in 2008 for the treatment of chorea in HD is tetrabenazine [50]. This drug has been 
used in Europe for several years to treat chorea and other movement disorders by 
reducing the quantity of dopamine released from vesicles in the brain by reversibly 
inhibiting the monoamine transporter type 2 (VMAT2) and therefore depleting central 
monoamines [49, 51]. Tetrabenazine also reduces dopamine by blocking dopamine 
receptors from passing on its message. However, there are some adverse side effects 
associated with this drug, such as sedation and somnolence, agitation, depression, 
akathisia, anxiety and hyperkinesia [19, 50, 51]. There are also some pharmacological 
approaches to treat or ameliorate other HD symptoms, including olanzepine for weight 
loss, selective serotonin reuptake inhibitors and mirtazapine for depression, antipsychotic 
drugs for psychiatric and behavioral aspects of this pathology, although they are not 
specific for Huntington’s disease [49]. In terms of treatments for cognitive dysfunction 
there is no medication approved distinctively for HD. An acetylcholinesterase inhibitor 
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called Rivastigmine has shown some tendency for cognitive improvement in HD [52] and 
some other agents used in  Alzheimer’s disease such as NMDA receptor antagonist 
memantine are also being studied since they were successful in early therapeutic 
intervention in HD mouse models [53]. A recent study carried out by the Huntington 
Study Group has shown that a new antihistamine, Dimebon, may improve cognition in 
individuals with HD [54]. 
There are numerous ongoing clinical trials for the treatment of HD. Among them 
is the largest therapeutic clinical trial to date for Huntington disease, the 2-Care study, 
with 608 participants and this trial will study the effects of co-enzyme Q10 (CoQ10) on 
the progression of functional decline There are also several new therapeutic targets and 
potential disease-modifying therapies in HD currently being studied and some of them 
will be elucidated in the next section. 
 
 
1.2. NOVEL STRATEGIES FOR THERAPEUTIC INTERVENTION 
IN HD 
 
In this section a general overview of some of the most promising approaches to the 
development of treatments for HD will be given in order to clarify the enormous 
spectrum of alternatives that are currently being explored for the development of novel 
therapies able to treat or reduce HD pathology phenotypes. Figure 1.1 highlights some of 
the potential disease-modifying strategies for HD.  
Special emphasis will be given to the Kynurenine Pathway, since this is the central 
theme of this thesis.  
 
 
19 
 
 
 
 
 
Figure 1.1. Possible strategies for therapeutic intervention in HD therapies. Therapies including gene 
silencing, transglutaminase inhibition, autophagy enhancers, HDAC inhibitors, excitotoxicity, 
mitochondrial dysfunction and NMDA are being currently explored. From [55]. 
 
 
1.2.1. Gene silencing approaches 
 
Gene silencing therapy has been a very hot topic since the initial characterisation 
of RNA interference (RNAi) in the nematode Caenorhabditis elegans in 1998 and it has 
been extensively studied as a potential therapy for many pathologies including viral, 
ocular and neurodegenerative diseases as well as cancer [56]. Gene silencing is a 
technique that includes the use of RNAi (small double-stranded RNA molecules of ~21 
nucleotides in length) and antisense oligonucleotide to switch off a specific gene by 
cleavage, degradation, or translational suppression of its correspondent mRNA and 
therefore suppressing the expression of the target protein [57]. The great potential of this 
technology is the fact that, in theory any small inhibitory RNAs (siRNAs) can be 
designed in order to knock down the expression of any target gene, leading to the 
treatment of a broad range of diseases, for example the ones caused by single mutations 
as occurs in HD. Several studies conducted in mouse models of HD provide evidence of 
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the efficiency of RNAi in decreasing the levels of Htt [57, 58]. They have shown an 
attenuation of striatal and cortical neuropathology and behavioral deficit as well as an 
increasing in the lifespan [57, 58].  
One of the issues associated with gene silencing therapy in neurological diseases 
is the fact that most of the siRNAs do not cross the blood brain barrier (BBB) [59, 60]. 
Novel methods are currently being developed to deliver treatments directly to the fluid 
surrounding the brain, such as viral based systems, liposomes, nanoparticles and cell-
penetrating peptides, among others [61, 62].  
Another drawback to overcome when using this strategy as a potential treatment 
for HD is the fact that the majority of therapeutic molecules suppress not only the mHtt 
but also the wild type, and it is known that the majority of HD patients are heterozygous 
at the HD locus, carrying one mutant and one wild-type allele [57]. It has been shown that 
wild type Htt plays important roles in embryonic development, normal adult function and 
is protective against apoptotic neuronal death and the complete suppression of wild type 
Htt in mouse models resulted in neurodegeneration and death [63, 64]. Ongoing research 
is currently investigating the use of allele-specific gene silencing in which just mHtt is 
suppressed preserving the expression of normal Htt [57, 64, 65]. 
 
 
1.2.2. Transglutaminase Inhibition 
 
As previously mentioned in Section 1.1.4, the aggregation of mHTT in inclusion 
bodies may have a protection function within the brain, although it is hypothesised that 
intermediate forms of mHTT aggregates are toxic and lead to cell death [43, 66, 67]. 
Transglutaminases (TG) are enzymes that catalyse the formation of -(-glutamyl) 
lysine isopeptide bonds between substrate proteins with consequential formation of cross-
linked insoluble protein complexes and are also related to polyamination reactions at 
glutamine residues into specific substrate proteins[68–70]. Tissue transglutaminases 
(tTG) are the most ubiquitous TG and it has been shown that they are present within the 
neurons and are increased in affected areas in HD brain [69, 71, 72]. Several studies also 
suggest that tTG may contribute to the aggregation of polyglutamine proteins, including 
mHtt, as the addition of a polyglutamine tract may result in a protein becoming a TG 
substrate, which can therefore be crosslinked to form insoluble aggregates [71, 73, 74].  
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Cystamine and its reduced form cysteine are TG competitive inhibitors that have 
been tested in several HD models, including Drosophila and mouse models, showing that 
they can slow down neurodegeneration, ameliorate the striatal volume loss and striatal 
neuronal atrophy and improve survival [72, 75, 76]. A trial in HD patients was carried out 
in 2006 and showed that cystamine bitartrate (CYSTAGON®) was tolerated quite well 
although its efficacy was not confirmed [77]. One of the possible reasons could be the 
fact that the doses administered in animal models were much higher compared to the ones 
used in this preliminary trial and also the fact that these drugs are not entirely permeable 
to the BBB [77, 78]. Raptor Pharmaceuticals has started phase II clinical trials in 2008 
testing a delayed release (DR) preparation of cysteamine bitartrate for HD and the results 
are expected in 2014 [79].         
One of the strategies that it is currently being studied as a promising therapeutic 
for HD is reducing the amount of the pathogenic protein by increasing the clearance of 
mHTT. There are two main pathways for degradation of abnormal proteins: the ubiquitin-
proteasome system and autophagy. The up-regulation of one of these pathways could be 
an attractive way to decrease the levels of the toxic protein, although in the case of the 
ubiquitin-proteasome pathway, this system can effectively digest normal polyQ 
containing proteins but not if they are found in aggregates [80]. Furthermore, this system 
fails to cleave between glutamine residues within polyglutamine tracts leaving the 
sequence intact and therefore it could possibly lead to increasing concentrations of 
isolated toxic peptides [81–84]. 
Autophagy has become a more valid approach because it can degrade protein 
complexes, such as mutant forms of Htt, and organelles, such as mitochondria. Some 
studies performed in Drosophila and mouse models have shown that autophagy induction 
can effectively reduce the levels of mHtt and its toxicity [85]. The up-regulation of 
autophagy can be done by blocking specific kinases called mammalian target of 
Rapamycin (mTOR) that play important roles in different cellular processes in addition to 
its inhibiting effects in autophagy [86]. When mTOR is repressed, either by natural 
mechanisms such as reduced levels of amino acids or growth factors, or by drugs, such as 
Rapamycin, its inhibitory effect is reduced, leading to increased autophagy [86].  
Although Rapamycin has been shown to be effective in the promotion of 
autophagy in mammalian brains there are some concerns regarding its long term use in 
humans [87]. As mentioned earlier, mTOR is not just important in autophagy but there 
are many other cellular processes, including regulation of ribosome biogenesis and 
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protein translation in which these proteins are involved and as a result it can lead to some 
complications, for example immunosuppressive effects and impairment in wound healing 
[80]. For these reasons, there are currently studies being undertaken to identify novel 
compounds that could promote autophagy independently of mTOR. Lithium and several 
other mood stabiliser drugs, such as sodium valproate and carbamazepine were identified 
as autophagic up regulators by decreasing the levels of inositol or IP3 and decreasing the 
aggregation and toxicity of mHtt in cell and animal models of HD [88]. Furthermore, 
lithium has been used for several years to treat some affective disorders and is known to 
cross the blood brain barrier [89]. 
More recently, some other studies performed in the Drosophila HD model had 
shown that a combination therapy, using both Rapamycin to modulate the mTOR-
dependent pathway and lithium to inhibit the mTOR-independent pathways, could 
maximise the benefits when compared to both treatments alone in addition to the fact that 
it would be able to reduce the dose levels of both drugs and therefore decreasing the side 
effects [90]. 
 
 
1.2.3. Histone deacetylase (HDAC) Inhibitors 
 
Transcriptional deregulation has been suggested to have a key role in the 
pathology of HD although the mechanism that leads to the interference of gene 
expression is not fully understood. Several studies carried out in HD mouse models had 
shown downregulation of specific genes at the level of messenger RNA (mRNA) 
expression [15, 91]. Interestingly, these genes are involved mainly in neurotransmitter 
signalling, calcium metabolism and transcription and are more prominent in the striatum, 
which is the most affected brain region in HD [92]. 
In general, gene expression is regulated by transcription factors, some of them 
responsible for the acetylation of histones (HAT) and leading to the activation of 
transcription, and others for the deacetylation (HDAC) resulting in the repression of gene 
expression. The proposed mechanism to elucidate the transcriptional dysregulation in HD 
has been linked to the fact that mHtt decreases histone acetyltransferase activity by 
binding different transcription factors, such as CREB-binding protein (CBP), which  
acetylates histones and opens up DNA for transcription, and therefore decreasing the 
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level transcription [92]. HDAC inhibitors, such as hydroxamic acids vorinostat (SAHA), 
sodium butyrate  and phenylbutyrate, have been studied in HD models and have proven to 
be effective in reducing cellular death in HD [93–95]. These compounds have been used 
as drug targets in cancer research. However, some of them are toxic and have serious side 
effects and as a result the current research is focused on the development of novel HDAC 
inhibitors that are more effective and with less side effects. 
A novel HDAC inhibitor called HDACi 4b was reported to be effective in 
preventing motor deficits and striatal atrophy in HD transgenic mice as well as 
significantly decreasing the compound toxicity, suggesting that this inhibitor may provide 
clinical benefits in HD patients and slowing down the progression of the disease [96]. 
 
 
1.2.4. NMDA antagonists 
 
The pathogenesis of some neurodegenerative disorders including HD have been 
linked with excessive or prolonged stimulation of amino acid receptors, particularly the 
subtype of glutamate receptors NMDA, in a process called excitotoxicity [97, 98]. These 
receptors have been directly related to excitotoxicity due to their Ca2+ hypersensitivity, 
slow deactivation, and desensitisation. This will lead to high intracellular levels of this 
mineral, damaging the cells either by activating a number of enzymes that will destruct 
structures such as components of the cytoskeleton, membranes, and DNA, or by 
increasing the formation of reactive oxygen [99]. It has been shown that NMDA receptors 
are the glutamate receptors that produce more striatal lesions and affect more specifically 
the medium sized spiny neurons, the neurons mostly affected in the early stages of HD 
[97]. 
Several studies have provided evidence of a direct relation between mHtt and 
NDMA receptor-dependent excitotoxic cell death [100], but the first direct demonstration 
of such a link was carried out in cell lines with full length Htt with 138Q repeats 
cotransfected with NMDAR. The results showed an increase in the NMDAR levels and 
apoptotic cell death when compared to 15Q mHtt [101, 102]. Since then, several other 
studies performed in mouse models also revealed an increased level of NMDA mediated 
cell death in medium spiny neurons [103]. Interestingly, they also found that the NMDA 
susceptibility and overstimulation is present when mice are just 3 to 4 weeks old, even 
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before the onset of symptoms, which supports the hypothesis that the persistent 
overstimulation of NMDA receptors over a lifetime plays a key role in 
neurodegeneration. They will activate numerous proteases due to increased levels of 
calcium and oxidative stress and therefore, will make the neurons more susceptible to 
stress and they will eventually degenerate [104]. 
NMDA receptors are complexes of two NR1 subunits with two other subunits that 
could be NR2A, NR2B, NR2C, NR2D or NR3 [105]. The medium spiny neurons express 
high levels of NR2B containing NMDAR compared to other regions of the brain. This 
could be indicative of their susceptibility in HD since it was shown that mHtt increases 
the current and excitotixicity mediated by specifically this type of NMDA receptors that 
could lead to neuronal dysfuntion [101]. Accordingly, NMDAR antagonists have been 
investigated as a potential treatment of HD. Several NMDAR blocker compounds 
including Amantadine [106], Riluzole [107], Lamotragine [108] and Remacemide [109] 
have been tested already in human trials, although none of them gave promising results as 
expected from the previous studies in mouse models.  
More recently, another NMDA antagonist called Memantine, which has been 
already FDA-approved for Alzheimer's disease, has been proposed as a possible therapy 
for HD. One study performed in 27 HD patients for two years had shown promising 
results with a delay of the progression of the disorder in terms of motor and cognitive 
symptoms [110]. Further studies are currently being carried out as a clinical phase III trial 
with 72 participants to measure the short-term memory, cognition and behaviour before 
and after treatment with Memantine [111]. 
Although a relationship between NMDAR overstimulation and neuronal death has 
already been reported, it is still unclear whether the formation of inclusion bodies is 
somehow modulated by synaptic activity. A recent study shows accurately that there is in 
fact a strong correlation between extrasynaptic NMDAR activity and IB formation [112]. 
They have shown that by reducing the extrasynaptic NMDAR activity using Memantine 
in mouse models, the levels of soluble toxic mHtt were decreased in addition to a 
preservation of mHtt inclusion bodies, suggesting one more time that IB are likely to be a 
protective mechanism to block mHtt toxicity. 
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1.2.5. Mitochondrial dysfunction and Reactive Oxygen Species  
 
The excitotoxicity process described in the previous section carried out by 
glutamate receptors NMDA has been closely related to other processes such as oxidative 
stress and mitochondria dysfunction through several complex mechanisms, one of them 
being the mitochondrial calcium homeostasis [113]. As previously mentioned, one of the 
elements responsible for NMDAR excitotoxicity is the high levels of Ca2+ and if such 
levels surpass a certain threshold it will also lead to mitochondrial damage and 
consequently cell death [113]. These processes are linked in a certain way that a 
dysfunction in mitochondria will cause a decrease in ATP levels and therefore, a 
depolarization of the cell membrane, which will facilitate the NMDA receptors activation 
by glutamate. These events will create a cycle in which the calcium influx will be 
constantly increased causing mitochondria disturbances and generation of reactive 
oxygen species (ROS) [97]. 
Mitochondrial dysfunction is recognised as a key process in neurodegenerative 
diseases due to its role in cell survival and death as well as its interaction with many 
proteins involved in other neurodegenerative disorders [114]. With respect to HD, it has 
been reported that mHtt binds to the mitochondria, changing their normal function and 
therefore dysregulating Ca2+ levels [115]. So what is the relationship between wild type 
Htt and mitochondria and how does mHtt cause dysfunction in this organelle? 
As previously described, wild type Htt is essentially a cytosolic protein but is also 
localised predominantly in the soma, dendrites and synaptic terminal of neurons [97]. It 
has been also reported to be associated with cellular organelles such as mitochondria, 
more specifically with the outer membrane of mitochondria [116, 117]. Although its role 
is not fully understood it is hypothesised that wild type Htt is involved in energy 
metabolism and organelle trafficking. When mHtt interacts with the mitochondria it 
decreases and depolarises the membrane potentials causing a dysregulation of 
mitochondrial Ca2+ handling [97, 114, 115]. A recent study also pointed out that it is not 
the full length mHtt that interacts with the mitochondria but the N-terminal mHtt 
fragments[118]. 
Several biochemical studies in HD tissues support the contribution of 
mitochondrial dysfunction in HD. It has been shown by nuclear magnetic resonance 
spectroscopy (NMR) that patients with HD present higher levels of lactate in the cortex 
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and basal ganglia when compared to controls, which is consistent with impairment of 
energy metabolism or mitochondrial dysfunction [114]. Furthermore, there is also 
evidence in post mortem HD brain tissue and HD mouse models that reveal lower levels 
of mitochondrial oxygen consumption and glucose metabolism, as well as several defects 
in the complexes II and III of the mitochondria electron- transport chain mitochondrial 
[119]. Interestingly, studies performed in mHtt (with a polyQ of 82 glutamates) knock-in 
mouse embryos has shown that the overexpression of complex-II subunits restores the 
activity of mitochondria preventing cell death [114, 118, 120]. 
Although the role of mitochondrial dysfunction in the pathogenesis of HD is still 
not completely clear, some biochemical measures such as lactate levels or the ratio 
lactate/pyruvate can be important as biomarkers to follow the progression of the 
disease.[114]. 
 
 
1.2.6. The Kynurenine Pathway 
 
The kynurenine pathway (KP) is the main route of tryptophan degradation in 
higher eukaryotics and perturbations in the levels of KP metabolites are likely to 
contribute to the pathogenesis of several neurodegenerative diseases, including HD as 
well as other pathologies such as malaria, cancer, depression and schizophrenia [6]. As 
this pathway is the central subject of this project, an overview of the KP will be given 
along with the neuroactive properties of KP metabolites and their role in 
neurodegeneration. The relationship between the kynurenine pathway with some of the 
main features involved in the neurodegenerative process, including oxidative stress, 
mitochondrial dysfunction, excitotoxicity and neuroinflamation will also be discussed. 
The kynurenine pathway (KP) degrades >95% of tryptophan in mammals by a 
series of enzymatic reactions that ultimately leads to the formation of the cofactor NAD+. 
The metabolites formed during this cascade include a subset that is neuroactive or has the 
capacity to generate free radicals.   
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Figure 1.2. Schematic representation of the kynurenine pathway of tryptophan degradation in 
eukaryotic cells. See the text for a detailed description of the KP. 
 
 
The initial step in the KP is the oxidative cleavage of the indole-ring present in L-
tryptophan, yielding N-formylkynurenine, which in the brain is catalysed by either 
indoleamine-2,3-dioxygenase (IDO) or tryptophan 2,3- dioxygenase (TDO2), followed by 
the synthesis of the first stable intermediate L-kynurenine (L-KYN) [121] (Figure 1.2). 
Subsequently, L-KYN is metabolised via three different routes. In the first, L-KYN is 
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deaminated to form the neuroactive metabolite kynurenic acid (KYNA) by the 
kynurenine aminotransferase (KAT) family of enzymes, four of which can catalyse this 
reaction in mammalian brains [122].  In the second route, the same substrate is degraded 
to anthranilic acid by kynureninase. And in the third route, L-KYN is hydroxylated by 
kynurenine 3-monooxygenase (KMO) into the free radical generator, 3-
hydroxykynurenine (3-HK). 3-HK is metabolised further into a second free radical 
generator, 3-hydroxyanthranilic acid (3-HANA) - by kynureninase and then oxidised into 
2-amino-3-carboxymuconic 6-semialdehyde by 3-hydroxyanthranilate 3,4-dioxygenase. 
This intermediate then undergoes non-enzymatic cyclisation yielding the excitotoxic 
metabolite quinolinic acid (QUIN), which is subsequently transaminated to generate 
nicotinic acid, and ultimately the final KP product NAD+ [7]. 
The physiological role of the KP was initially thought to be limited to the 
formation of the coenzyme NAD+, which is involved in several biological processes, such 
as redox reactions essential for mitochondrial function and energy metabolism [123]. 
Subsequent studies have established that the metabolites produced by this biosynthetic 
pathway – known as kynurenines – play a variety of roles in the peripheral immune 
system and the central nervous system. Kynurenines are involved in peripheral 
immunomodulation which inhibits growth of intracellular pathogens, the maintenance of 
maternal immune tolerance which prevents embryo rejection, and immune surveillance 
[124]. KP metabolites also modulate T cells by suppressing their proliferation and 
inducing apoptosis, thereby mediating immune tolerance [125].  Of particular importance 
in the latter process is IDO, which has been found to promote immune tolerance to 
foreign antigens in cases of over-activation of the immune system, preventing tissue 
damage [126, 127]. However, this immune suppression can also result in the inability of 
the immune system to prevent tumour growth and survival. Indeed, IDO has been shown 
to be overexpressed in tumours [128, 129]. Recent studies have also found a correlation 
between IDO activity and aryl hydrocarbon receptor (AHR) activation by the endogenous 
ligand L-KYN, which appears to be important in promoting generation of regulator T 
cells and therefore suppressing self-reactive cells and immune responses [130, 131]. IDO 
inhibitors have been shown to significantly promote tumoral immune rejection and 
increase the efficiency of chemotherapeutic agents [132, 133]. Complementary recent 
work also suggests that TDO activity in tumour cells constitutively generates L-KYN, 
which in turn serves as a ligand for the AHR, thereby suppressing antitumor immune 
responses and promoting tumor cell survival [134]. 
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In addition, KP metabolites play important roles in the central nervous system in 
both normal physiology and disease states. These metabolites were first linked with 
neurological conditions in 1978 when the stimulant and convulsive effects of kynurenines 
in the murine brain were described, with a particularly strong effect of QUIN observed in 
motor excitement [135]. Subsequently, it was found that QUIN selectively activates N-
methyl-D-aspartate (NMDA) receptors, which can lead to excitotoxicity and axon-sparing 
lesions in cortical neurons [136, 98]. QUIN has been shown to stimulate lipid 
peroxidation, production of reactive oxygen species and mitochondrial dysfunction [137, 
138]. Studies performed in organotypic cultures of rat corticostriatal system indicate that 
concentrations of QUIN even just slightly higher than physiological concentrations can 
cause neurodegeneration after a few weeks of exposure [139]. Spinal neurons are 
especially sensitive to QUIN variations, which cause cell death in nanomolar 
concentrations [140]. 
At high micromolar concentrations, KYNA is a non-selective NMDA receptor 
antagonist and can also block excitatory neurotransmission of other ionotropic aminoacid 
receptors, such as kainate and AMPA receptors [7, 141]. KYNA is also a ligand for 
GPR35, an orphan G protein-coupled receptor [142]. In addition, KYNA is a non-
competitive antagonist of 7-nicotinic acetylcholine receptors (7nAChRs), which are 
likely to be the primary target of endogenous KYNA in the brain, and therefore inhibition 
of KYNA synthesis leads to increased levels of acetylcholine and the neurotransmitters 
glutamate and dopamine [7]. Consequently, KYNA has been linked to a myriad of 
behaviours that involve cholinergic, glutamatergic, and dopamingeric neurotransmission 
[7]. Furthermore, KYNA has antioxidant capacity due to its ability to scavenge hydroxyl, 
superoxide anion and other free radicals [121]. As an important modulator of glutamate 
levels, endogenous KYNA levels have been found to provide critical neuroprotection 
against excitotoxic lesions induced by QUIN [143]. The therapeutic potential of KYNA 
as a neuroprotective agent has been considered, although its applicability is limited due to 
the poor ability to cross the blood-brain barrier (BBB) [144].  Thus, KYNA analogues are 
being developed and tested for neuroprotection [145, 146]. The level of KYNA is reduced 
in several neurodegenerative diseases such as HD and Alzheimer’s disease (AD) [147], 
which likely plays an important role in modulating neurotoxicity.  
Two additional KP metabolites have been implicated in neurodegeneration: 3-HK 
and 3-HANA. These tryptophan metabolites are neurotoxic because they induce the 
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formation of free radicals and elevate the oxidative stress level causing neuronal death 
[148, 149]. 3-HK and 3-HANA also stimulate the formation of chemokines by inducing 
target receptors in astrocytes, thereby potentiating brain inflammation [150, 151]. The 
concentration of these KP metabolites are in the range of nanomolar levels in mammalian 
brains but they have been found to be significantly increased in pathological conditions, 
such as HD [152], Parkinson’s disease (PD) [153] and human immunodeficiency virus 
(HIV)-1-associated dementia [154]. Neuronal cell culture studies also provide strong 
evidence that 3-HK and 3-HANA potentiate cell death with apoptotic features, with 
cortical and striatal neurons being the most vulnerable to KP metabolite toxicity [148]. 
Furthermore, 3-HK potentiates QUIN-induced excitotoxicity, such that intrastriatal co-
injection of both metabolites results in substantial neuronal loss, whereas the same doses 
applied individually do not cause neurodegeneration [155].  
In the brain, the enzymes of the KP are primarily localised in microglia and 
astrocytes and not in neurons. Surprisingly, astrocytes do not seem to have kynurenine 3-
monooxygenase and consequently induce the activity of KYNA. However, microglia 
contain very low levels of KAT and therefore induce the formation of metabolites in the 
QUIN branch of the KP [156]. After these metabolites are produced both in astrocytes 
and microglia they will be released in the extracellular milieu and affect pre and post 
synaptic neurons [157]. 
Figure 1.3 summarises the effects of the KP metabolites in some of the aspects of 
neurodegeneration, not only in HD but also in many other neurological diseases.  
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Figure 1.3. The effects of neuroactive kynurenine pathway metabolites on the main features of the 
neurodegenerative process. (3-OH-L-KYN: 3-hydroxy-L-kynurenine, KYNA: kynurenic acid, L-KYN: L-
kynurenine, NMDA: N-methyl-D-aspartate, QUIN: quinolinic acid, ROI: reactive oxygen intermediates; 
thick solid lines: activation, thick dotted lines: inhibition [113]. 
 
 
Alterations in levels of KP metabolites have been implicated in the 
pathophysiology of several neurological conditions such as HD, Alzheimer’s (AD) and 
Parkinson’s disease, AIDS-dementia complex, amyotrophic lateral sclerosis, depression 
and schizophrenia [3, 37]. The most compelling evidence supporting a role for KP 
metabolites in neurodegenerative disease comes from studies in HD. Levels of 3-HK and 
QUIN are increased in the neostriatum and cortex of early stage HD patients, as well as in 
the brains of transgenic HD mice [158, 159].  Importantly, the elevated levels of 3-HK 
and QUIN in HD mouse models correlate with the onset of HD pathology [160]. 
Exacerbating these effects, KAT activity and KYNA levels are significantly reduced in 
the striatum of HD patients [161]. Both the absolute levels of the neuroactive KP 
metabolites and the relative levels of the neurotoxic metabolites to KYNA have been used 
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to support the hypothesis that the increased flux through the central branch of the KP may 
play an important role in HD pathology. 
Although it is not clear how expression of mHtt leads to modulation of the KP, it 
has been demonstrated that mHtt fragments bind to mitochondria, affecting the 
interaction between trafficking proteins and these organelles and thereby the transport and 
distribution of mitochondria in neuronal processes [118]. Mitochondrial impairment in 
HD has been correlated with the pathological changes in the KP, particularly decreased 
activity of KAT enzymes, leading ultimately to an exacerbation of QUIN toxicity [162]. 
The localisation of KMO to the outer mitochondrial membrane further suggests that 
dysfunction of mitochondria may directly modulate activity of this KP enzyme, and 
thereby affect KP metabolism. The expression of mHtt deregulates transcription, thereby 
triggering KP activation in microglia both in vitro and in vivo, suggesting a mechanism 
for mHtt-induced perturbations in the KP, and providing additional evidence that this cell 
type contributes to neurodegeneration in HD [163, 164]. Moreover, the treatment of HD 
model mice with either HDAC inhibitors (which modulate gene expression) or KMO 
inhibitors reduces 3-HK levels by comparable amounts, suggesting a direct link between 
regulation of gene expression and KP flux. Furthermore, a direct connection between 
mHtt toxicity and perturbations in the KP is highlighted by observations in Drosophila 
that exogenous 3-HK is only neurotoxic in HD flies, and not control flies. This indicates 
that while the KP is a requisite component of mHtt toxicity, perturbation of 3-HK levels 
alone is not sufficient to reproduce HD phenotypes - and that additional mHtt-dependent 
cellular dysfunction plays a role [4]. Work carried out in HD transgenic mice has shown 
that increased 3-HK levels in the brain might be caused by enzymatic dysfunction, in 
particular upregulation of KMO activity and downregulation of kynureninase activity, 
shifting the KP towards formation of neurotoxic metabolites [165]. Taken together, these 
and other studies strongly indicate that mHtt potentiates cellular modifications that induce 
flux through the neurotoxic branch of the KP. 
 
 
1.2.6.1. Targeting the Kynurenine Pathway in HD 
 
As stated above, several studies support the hypothesis that the KP plays a key 
role in neurodegeneration in HD. A study supporting the therapeutic potential of the KP 
was conducted using Saccharomyces cerevisiae as model for HD [166]. In a genome-
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wide loss-of-function suppressor screen 28 genes were found to reduce the toxicity of 
mHtt. One of the most potent suppressors was Bna4, the yeast orthologue of kynurenine 
3-monooxygenase. Additional experiments reported in this study showed that the 
elimination of KAT enhances the toxicity of mHtt and elimination of other genes 
throughout the KP directly link the levels of 3-HK and QUIN with mHtt toxicity. 
Furthermore, upon suppression of KMO, there were only very low levels of 3-HK and 
QUIN and the formation of ROS were very similar to the controls, suggesting a direct 
link between KP and formation of free radicals, as previously reported.  
Studies performed in transgenic Drosophila melanogaster also explored the KP as 
a potential therapeutic target in HD, especially the enzymes KMO and TDO [167]. 
Similar results to those described above have been reported regarding inhibition of KMO. 
They have shown that genetic and chemical inhibition of this enzyme led to a reduction in 
3-HK levels and an increase in KYNA, yielding a consequent decrease in 
neurodegeneration. They also found for the first time that the inhibition of TDO also 
shows a neuroprotective effect in the same way as KMO in modulating the KP towards 
KYNA. The protective effect of KMO inhibition was reduced when flies were fed 
directly with 3-HK. Furthermore, feeding of KYNA to HD model flies ameliorated 
neurodegeneration, providing further evidence that these metabolites directly modulate 
neurodegeneration. Furthermore, a direct correlation between mHtt and KP was also 
reinforced by the fact that increased concentrations of 3-HK were only neurotoxic in 
Htt93Q mutants when compared to Htt20Q, even when this last mutant was sufficient to 
induce 3-HK formation, suggesting again that the length of polyQ in Htt generates 
cellular defects that will further modulate the KP [167]. 
Perhaps most compellingly, studies carried out in HD transgenic mice suggested 
that the increased levels of 3-HK present in the brain might be caused by enzymatic 
dysfunction, mainly up-regulation of KMO and down-regulation of kynureninase, shifting 
the KP towards formation of neurotoxic metabolites and ROS and consequently, 
neurodegeneration [165]. Treatment of R6/2 mice with HDAC and KMO inhibitors 
reduces the level of 3-HK by comparable amounts, suggesting a direct link between 
HDAC complexes and KP activation. They suggest that the dysregulation of HDAC 
transcription induced by mHtt is carried out before the activation of the QUIN branch of 
KP and could therefore modulate this pathway [165]. 
In combination, these results provide strong evidence that the modulation of the 
KP can prevent neurodegeneration and therefore the inhibition of key enzymes in this 
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pathway can be a valuable therapeutic approach, not only for HD but also to other 
neurodegenerative, inflammatory and psychiatric disorders. KMO enzyme has been of 
particular interest since it has a central role in modulating the KP and its inhibition could 
significantly decrease the neurotoxic metabolites in the QUIN branch and possibly shift 
the pathway towards the production of neuroprotective KYNA. To date several KMO 
inhibitors have been developed and characterised. The next section will be dedicated to an 
overview of the KMO chemical inhibitors currently available. 
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1.2.6.2. KMO inhibitors 
 
A selection of published KMO inhibitors is shown in Table 1.1: 
 
 Table 1.1. Selection of KMO inhibitors 
 
 
 
 
 
 
Compound Structure IC50 
Enzyme 
source Reference 
Nicotinylalanine 
(NAL) 
 
900±180 μM Liver, Brain [168, 169] 
m-
nitrobenzoylalani
ne 
(mNBA) 
 
3.0±0.2 μM 
0.77±0.11 μM 
Brain 
Kidney [170] 
3,4-
dichlorobenzoylal
anine 
(FCE28833, 
PNU156561) 
 
0.2 μM 
0.23±0.03 μM 
0.33±0.03 μM 
Brain 
Liver 
Kidney 
[171] 
UPF 648 
 
0.040 μM Brain [172] 
Ro 61-8048 
 
0.037±0.003 
μM Kidney [173] 
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The first KMO inhibitor to be described was nicotinoylalanine (NAL) and this 
compound is a simple analogue of the substrate L-kynurenine [168, 169]. The efficiency 
of NAL was tested in rat brains and it was shown to inhibit the production of QUIN and 
increase the concentration of KYNA, as well as being an effective anticonvulsant [168, 
169]. However, due to its low potency and selectivity (IC50 = 900 M ) this substrate 
analogue was further optimised into a new compound called m-nitrobenzoylalanine (m-
NBA) with an IC50 = 0.9 M [170]. Rats injected with m-NBA presented higher 
concentrations of KYN (13 times) and KYNA (5 times) in the brain compared to controls 
and as for NAL, it is also competent in decreasing convulsions activity and spontaneous 
locomotor activity [170]. In 1996 a series of KYN analogues were also published, with 
3,4-Dichlorobenzoylalanine (FCE 28833, PNU 156561) being the most potent KMO 
inhibitor with an IC50 = 0.2 M [171]. This compound differs from m-NBA in the 
benzoylalanine, with a 3,4-dichloro substitution instead of the nitro group. The same 
pharmaceutical company, Pharmacia, started to explore the benzoylalanine side chain 
and concluded that the carboxylic acid has a key role in the activity of these compounds, 
while the elimination of the amino group does not significantly influence its activity 
[172]. Furthermore, it was also shown that the S-isomer is preferred.  From this study, 
KMO inhibitors started to be developed in terms of side chains substitutions. It was found 
that the incorporation of a cyclopropyl ring in the side chain led to a novel and more 
potent inhibitor at nanomolar concentrations [172]. This new compound (UPF 648) was 
first evaluated in a gerbil model and was found to be more selective towards KMO than 
KAT, and increases the levels of kynurenine and KYNA in the plasma and brain. Since 
then, it has been used in several in vivo and in vitro studies to test and validate the 
hypothesis of KMO inhibition as a therapeutic strategy in HD. 
On study showed that intrastriatal injections of QUIN in mice with a targeted 
deletion of KAT produced larger brain lesions when compared to controls, thus 
demonstrating QUIN neurotoxicity. However, the mice showed significant amelioration 
when treated with UPF 648, which suggests that this inhibitor can effectively reduce the 
3-HK and QUIN levels and therefore, compensate the lack of the neuroprotective 
metabolite KYNA [143]. Furthermore, inhibition of KMO via introduction of UPF 648 
into the brain not only decreases 3-HK and QUIN levels, but also increases levels of 
KYNA and neuroprotection in rodents [174, 175]. 
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A screen for novel KMO inhibitors led to the identification of the compound 3,4-
dimethoxy-N-[4-(3-nitrophenyl)thiazol-2-yl]benzenesulfonamide (Ro-61-8048), which 
has a high affinity for KMO (IC50 = 37 nM) [173]. This compound was tested both in vivo 
and in vitro and found to inhibit rat and gerbil KMO after oral administration, as well as 
increase the levels of KYNA in extracellular hippocampal fluid [173]. Ro 61-8048 has 
also been extensively used as a tool to study the effects of KP manipulation in several 
diseases. For example, treatment with this inhibitor significantly decreased cell death 
while increasing the concentration of KYNA in a model of post-ischemic neuronal death 
using hippocampal slice cultures subjected to oxygen and glucose deprivation [176]. This 
compound has also been tested in a primate model of PD, where the prolonged 
administration of Ro 61-8048 was found to increase the serum levels of L-KYN and 
KYNA, while reducing levodopa-induced dyskinesia [177].  
Regarding HD, Ro 61-8048 was tested in a HD yeast model expressing Htt103Q 
and significantly reduced 3-HK levels and improved yeast growth [166]. This compound 
was also tested in Drosophila and mice models of HD with the same neuroprotective 
benefits by shifting the KP towards production of KYNA [163, 167].  
Surprisingly Ro 61-8048 does not seem to cross the blood brain barrier in rodents 
and therefore, the protective effects of this compound is hypothesised to be caused by an 
increase in the blood levels of kynurenine and the subsequent transport of this metabolite 
across the BBB and the preferential conversion into KYNA in the brain [178]. 
Furthermore, this study also reported the metabolic instability of this drug and as a result 
they developed a slow-release prodrug, 2-(3,4-dimethoxybenzenesulfonylamino)- 4-(3-
nitrophenyl)-5-(piperidin-1-yl)methylthiazole, called JM6 [178]. This prodrug was tested 
not only in HD but also in AD mice models and found to ameliorate several disease-
relevant phenotypes including synaptic loss and shortened lifespan [178].  
As mentioned for Ro 61-8048, JM6 does not cross the BBB and therefore, the 
protective effects of this compound were also caused by the inhibition of KMO in blood 
cells. It was also claimed that this type of inhibition, compared to direct inhibition in the 
brain, could be useful when combined with other therapies in which compounds cross the 
BBB, thus avoiding toxic effects due to simultaneous use of several drugs.  Although this 
study has taken an enormous step forward in understanding the role of the KP metabolites 
in the periphery and their effects in the brain, further studies will be needed to accurately 
determine the extent of efficacy of this methodology. While these approaches for KMO 
inhibition in the periphery have shown great therapeutic promise for neurodegenerative 
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diseases,  the development of KMO inhibitors able to cross the BBB is a vital strategy to 
pursue as the delivery of KMO inhibitors directly to the brain may reduce levels of 
neurotoxic metabolites, in addition to increasing levels of neuroprotective KYNA [174, 
179]. 
The high-resolution crystallographic structure of KMO – both with native KMO 
and ligand-bound enzyme - would aid in the rational design of novel KMO inhibitory 
compounds, which may ultimately expedite clinical application of these compounds.  
Since there was no structural knowledge of this enzyme, the investigation of the binding 
modes of possible KMO inhibitors has been carried out using structure and ligand-based 
computer-aided design tools based on structurally and functionally related enzymes [180, 
181]. Nonetheless, obtaining the crystal structure of KMO will be necessary to truly 
inform rational design of novel inhibitors. 
 
 
1.3. KYNURENINE 3-MONOOXYGENASE (KMO), A 
FLAVOPROTEIN MONOOXYGENASE 
 
This section will be dedicated to the molecular characterisation of Kynurenine 3-
monooxygenase. A detailed description of this enzyme will be given in terms of enzyme 
classification and catalytic mechanism, and a series of motifs and domains from similar 
enzymes will be revealed in order to predict important structural features of KMO. 
Studies carried out on the expression and purification of KMO from different organisms 
will also be presented as possible strategies to pursue and optimise in the current project. 
 
 
1.3.1. Introduction to Flavoproteins 
 
Flavoproteins, as the name suggests, are a group of enzymes with flavin adenine 
dinucleotide (FAD) or flavin mononucleotide (FMN) as a covalently or noncovalently 
bound prosthetic group and were first described in 1933 by Otto Warburg [182] (Figure 
1.4A). A yellow protein from yeast cells was isolated and catalysed the oxidation of 
NADPH using oxygen as a second substrate. Nowadays hundreds of flavoproteins, with a 
variety of functions ranging from important roles in signal transduction, development of 
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mammalian foetuses to photosynthesis and DNA repair are known [183]  . They also play 
a crucial role in redox reactions in biological systems due to their involvement in single 
and double electron transfer processes and provide flexibility in terms of substrates and 
reactions catalysed [183]. 
In general, flavoenzymes catalyse reactions that can be separated into reductive 
and oxidative half-reactions. In the reductive half-reaction the substrate reduces the flavin 
and in the oxidative half-reaction the flavin is re-oxidised by an electron acceptor (Figure 
1.4B). These reactions will be further explored and characterised in section 1.4.2.1.. 
Flavoproteins can be classified based on their function into many subclasses, for 
example electron transferases, photolyases, synthases, dehydrogenases, disulfide 
reductases, oxidases, and monooxygenases [184]. Kynurenine 3-monooxygenase is a 
member of flavoprotein monooxygenases and therefore the next sections will be 
dedicated exclusively to this class of enzymes. Further information regarding the other 
classes of flavoproteins are detailed in references [184–186]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. Schematic representation of Flavin Adenine Dinucleotide  A: Flavin Adenine Dinucleotide 
molecule. B: Schematic representation of the three different redox states of flavin coenzymes, each state 
presenting different colours and the reduced form is colourless. 
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1.3.2. Flavoprotein monooxygenases 
 
Flavoprotein monooxygenases are a vast collection of enzymes that catalyse the 
insertion of one atom of molecular oxygen into a substrate, using NAD(P)H  to reduce the 
flavoenzyme cofactor from FAD to FADH2. This species will then react with molecular 
oxygen to form flavin C4a peroxide, which is the reactive and unstable oxygen species 
responsible for incorporation of one molecule of oxygen into the substrate while the other 
is reduced into water [187] (Figure 1.5). Fraaije et al. (2006) divided flavoprotein 
monooxygenases into six major classes from A to F (Table 1-2) [187]. The focus of this 
work was on Class A flavoprotein monooxygenases. 
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Table 1.2. Classes of external flavin monooxygenases (adapted from [187]) 
 
Sub-
class General characteristics Reactions Cofactor Coenzyme 
Structural 
features 
A  Encoded by single gene 
 NADP+ is released after 
flavin reduction 
Hydroxylation 
Epoxidation 
FAD NAD(P)H One dinucleotide 
binding domain 
(Rossman fold) 
binding FAD 
B  Encoded by single gene 
 keep the coenzyme 
NADPH/NADP+ bound 
duringcatalysis 
Baeyer–
Villiger; N-
oxidation 
FAD NADPH Two dinucleotide 
binding domains 
(Rossmann fold) 
binding FAD and 
NADPH 
C  Encoded by multiple 
genes encoding one or 
two monooxygenase 
components and a 
reductase component 
 
Light emission; 
S-oxidation 
Light emission; 
S-oxidation 
- FMN 
NAD(P)H 
TIM-barrel fold 
D  Encoded by two genes 
encoding a 
monooxygenases and a 
reductase 
 
Hydroxylation - FAD 
NAD(P)H 
No structure 
available 
E  Encoded by two genes 
encoding a 
monooxygenases and a 
reductase 
 
Epoxidation - FAD 
NAD(P)H 
No structure is 
available 
F  Encoded by two genes 
encoding a 
monooxygenases and a 
reductase; 
Halogenation - FAD 
NAD(P)H 
Two domain 
structure: one 
FAD binding 
domain 
(Rossmann fold) 
and a helical 
domain 
 
 
 
 
1.3.2.1. Class A flavoprotein monooxygenases 
 
Class A monooxygenases are encoded by a single gene, contain a tightly bound 
FAD cofactor and depend on NAD(P)H as a coenzyme. An electrophilic attack to the 
aromatic ring is carried out by the reactive species, C(4a) hydroperoxyflavin [187]. The 
majority of substrates are aromatic compounds with hydroxyl or amino groups. An 
interesting feature about this class of flavin monooxygenases is that the reduction of the 
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enzyme-bound FAD- by NADPH is strongly stimulated by formation of the enzyme-
substrate complex - and therefore, NADPH is only used when substrate is present in the 
reaction [188]. 
One of the  enzymes used as a model system for this class of flavin 
monooxygenases is p-hydroxybenzoate hydroxilase (PHBH, EC 1.14.13.2), with its 
structure published in 1979 [189]. Since then, this enzyme has been studied in great detail 
due to the ability to distinguish almost all of the intermediates in the catalytic cycle by 
spectroscopic techniques, based on different absorbance and fluorescence properties of 
each species. As a result, similar experimental strategies have been used to study the 
catalytic mechanism of numerous flavoprotein monooxygenases and it has become a 
model for enzymes involved in the oxygenation of aromatic compounds.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5. Reaction mechanism of p-hydroxybenzoate hydroxylase. The first step involves the 
substrate binding and reduction of flavin by NADPH. Next, the reduced FAD reacts with oxygen to form 
the first intermediate flavin C(4a)-hydroperoxide. As this species is extremely reactive it instantly 
hydroxylates the substrate, forming the product 3,4-diOHB, water and the second intermediate flavin C(4a)-
hydroxide. In the final step this gets hydrated, leading to oxidised enzyme and the cycle is completed 
(Adapted from  [183]). 
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Since the first structure of this enzyme was published, many other studies have 
been reported, showing enzyme complexes with substrates substrate analogues, products 
and NADPH (Figure 1.6). This has been extremely important, together with multiple 
sequence alignments studies, to identify motifs or putative sequences involved in 
catalysis and ligand binding of flavoproteins hydroxylases. 
 
 
Figure 1.6. Crystal structure of p-hydroxybenzoate and proposed interdomain binding of NADPH. 
Unlike the majority of flavin monooxygenases this enzyme does not present a recognisable domain to bind 
NADPH. Interestingly NADPH binds in an extended conformation at the surface of the protein in a channel 
that crosses the binding site of FAD (Adapted from [190]). 
 
 
The first clear motif found in PHBH was the dinucleotide-binding motif, 
containing the sequence xhxhGxGxxGxxxhxxh(x)8hxhE(D) where x is any residue and  h 
is a hydrophobic residue. This sequence is highly conserved among proteins that use 
NADP(H) and FAD as coenzymes and consists of βαβ units, generally 6 β-strands and 4 
α- helices [191, 192], which are generally found at the N-terminal part of the protein 
sequence (Figure 1.7). The central part of this consensus sequence, GxGxxG, is called the 
Rossmann fold [193]. There is also a second short motif in the middle of the sequence of 
flavoprotein hydroxylases, GD, which contacts with the riboflavin moiety of FAD [194]. 
Particularly in PHBH, this motif is localised in the re-side of the isoallaxazine ring of 
FAD, close to the substrate binding site[195]. Another short amino acid sequence motif 
for this group of enzymes, DG, was discovered in 1997 by Eppink et al. [196], and 
according to their crystallographic and site-directed mutagenesis studies of PHBH was 
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suggested to be involved in FAD binding and could also serve as the NADPH recognition 
site.   
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Figure 1.7. Multiple sequence alignment of Homo sapiens KMO with 7 structural related proteins. 
The amino acid sequences were aligned by the CLUSTAL method. 1KMO (Kynurenine 3-monooxygenase, 
Accession number NP_003670), 1PBB (P-Hydroxybenzoate Hydroxylase, Accession number 1PBB), 
2XDO (Tetracycline Degrading Monooxygenase Tetx2, Accession number 2XDO), 3ALL (2-Methyl-3-
Hydroxypyridine-5-Carboxylic Acid Oxygenase, Accession number 3ALL), 2QA1(PGAE- Aromatic 
Hydroxylase Involved In Angucycline Biosynthesis, Accession number 2QA1), 3FMW (Mtmoiv, A 
Baeyer-Villiger Monooxygenase From The Mithramycin Biosynthetic Pathway, Accession number 3FMW 
), 3C96 (Flavin-Containing Monooxygenase Phzs From Pseudomonas Aeruginosa, Accession number 
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3C96) and 1PN0 (Phenol Hydroxylase From Trichosporon Cutaneum, Accession number 1PN0). The 
boxed fragments represent the common motifs found in flavoprotein monooxygenases. 
 
 
1.3.3. Kynurenine 3-monooxygenase (KMO) 
 
KMO is categorised as a class A flavoprotein monooxygenase and, as described in 
the previous section, it is an NADPH-dependent enzyme that hydroxylates an aromatic 
substrate and contains a tightly bound FAD cofactor. It catalyses the hydroxylation at the 
C3 position of L-kynurenine into 3-hydroxykynurenine with the consumption of one 
molecule of NADPH and O2 per turnover [9, 197].  
 
 
 
 
 
 
 
Figure 1.8. Reaction catalysed by kynurenine 3-monooxygenase. L-kynurenine is hydroxylated at 
position 3 into 3-hydroxy-kynurenine in the presence of molecular oxygen and NADPH. 
 
Based on a number of spectroscopic and crystallographic studies on other 
members of this class of flavoprotein monooxygenases, it is hypothesised that the 
mechanism of action of KMO is similar to the reaction mechanism of p-hydroxybenzoate 
hydroxylase. In the reductive half-reaction, L-kynurenine binds to the oxidised KMO and 
FAD is reduced by NADPH to FADH2. In the oxidative half-reaction, the reduced L-
KYN-KMO complex reacts with dioxygen, forming the intermediate C(4a)-
hydroperoxide that quickly hydroxylates the substrate L-KYN into 3-HK and releases one 
molecule of water [198]. 
KMO (EC 1.14.1.2) was first described in 1956 and is principally localised in the 
outer membrane of mitochondria [199, 200]. It is highly expressed in liver, kidney, 
endothelial cells and monocytes and lower concentrations were also found in the brain, 
specifically in microglia and macrophages [163, 201–204]. Interestingly, no expression 
was found in astrocytes where other metabolites from the KP are produced in large 
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amounts, such as KYN and KYNA, or in neurons [205], supporting the hypothesis that 
the over-activation of microglia by mHtt induces the expression of the neurotoxic 
metabolites 3-HK and QUIN, therefore contributing to neurodegeneration. 
A number of studies have been published describing the activity of KMO from 
different organisms, in terms of substrate, coenzyme and cofactor specificity, as well as 
the proposed catalytic mechanism [206–214]. Almost all studies involving class A 
flavoproteins monooxygenases rely on the unique optical properties of the FAD cofactor. 
Since this cofactor is tightly bound in the active site, the spectral changes during catalysis 
can be monitored using rapid reaction kinetic instruments, giving valuable information 
regarding specific steps in the reaction mechanism. The binding of substrates or inhibitors 
can also be studied by spectroscopic methods, yielding dissociation constants and 
conformational changes in the active site [215]. 
The first attempts to purify KMO were carried out by Nisimoto et al. (1975). The 
enzyme was isolated from rat liver mitochondria and purified using a combination of 
anion exchange chromatography and gel filtration techniques, with phospholipids in the 
purified preparation [210, 211]. It was suggested that native KMO from this organism is 
associated with the hydrophobic region of the mitochondrial outer membrane and 
therefore, the use of detergents throughout purification was a requirement to stabilise the 
protein. Although purified protein was obtained, the yield and the specific activity was 
rather low [210, 211]. Other studies were also performed on KMO from other organisms 
such as Saccharomyces cerevisiae [212], Saccharomyces carlsbergensis [213] and 
Schistocera gregaria [214], Pseudomonas fluorescens [207] and Homo sapiens [208], 
describing methods for expression and purification of this enzyme, as well as enzymatic 
assays where some kinetic parameters were established (see Table 1.3). 
Special attention will be given to two particular studies: the first study, conducted 
by Breton et al. (2000), is one of the few studies on human KMO and therefore the only 
data available for direct comparison with the work presented in this thesis [208]. The 
second report, by Crozier-Reabe et al. (2008), was performed in KMO from 
Pseudomonas fluorescens and presents a complete and detailed study on the reaction 
mechanism of this enzyme was and has been very informative for the development of 
kinetic assays in the present work [198]. 
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Table 1.3: Kinetic parameters of KMO from different organisms 
 
 
It has proven to be very difficult to study human KMO as this enzyme is 
membrane associated and it has been extremely difficult to obtain sufficient quantities of 
protein for further characterisation [10]. The first study to produce sufficient quantities of 
this enzyme was performed by Breton et al. (2000) using recombinant human KMO 
[208]. The protein was expressed in COS-1 cells as a glutathione S-transferase (GST) 
fusion protein and purified using gluthathione-sepharose resin. The biochemical 
characterisation of the enzyme showed an optimal pH of 7.5, similar to that described for 
pig and rat liver KMO enzymes (Table 1.3), as well as similar kinetic parameters when 
compared to native KMO from other organisms. This provides evidence that the 
recombinant enzyme shows the same behaviour as KMO from tissue origin and can 
therefore be used as a main strategy to obtain adequate levels of protein for further 
biochemical and mechanistic characterisation. In the same study, different potential 
substrates were also tested and it was shown that this enzyme is highly specific to L-
kynurenine and shows a preference for NADPH as a coenzyme and FAD as a cofactor 
with both presenting a 1:1 stoichiometry. It was also hypothesised that binding of the 
enzyme with one substrate does not influence its affinity to the other [208]. Although the 
data reported in this study described an important strategy to express and purify 
recombinant human KMO, the yield obtained was still not sufficient for structural studies.  
An informative on the reaction mechanism of KMO was performed by Crozier-
Reabe et al. (2008.) The authors explored separately the reductive and oxidative half-
Source 
organism 
KM L-KYN 
(M) 
KM NADPH 
(M) 
pH- 
optimum 
Localisation References 
Pseudomonas 
fluorescens 
11.8 8.5 8.5 - [198, 207] 
Saccharomyces 
cerevisiae 
40 16 8.0 promitochondrion [212] 
Rattus 
norvegicus 
25 23 7.5-8 Mitochondrial 
outer membrane 
[9] 
Sus scrofa 16 - 8.0 Mitochondrial 
outer membrane 
[216] 
Homo sapiens 13 - 7.5 Mitochondrial 
outer membrane 
[10, 208] 
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reactions of KMO from Pseudomonas fluorescens [198]. As described in section 1.4.2.1 
(class A monooxygenases), the oxidative half-reaction of class A flavoprotein 
monooxygenases starts with the reduction of oxygen by the reduced flavin to form the 
first intermediate C(4a)-hydroperoxide.  Once formed, it will then react with the aromatic 
substrate in an electrophilic substitution reaction, and the distal oxygen is inserted 
typically in the ortho position of the activated ring, forming the hydroxylated product, 
water and the second intermediate flavin C(4a)-hydroxide, which will be hydrated to form 
the oxidised enzyme.  
Crozier-Reabe et al. (2008) have shown that the oxidative half-reaction of 
Pseudomonas fluorescens KMO is similar to the majority of class A flavoprotein 
monooxygenases with some events differing after hydroxylation of the aromatic 
substrate. According to their results, the second intermediate C4(a)-hydroxyflavin was 
not observed and it was suggested that the dehydration of  hydroxyflavin does not depend 
on the release of the product and takes place instantly after the hydroxylation of the 
aromatic substrate. One interesting result from this study is that Pseudomonas fluorescens 
KMO does not appear to be able to distinguish efficiently between the physiological and 
substrate-like molecules. They have tested two different KMO inhibitors, BA or m-NBA, 
and both had shown absorbance data similar to that observed with the native substrate L-
Kyn when mixed with dioxygen, with the formation of hydroperoxyflavin followed by a 
decay of this species and an accumulation of hydrogen peroxide and the oxidized enzyme 
without hydroxylation of the aromatic ring.  These results support the idea that the 
oxidative half-reaction of this enzyme is not fully dependent on the interaction between 
the activated ring of the substrate with the enzyme and can instead undergo the 
subsequent steps of catalysis in the presence of the wrong ligand, regardless of the fact 
that the ligand is not bound and the product is not formed [198]. The consequences of this 
mechanism might be of particular importance in terms of the therapeutic use of these 
inhibitors, since the accumulation of higher levels of hydrogen peroxide is not 
recommended as a therapeutic strategy and therefore other approaches may have to be 
pursued in order to design novel KMO inhibitors. 
In terms of the reductive half-reaction, results from the same study showed that 
the mechanism of the enzyme is the same as the majority of class A flavoprotein 
monooxygenases, with the reduction by NADPH stimulated when the aromatic substrate 
is bound. There was also evidence supporting the hypothesis of the dynamic motion of 
the flavin isoalloxazine during catalysis. This hypothesis, called “waving flavin”, has 
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been extensively studied, particularly for PHBH [190, 217, 218] and phenol hydroxylase 
(PHHY) [219] enzymes, and involves movement of the isoalloxazine ring from the active 
site towards an “out” conformation, in order to make contact with the nicotinamide ring at 
the protein surface. Crozier-Reabe et al. (2008) reported evidence for two different flavin 
states in the product release step [198]. 
Finally, an additional aspect common to class A flavoprotein monooxygenases is 
the sensitivity to anions in both the reductive and oxidative half reactions [220, 221]. As 
expected, Pseudomonas fluorescens KMO is also inhibited by anions and it was 
hypothesised that ions might bind in the vicinity of the active site and therefore influence 
the flavin reactivity [208].   
 
 
1.3.3.1. Structural features of Kynurenine 3-monooxygenase 
 
 
Despite intense research in the development of novel KMO inhibitors, there is no 
information regarding the crystal structure of KMO from any organism. The investigation 
of the binding modes of possible inhibitors in order to understand the mechanism of 
action of this enzyme has been carried out using structure and ligand-based computer-
aided design tools based on structurally and functionally related enzymes [180, 181]. 
From the multiple sequence alignment of KMO with other structurally-related proteins 
(Figure 1.7), in combination with functional studies carried out with other flavin 
monooxygenases, particularly the enzyme PHBH, there is evidence that KMO and PHBH 
are functionally related. Despite the fact that they only share 18 % identity, they are both 
NAD(P)H-dependent flavoproteins that catalyse the hydroxylation of aromatic 
compounds. The fact that the PHBH crystallographic structure is known in complex with 
the substrate and the product could be useful in predicting the interaction of KMO with its 
physiological substrate and ultimately, in the design of new inhibitors. Attempts were 
made by Pellicciari et al. (1996) to build a pseudo model of the active site of KMO based 
on PHBH [180]. It was assumed that these two enzymes have similar mechanisms and 
therefore, KMO might share the same non-covalent interactions with the substrate with a 
similar active site. The aromatic ring of the substrate L-kynurenine was forced to match 
the aromatic ring of the p-hydroxy benzoic acid. Due to the limited knowledge of the 
primary sequence of KMO at this time, the results of this study are not entirely reliable 
for the development of novel KMO inhibitors.  
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As pointed out in the previous section, there are published reports describing 
strategies for expression and purification of KMO from higher organisms, including 
humans. However, it has proven to be extremely difficult to obtain sufficient quantities of 
this enzyme for structural studies and therefore it might explain the lack of structural 
knowledge of this enzyme. A more realistic approach would be to try to optimise the 
expression levels in COS-1 cells or to overexpress recombinant KMO in lower organisms 
such as Escherichia coli, Pichia pastoris or Saccharomyces cerevisiae. 
The amino acid sequence of Homo sapiens KMO shows 74.4%, 40.6%, 34.1% 
and 31.7% identity with those of Ratus norvegicus, Drosophila melanogaster, 
Saccharomyces cereviseae and Pseudomonas fluorescens, respectively (Figure 1.9). The 
residues coloured in blue are conserved among the five species and, as previously shown 
in Figure 1.7, some of these motifs are characteristic of flavin monooxygenases that 
require NADP(H) and FAD as coenzymes. Additionally, other conserved regions can 
support the hypothesis that KMO from different organisms are functional and structurally 
related and therefore, can be used as good homology models for the study of human 
KMO. 
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Figure 1.9. Multiple alignment of the amino acid sequence of KMO from different organisms. Homo 
sapiens KMO (Accession nº NP_003670), Rattus norvegicus KMO (Accession nº NP_067604),  
Drosophila melanogaster KMO (Accession nº A1Z746), Saccharomyces cerevisiae KMO (Accession nº 
P38169), Pseudomonas fluorescens (Accession nº Q84HF5). The residues are coloured according to the 
percentage of the residues in each column that agree with the consensus sequence. The boxed fragments are 
motifs conserved among KMOs from different organisms excluding the motifs characteristics of 
flavoprotien monooxygenases. 
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1.4. RESEARCH AIMS  
 
 
There is a good deal of evidence supporting the hypothesis that the KP plays a 
critical causative role in the pathophysiology of several neurodegenerative disorders. It is 
clear that the modulation of neuroactive kynurenine metabolites, such that levels of 
KYNA are increased relative to 3-HK and QUIN, is desirable for neuroprotection. In 
particular, KMO, which lies at a critical branchpoint in the pathway, is of great interest as 
its inhibition ameliorates neurodegeneration by shifting the flux towards the 
neuroprotective branch of the KP. Despite great interest in the therapeutic potential of 
KMO inhibitors, to date none have been tested in clinical trials. The most promising 
KMO inhibitory compounds, such as Ro 61-8048, do not readily cross the blood-brain 
barrier (BBB), with at most ~1% of the drug reaching the brain, the major site of 
pathology in HD. In order to pursue KMO as a drug target for HD, it is critical to identify 
high-affinity inhibitors of KMO that readily penetrate the BBB. In order to rationally 
design novel KMO inhibitory compounds it is vital to obtain structural information for 
this protein, both native and bound to existing drugs. In addition, functional and 
mechanistic studies with wild-type and site-directed mutant versions of KMO will 
provide critical information for future drug design. However, performing these analyses 
will require large quantities of purified recombinant human KMO.  
The aim of this thesis was to produce high levels of KMO protein for structural, 
functional, and mechanistic studies, with the final goal of developing novel inhibitors 
capable of crossing the blood-brain barrier. Our aim was to develop the underpinning 
work by solving the crystal structure of KMO to allow the development of new inhibitors, 
using a knowledge-based approach that embraces X-ray crystallography and biophysical 
analysis of inhibitor binding for future synthesis, and analysis of the efficacy of new 
inhibitors in HD cell models and in HD model mice. 
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1.5. OVERVIEW 
 
Chapter 1 and 2 serve as the introduction and general materials and methods 
leading on to the research work presented in Chapters 3, 4 and 5. Finally a general 
discussion will be presented in Chapter 6 followed by conclusion and future work. 
Initial studies were focused on the generation of several expressing clones of human 
KMO (HsKMO) as both full length and truncated forms by conventional site-directed 
mutagenesis. We explored several constructs with redefined domain boundaries, by 
deleting domains that could possible lead to incorrect folding and protein insolubility in 
order to screen for suitable protein truncates that allow crystallisation. We have used 
Pichia pastoris for over-expression of recombinant HsKMO. The yeast Pichia pastoris 
has the advantage of eukaryotic expression systems with regards to protein folding, post-
translational modifications, and protein processing besides the benefit of being easy to 
manipulate. We have purified recombinant forms of HsKMO using a combination of 
traditional chromatographic methods and affinity chromatography using nickel-based 
resins. Purified enzymes were subject to detailed characterisation by biophysical and 
kinetic methods. Aside from spectrophotometric characterisation and analysis of 
recombinant HsKMO, the binding of KMO enzymes and variants to physiological 
substrate and potential KMO drugs were also performed by spectrophotometric titrations 
in order to determine dissociation constants (Kd) for further comparison with published 
results. Crystallisation trials were undertaken to obtain human KMO structures. 
Due to the difficulty in expressing full length HsKMO in Pichia pastoris, we also 
tried to over-express and purify this enzyme in insect cells using the baculovirus system. 
Since this protein is membrane associated, the expression of the full length is challenging 
in lower organisms such as Pichia pastoris because these proteins tend to be toxic for the 
host as well as the fact that the translation and chaperone systems of these organisms are 
not well adapted to the biosynthesis of human protein. In addition, eukaryotic proteins 
may undergo post-translational modifications that only higher eukaryotic cell lines 
provide the necessary machinery.  
Full length HsKMO was extracted from the host cell membrane by the addition of 
detergents to allow solubilisation. A series of detergents were tested in order to choose 
the one able to provide active, homogeneous and stable protein. Purification was also 
performed using a combination of traditional chromatographic methods and purified 
enzyme was subject to detailed characterisation by biophysical and kinetic methods. 
55 
 
Successful purification of active, detergent solubilised forms of the enzyme allowed the 
screening of crystallisation conditions for those particular KMO-detergent forms. The 
results of expression and characterisation of full length and truncated forms of HsKMO 
form the basis of Chapter 3. The poor stability and low expression yield of human KMO 
however prevented crystallisation, the details will be described in the same Chapter. We 
thus turned our attention to Saccharomyces cerevisiae KMO (ScKMO), which is highly 
related to human KMO (38 % identity and 51 % similarity). 
We overexpressed and purified ScKMO for crystallisation trials to provide a structural 
model for human KMO. The same techniques applied for HsKMO were also employed 
for the complete characterisation of ScKMO and the results will be presented in Chapter 
4. Kinetic and inhibitor studies using both human and yeast enzymes were performed in 
parallel in order to validate our model and to prove that ScKMO is a good homology 
model for the study of HsKMO. 
Established crystallisation conditions enabled us to ultimately determine the structure 
of ScKMO by Single Wavelength Anomalous Dispersion (SAD) technique utilising the 
anomalous signal from SeMet. Further work was then pursued to determine structures in 
presence of KMO substrate and drugs (Chapter 5). 
We validated our model by targeting active site residues and performed inhibitor 
binding and kinetic assays. This analysis will provide important functional verification of 
the importance of residues to inhibitor binding inferred from the structural studies. These 
results will be shown in Chapter 5.  
A number of strategies to further elucidate the mechanism of KMO catalysis and 
future structural work will be suggested in Chapter 6 followed by final conclusions. 
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CHAPTER 2 
GENERAL MATERIALS AND METHODS 
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2. GENERAL MATERIALS AND METHODS 
 
2.1. MATERIALS 
 
All chemicals and reagents were purchased from Sigma-Aldrich and Fisher Scientific 
unless otherwise stated and were of the highest grade available.  
Restriction endonucleases and other DNA modifying enzymes were purchased from 
New England Biolabs.  
E. coli and Pichia pastoris growth media were obtained from Formedium, High-Five 
(Hi5) cells were cultured in Express five SFM media from Invitrogen.  
As the expression of kynurenine 3-monooxygenase was carried out in three different 
hosts, each one with specific strains, plasmids, reagents, buffers and antibiotics, the 
description of the materials used in each procedure will be reported in each of the 
methodology sections. 
 
 
2.2. METHODS 
 
 
2.2.1. Protein Engineering and Primer Design 
 
 
2.2.1.1. Human full-length and truncated kynurenine 3-monooxygenase 
for expression in Pichia pastoris 
 
Full-length human kynurenine-3-monooxygense (KMO UniProtKB accession 
number O15229) was ‘codon optimised’ by Qiagen for overexpression in eukaryotic 
cells. Deletion mutants (KMO383 and KMO423) were constructed by the 
manipulation of the full-length gene and named so that the last residue before the 
truncation is indicated. The KMO gene was used as a template in the PCR reaction; the 
forward and reverse primers are shown in Table 2.1. Primers contained the restriction 
cloning sites EcoRI and XbaI at the 5’ and 3’ ends, respectively. As these constructs will 
be expressed in Pichia pastoris, the insert might contain the initiation codon as a part of a 
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yeast consensus sequence (G/A)NNATGG [222] for proper initiation of translation in the 
this host and therefore the fragment GTC was inserted before the start codon. 
 The constructs were amplified, digested with EcoRI and XbaI and inserted into 
pPICZ-B vector (Invitrogen) for expression of recombinant KMO protein with a C-
terminal polyhistidine (6xHis) tag in Pichia pastoris. Amplification conditions were 98°C 
for 30 s, 30 cycles of 98°C for 10 s and 72°C for 45 s followed by a final polymerization 
step of 72°C for 10 min. The vector was pre-treated with calf intestinal alkaline 
phosphatase (New England BioLabs) and digested with the same restriction enzymes. 
The purified PCR product and pre-treated vector were self-ligated with QuickLigation Kit 
(New England BioLabs) and used for transformation into XL10-Gold Ultracompetent 
Escherichia coli cells (Agilent) in Low Salt Lisogeny Broth (LB) medium containing 25 
g/mL zeocin. Successful transformants were isolated and submitted for DNA 
sequencing by MWG Eurofins using the following forward (5’AOX) and reverse 
(3’AOX) primers: 5’- GAC TGG TTC CAA TTG ACA AG 3’,  3’- GCA AAT GGC 
ATT CTG ACA TCC. The maintenance of plasmid DNA stocks and the genes of interest 
for protein engineering methods were done using either E. coli strains XL-1 Blue 
(Strategene) or Novablue (Novagen) super competent cells using the QIAprep® Spin 
Miniprep Kit (Qiagen) and stored at -20°C until further use.  
 
Table 2.1.  KMO constructs cloned into pICZ-B vector for overexpression Pichia 
Pastoris 
1KMO constructs were cloned into pPICZ-B vector for expression of recombinant KMO protein with N-
terminal polyhistidine (6xHis) tag in Pichia pastoris. The letters in bold indicate the engineered EcoRI and 
XbaI restriction cloning sites in the forward and reverse primers, respectively. The underlined letters 
indicate the yeast consensus sequence. KMO deletion mutants were named so that the last residue before 
the truncation is indicated. 
 
 
KMO constructs1 Sense primer Anti-sense primer 
KMO-His6 5’-G GCC GAT TTC GTC ATG GAC AGC AGC GTG 
ATC CA-3’ 
5’-GGC CGC TCT AGA CCG GCT GAT CAG GTT 
GCT-3’ 
 
KMO383-His6 The same as above 
5’-GGC CGC TCT AGA GTT GAT CAC TTT TTT CTG 
C-3’ 
 
KMO423-His6 The same as above 
5’-GGC CGC TCT AGA CCG TTC CAT GTT TTT CTG-
3’ 
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2.2.1.2. Human full length Kynurenine monooxygenases for expression 
in Insect cells 
 
 The gene encoding full-length human kynurenine-3-monooxygense was 
synthesised by Genscript (Piscataway, NJ, USA) and was ‘codon optimised’ for 
overexpression in mammalian cells. The gene was sub-cloned into the pAcGHLT-A GST 
baculovirus transfer vector (BD Biosciences) as an NdeI - EcoRI fragment for 
overexpression in insect cells using the following forward and reverse primers: 5’-GGC 
ATA TGC ATG GAC AGC AGC GTG ATC CAG CGG AAG-3’; 5’-CCC GAA TTC 
CTA CCG GCT GAT CAG GTT GCT G-3’. 
Nucleotide C was inserted between the restriction sites and the gene specific 
region to ensure the expressed protein was in frame. Amplification conditions were 98°C 
for 30 s, 30 cycles of 98°C for 10 s and 72°C for 45 s followed by a final polymerization 
step of 72°C for 10 min. PCRs were carried out in a Techne PHC-2 thermal cycler using 
Phusion High Fidelity DNA polymerase (Fynnzymes). The purified PCR product and 
pre-treated vector were self-ligated with QuickLigation Kit (New England BioLabs) and 
used for transformation in XL10-Gold Ultracompetent Escherichia coli cells (Agilent). 
Successful transformants were isolated and submitted for DNA sequencing by MWG 
Eurofins. The maintenance of plasmid DNA stocks were carried out as described in the 
previous section. 
 
 
2.2.1.3. Saccharomyces cerevisiae Kynurenine 3-monooxygenase for 
expression in E. coli 
 
Synthetic kynurenine 3-monooxygenase gene (BNA4 UniProtKB accession 
number P38169) from Saccharomyces cerevisiae was ‘codon optimised’ for 
overexpression in E. coli by Genscript. The gene was excised from the vector using NdeI 
and Xba I restriction enzymes and sub-cloned into pET15b (Merck) and pET24b (Merck) 
vectors pre-digested with the same restriction enzymes, for expression of recombinant 
KMO with N- and C-terminal His6-tags, respectively. The gene fragment and pre-treated 
vectors were self-ligated with QuickLigation Kit (New England BioLabs) and used for 
transformation into XL10-Gold ultracompetent Escherichia coli cells (Agilent). 
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Successful transformants were isolated and submitted for DNA sequencing by MWG 
Eurofins. 
ScKMO deletion mutants (named so that the last residue before the truncation is 
indicated) and single amino acid changes (named KMO, KMO-R83A and 
KMO-R83M) were generated using the Stratagene Quickchange site-directed 
mutagenesis kit. Forward and reverse primers are shown in Table 2.2. Amplification 
conditions were 95°C for 30 s, 16 cycles of 95°C for 30 s and 55°C for 1 min and 68°C 
for 7 min. PCR products were incubated for 1 hour to digest the methylated template 
DNA and transformed into XL1-Blue supercompetent cells (Stratagene). Successful 
transformants were isolated and submitted for DNA sequencing by MWG Eurofins to 
verify the presence of the desired mutations. The maintenance of plasmid DNA stocks 
were carried out as described in Section 2.2.1.2. 
 
Table 2.2. ScKMO deletion and single amino acid changes mutants were cloned into 
pet15b vector for overexpression E.coli. 
BNA4 constructs Sense primer Anti-sense primer 
KMO394 5'- C AAA AAA CTG GAC GCT TAG CTG 
TTC AGT ATC ATC -3' 
5’-GAT GAT ACT GAA CAG CTA AGC GTC CAG TTT TTT 
G- 3' 
KMO394-R83A 5'-G ATC CCG ATG AAA GGC GCT ATG 
ATC CAC GAT CTG-3’ 
5'-CAG ATC GTG GAT CAT AGC GCC TTT CAT CGG GAT 
C-3'   
KMO394-R83M 5'-C ATG ATC CCG ATG AAC ATG ATG 
ATC CAC GAT CTG AAA G-3' 
5'-C TTT CAG ATC GTG GAT CAT CAT GCC TTT CAT 
CGG GAT CAT G-3' 
The letters in bold in the forward and reverse primers indicate an engineered stop codon for the deletion 
mutant KMO394. Mutated nucleotides to change amino acid are underlined in the forward and reverse 
primers 
 
 
2.2.2. Agarose  Gel Electrophoresis 
 
Agarose gels (1 %) were used to visualise and separate DNA, specifically PCR 
products, digested fragments and vectors. 1 % (w/v) agarose was resuspended in 1 x TAE 
buffer and heated until the agarose was dissolved, followed by addition of 1.2 g/mL 
ethidium bromide. The mixture was finally poured into a gel cast and allowed to solidify. 
DNA samples were mixed with 6 x loading dye (Fermentas) in volumes depending on the 
concentration of DNA. Samples were loaded into the wells along with 1 kb DNA ladder 
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(Fermentas) and the gels were run with a Sub-Cell GT system (BioRad) at 80 V for 40 
min or until the loading dyes were clearly separated. The gels were visualised using a 
GENE FLASH Syngene Bio Imaging system and the gel was photographed using a 
Computar H6Z0812 lens attached to a Sony UP-895MD printer. 
 
 
2.2.3. Protein Expression 
 
 
2.2.3.1. Expression in Pichia Pastoris 
 
Large-scale preparation of DNA from XL10-Gold ultracompetent Escherichia coli 
cells were performed using the QIAprep Spin Maxiprep Kit (Qiagen) to obtain 10 g of 
the relevant constructs and linearised overnight with the restriction enzyme PmeI (New 
England BioLabs). Pichia pastoris strain SMD1168H (Invitrogen) was transformed with 
the linearised construct by electroporation, according to the Invitrogen protocol (Catalog 
no. V190–20), and grown on YPDS agar plates (1 % yeast extract, 2 % peptone, 1 M 
sorbitol, 2 % Agar and 2 % glucose) containing 100 g/ml zeocin for 3-4 days at 30ºC or 
until colonies were formed. Positive integrants were selected in a zeocin dose-dependence 
and used for preliminary expression trials. Glycerol stocks from each transformant 
containing the plasmid of interest were maintained for long-term storage. 
  
         Expression trials were carried out to find optimal protein expression conditions. 
Ideal conditions were chosen based on immunodetection of soluble protein using the 
KMO polyclonal rabbit antibody (Proteintech). Cells were grown in Buffered Glycerol 
complex Medium - BMGY (1 % yeast extract, 2 % peptone, 1 M potassium phosphate pH 
6.0, 10 % Glycerol 0.002 % Biotin and 13.4 % ammonium sulphate without amino acids) 
for 18-20 hours at 30ºC to generate a high number of cells before harvesting. The cells 
were resuspended in Buffered Methanol Complex Medium - BMMY (the same 
components as BMGY with the exception that the glycerol was replaced by 0.5 % 
Methanol) for protein production and grown under the same conditions for a further 24 
hours in 2 L baffled flasks. Cells were harvest by centrifugation and the cell pellet stored 
at -20ºC. 
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2.2.3.2. Expression in Insect cells 
 
Baculovirus transfer vector pAcGHLTA:KMO was co-transfected into High-Five 
(Hi5) cells cultured in Express five SFM media (Invitrogen) along with linearised 
baculovirus DNA (Oxford expression technologies - cathepsin deleted strain) and the 
recombinant virus generated was amplified to a high titre stock in Hi5 cells. Test 
expressions were carried out by varying the virus concentration (MOI – multiplicity of 
infection) and times of incubations. After incubation, the plates were processed to 
generate samples for SDS-PAGE, small-scale glutathione sepharose purification and 
Western blotting. 
10L Cellbag- disposable bioreactors (GE Healthcare) were used to scale up for 
insect cell infection. The Cellbag was filled with 0.5 L of Express five SFM media 
followed by inoculum in order to give a starting cell count of approximately 0.5-0.6 x 106 
cells/mL. The Wave bioreactor system (GE Healthcare) was set at 28ºC, rocking speed of 
16 rpm and an angle of 7º. After 2-3 days, or when the cell density reached 4 x 106 
cells/mL, 2.5 L of fresh media was added and the process was repeated again for 2-3 
more days to reach the same cell density. 2.5 L of media was added to bring the total to 5 
L, together with the concentrated virus. The speed was increased to 28 rpm and the angle 
to 9º and the culture was kept for 3-4 days after adding the virus to the cells. The cells 
were then harvested at 3.000 rpm for 10 min, the pellets were snap frozen and kept at -
80ºC. The stock virus was maintained for 1 month at 4oC and re-amplified after that 
period. 
 
 
2.2.3.3. Expression in Escherichia coli 
 
The relevant ScKMO constructs were expressed in E. coli BL21(DE3) (Merck) 
under control of the T7 RNA polymerase promoter in pET15b and pET24b vectors. 
Transformed cells were grown in Lisogeny Broth (LB) media (Fermentas) with 
appropriate antibiotics overnight at 37ºC and used for the inoculum of 10 L of LB 
medium, which was divided into 750 mL cultures in 2 L conical flasks. Cultures were 
grown at 37ºC to an optical density at 600 nm of ~0.3 and the temperature was reduced to 
27ºC. Cells were induced by the addition of 0.1 mM isopropyl -D-thiogalactopyranoside 
(IPTG) and grown (16-20 h) at 27ºC before being harvested by centrifugation and stored 
63 
 
at -20ºC. Expression host strain BL21(DE3) and plasmid maintenance strains XL-1 Blue 
and Novablue were maintained on LB Agar plates at 4ºC for short term stocks. 
 
 
2.2.4. Protein Purification 
 
 
2.2.4.1. Human full-length and truncated kynurenine 3-monooxygenase 
expressed in P. pastoris 
 
Cell pellet from was thawed at room temperature and resuspended in buffer A (20 
mM potassium phosphate buffer pH 7.5, 10 % glycerol, 300 mM NaCl and 50 M FAD) 
containing protease inhibitors. Cells were lysed by sonication on ice (20 s bursts at 40 % 
amplitude on a Bandelin Sonopolus instrument, with 40 seconds time between pulses for 
20 minutes). Cell debris was removed by centrifugation at 18.000rpm for 30 min. 
Soluble lysate was loaded onto a 5 mL HisTrap FF Ni Sepharose 6 Fast Flow 
column (GE Healthcare) pre-equilibrated with buffer A. Protein was eluted with a 50-250 
mM imidazole linear gradient. Yellow fractions containing partially purified KMO were 
pooled and diluted 10 times in buffer B (20mM phosphate buffer pH 7.5, 10 % glycerol, 7 
mM mercaptoethanol) to reduce the salt and imidazole concentrations.  
Protein was subsequently loaded onto a 10 mL Blue Sepharose 6 fast flow column 
(GE Healthcare) equilibrated with buffer B. The protein was eluted using a linear gradient 
to 2.5 M NaCl prepared in buffer B. Fractions containing HsKMO were pooled and 
diluted 10-fold in buffer B to reduce the NaCl concentration. Protein was concentrated 
and chromatographed using a Superdex 200 10/300 GL (GE Healthcare) equilibrated with 
buffer C (50mM BisTris pH 6.5, 150 mM NaCl, 4 mM DTT). Pure fractions were 
collected and stored at -80ºC. The purity of the final fractions were analysed by SDS-
PAGE and samples for crystallogenesis were concentrated to 12 mg/mL. 
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2.2.4.2. Human full length kynurenine 3-monooxygenase expressed in 
insect cells 
 
Cell pellet was thawed at room temperature and resuspended in buffer A (20 mM 
potassium phosphate buffer pH 7.5, 10 % glycerol, 150 mM NaCl, 7 mM -
mercaptoethanol, 50 M FAD,  supplemented with protease inhibitors PMSF (Sigma-
Aldrich). Different detergents were tested to solubilise KMO. Cells were lysed by 
sonication on ice (10 seconds bursts at 20 % amplitude on a Bandelin Sonopolus 
instrument, with 1 minute time between pulses for 5 minutes) and cell debris was 
removed by centrifugation at 15.000 rpm for 30 min. 
The effect of a number of various detergents, which have previously been 
successful in producing crystals of membrane proteins (Table 2.3), were investigated in 
the extraction and purification of HsKMO. The amount of detergent used during 
extraction and purification procedures was chosen based on the critical micelle 
concentration (CMC) for each detergent. In general, a detergent must be used at 
concentrations above its CMC in order to act as an effective solubiliser [223]. Dot-blot 
analysis with human anti-KMO antibody of HsKMO soluble lysate was performed using 
the detergents stated in Table 2.3. This technique differs from the Western blot because 
the protein samples are not separated electrophoretically. The samples were applied 
directly on a membrane (as a dot) and were detected with anti-KMO antibody. 
 
 
Table 2.3. Selection of detergents used to solubilise human kynurenine 3-
monooxygenase.  
 
 
 
 
 
 
 
 
 
Detergent name CMC (mM) [224, 223] 
Triton X-100 0.17-0.3 
CHAPS 8 
Fos-choline 12 1.5 
n-Dodecyl-maltoside(DDM) 0.17 
LDAO 1.7-2.2 
n-octyl--D-glucoside 25 
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Soluble lysate was incubated in a batch for 3 hours with 3 mL pre-equilibrated 
glutathione uniflow resin (Clontech). The resin was then packed and washed with buffer 
B. 0.5 mL fractions were eluted with buffer C (buffer B + 33 mM glutathione) and 
fractions containing GST-KMO were pooled, concentrated and loaded onto a  Superdex 
200 (10/30) size exclusion chromatography column (GE Healthcare) equilibrated with 
buffer D (20 mM Hepes pH 7.5, 5 % glycerol, 150 mM NaCl, 7 mM -mercaptoethanol, 
50 M FAD and 0.012 % DDM). The GST part of the fusion protein was cleaved from 
HsKMO by overnight incubation and gentle shaking with thrombin (1 unit/100 g of 
protein) before size exclusion chromatography. Pure GST-HsKMO or cleaved HsKMO 
were pooled and stored at -80ºC. The purity of final fractions were analysed by SDS-
PAGE. 
 
 
2.2.4.3. Saccharomyces cereviseae kynurenine 3-monooxygenase 
expressed in E.coli 
 
The protocol described in Section 2.2.4.1 was followed to purify ScKMO. Protein 
was concentrated and passed down a Superdex 200 10/300 GL (GE Healthcare) 
equilibrated with buffer C (25 mM Amonium Acetate pH 7.0, 150 mM NaCl, 7 mM 2-
mercaptoethanol). Pure fractions were collected and stored at -80ºC. Samples for 
crystallogenesis were concentrated to 14 mg/mL. The His-tag was cleaved from ScKMO 
by overnight incubation with thrombin (1 unit/1 mg of protein) with gentle shaking before 
loading onto the 10 mL Blue Sepharose 6 fast flow column. 
 
 
2.2.5. SDS-PAGE  and Gel staining 
 
For protein purification analysis, the RunBlue (Expedeon) electrophoresis system 
(Invitrogen) with 12 % RunBlue pre-cast gels was used at 180 V for 45 min. Broad range 
prestained protein marker  between 7-175 kDa (P7708V, New England BioLabs) was 
used in each run. Otherwise, SDS-polyacrylamide gels were made with 5 % and 12.5 % 
polyacrylamide for resolving and stacking gels respectively. Gels were run in a Mini-
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Protean III gel system (BioRad) at 180 V for 1 hour. Gels were stained with Comassie 
stain InstantBlue (Expedeon). 
 
 
2.2.6. Protein identification – MALDI and Western Blotting 
 
Purified proteins were identified by trypsin-digest and MALDI-TOF peptide 
identification using the software Mascot (Matrix Science). The results were first matched 
against a set of sequences limited to the sample species using the Uniprot database and 
also against the generic database SwissProt to identify any contaminants within the 
sample. This technique was carried out in the Protein Mass Spectrometry Core Facility 
(University of Manchester) by Dr. Emma Jayne Keevil. 
Expressed and purified proteins were also identified by Western Blotting, using 
either His-tag monoclonal (Invitrogen) or rabbit KMO polyclonal (Proteintech) primary 
antibodies. PVDF membranes were used and proteins from the SDS-PAGE gel were 
transferred to the membrane in a XCell IITM Blot Module (Invitrogen) at 30 V for 1 hour 
and then processed according to the WesternBreeze chemiluminescent imunodetection kit 
(Invitrogen) protocol. After blotting, membranes were washed 2 times with water for 5 
min, incubated with the blocking solution (Invitrogen) for 30 min followed by 1 hour 
incubation with the primary antibody solution. At that point, the membranes were washed 
with antibody washing solution and incubated with the appropriate secondary antibody 
(anti-mouse or anti-rabbit depending on the primary antibody used) for 30 min followed 
by a final wash with washing solution. Finally, the membranes were washed with water 
and incubated with chemiluminiscent substrate solution for 5 min. The PVDF membrane 
was exposed to an X-ray film (X-OMAT AR, KODAC) for 30 seconds to 2 minutes in a 
dark room and scanned using the X-ray film processor (Minimedical -90, ImageWorks). 
 
 
2.2.7. UV/visible spectroscopy 
 
UV/Visible absorption spectra were recorded on a Cary UV-50 Bio UV/Visible 
scanning spectrophotometer (Agilent Technologies) using 1 cm path length quartz cells. 
Assuming a single binding site of FAD per KMO active site, the protein concentration 
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was estimated based on the extension coefficient for free FAD at the wavelength 
maximum for the isoalloxazine ring of the flavin at 450 nm (11,300 M–1 cm–1). 
The dependence of the observed rate constant for reduction of KMO on the 
concentration of NADPH were conducted spectroscopically by mixing anaerobically 20 
M KMO with 500 M of L-KYN and different concentrations of NADPH (10M – 
20mM) and monitoring the absorbance changes of the FAD at 450 nm to get an apparent 
rate constant depending on the concentration of NADPH.  
 
 
2.2.8. Kinetic Analysis 
 
Steady-state kinetic parameters for KMO were obtained by initial rate measurements 
of enzyme activity. KMO catalyses the NADPH-dependent hydroxylation of L-
kynurenine to 3-hydroxykynurenine and the enzymatic reaction can be monitored by 
following the decrease in absorbance of NADPH at 340 nm. Activity assays were carried 
using a 1 cm path length quartz microcuvette (Starna Scientific) at 37ºC for HsKMO and 
30ºC for ScKMO. 0.2 - 1 M of pure enzyme was added to 200 l reaction buffer (20 
mM potassium phosphate pH 8.0-8.5, 7 mM -mercaptoethanol) containing different 
concentrations of NADPH and L-kynurenine (Sigma-Aldrich) and the time-dependent 
absorbance change at 340 nm was recorded using a UV-vis Cary 50 spectrophotometer 
(Agilent Technologies). Assays at each reaction condition were performed in triplicate. 
Apparent Michaelis constants, Km, for L-kynurenine and NADPH were determined by 
varying the concentration of the first substrate at a constant concentration of the second 
substrate and vice versa. Reaction data were fitted to the standard Michaelis-Menten 
equation using Origin Software (OriginLab, Northampton, MA). 
 
                                                                                                                       (1) 
 
where  is the reaction rate, kcat the maximum turnover rate and Km the Michaelis-Menten 
constant. 
 
Assays of the pH dependence were conducted as previously described with 200 
M of L-KYN, 200 M NADPH and 20 mM MES, 20 mM HEPES and 20 mM CAPS 
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buffer at varied pH. The buffer was titrated with H2SO4 and NaOH to a range of pH 
values (5.0-10.0). Temperature dependence and its effect on the stability of the enzyme 
was also studied by following the decrease in absorbance of NADPH at 340 nm using 
buffer at different temperatures (10-50 °C)  Data for the temperature dependence was 
fitted to a Gaussian curve (Equation 2) and the pH profile was fitted to the two 
macroscopic pKa value equation (Equation 3). 
 
                                                                                              (2)                                                                                       
 
where µ is the mean of the distribution and σ is the standard deviation. 
 
                                         (3)                                                    
 
where Amax is the maximum enzyme activity, pKa and pKb the negative log of the acid and 
base dissociation constants. 
 
 
2.2.9. Product Analysis by HPLC 
 
Kinetic analysis was alternatively monitored by following the formation of the 
product 3 hydroxykynurenine by C18 reversed-phase HPLC. 0.2 - 1 M of pure enzyme 
was incubated in 200 l reaction buffer (20 mM potassium phosphate pH 8.0-8.5, 7 mM 
-mercaptoethanol) containing different concentrations of NADPH and L-kynurenine 
KMO inhibition by the potential KMO drug UPF 648 (supplied by Dr. Flaviano Giorgini, 
University of Leicester) was also measured by product analysis quantification. Enzyme 
(100nM) was incubated at 30-37ºC in 1 mL reaction buffer (20 mM potassium phosphate 
buffer pH 8.5, 7 mM -mercaptoethanol) containing 2 mM NADPH, 500 M L-KYN and 
different concentrations (0-2M) of the inhibitor UPF 468. The reaction was stopped with 
8 % trifluoracetic acid at different time points during the assay. Precipitated protein was 
removed by centrifugation and the supernatant was analysed by C18 reversed-phase HPLC 
equilibrated with 50 mM ammonium acetate, pH 3.0, containing 1 % methanol and 0.1 % 
heptanesulfonic acid; elution from the column was with 50 mM ammonium acetate, pH 
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4.5, containing 5 % methanol and 0.5 % heptanesulfonic acid, and monitored at 229 nm. 
3-hydroxykynurenine was quantified by comparison with a 3-hydroxykynurenine 
calibration curve. Each experiment was performed in triplicate. The data was fitted to the 
Morrison equation (Equation 4): 
 
                                                            (4) 
 
where υ0 is the enzyme activity without inhibitor, υi is the enzyme activity ligand 
concentration I, [E] is the enzyme concentration, [I] is the inhibitor concentration and Ki 
is the inhibition constant. 
 
2.2.10. Fluorescence spectroscopy  
 
Fluorescence emission measurements were performed using a Cary Eclipse 
Fluorimeter  (Agilent Technologies) in order to determine dissociation constants (Kd) for 
KMO / inhibitors by ligand perturbation of the flavin fluorescence. The exciting light was 
provided from a xenon light source and excitation and emission slit widths were 5 nm. 
Fluorescence emission spectra were recorded from 470 to 700 nm using an excitation 
wavelength of 450 nm. The perturbation in FAD fluorescence was monitored at 520 nm 
upon titration of L-kyn and UPF 648 into 5 M KMO (20 mM KPi pH 8, 50 mM NaCl 
and 7 mM -mercaptoethanol) at 25ºC. Kd values were calculated by fitting plots of the 
relative difference in emission between KMO-ligand complex and free KMO at 520 nm 
versus the ligand concentration to equation 5 This equation is a variation of the Morrison 
equation (Equation 2) and is used for tight binding ligands or when Kd values are similar 
in magnitude to the concentration of enzyme used, in which case substantial amounts of 
both enzyme (E) and ligand (S) are consumed in the ES complex as the titration 
progresses. All data fitting was done using Origin software (OriginLab, Northampton, 
MA).  
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                                                                 (5) 
 
where Eobs represents the fluorescence emission difference at each ligand titration X, Emax 
the maximal emission change at saturating ligand concentrations, [E] the enzyme 
concentration, Kd the dissociation constant for the ligand bound to the protein.  
 
 
2.2.11. Stopped-Flow Spectroscopy 
 
The kinetics of the reductive and oxidative half reactions of KMO was monitored 
separately using an Applied Photophysics SX18 MVR stopped-flow spectrophotometer in 
an anaerobic glove box (Belle Technology) to maintain oxygen levels below 2 ppm. 
Multiple wavelength data were collected using a photodiode array (PDA) detector and 
single wavelength data were recorded using a photomultiplier tube detector. 
The reductive half-reaction was initiated by anerobically mixing the oxidised enzyme 
with NADPH at 15ºC. One syringe of the stopped-flow apparatus was filled with 20 M 
anaerobic enzyme in 20 mM potassium phosphate buffer pH 8.0, 50 mM NaCl and 7 
mM-mercaptoethanol and the other syringe with different concentrations of anerobic 
NADPH (10 M - 20 mM). All experiments were carried out with anaerobic buffer 
saturated by extensive bubbling with N2 gas. After mixing both solutions in the stopped-
flow apparatus, the absorbance decrease at 450 nm was used to measure the reduction of 
the flavin cofactor. All measurements were repeated at least 3 times, and transients were 
analysed by fitting to a standard single or double-exponential functions using Spectra 
kinetics software (Applied Photophysics), to generate apparent rate constants (kobs).  The 
same experiments were conducted with saturated concentration of L-KYN and KMO 
inhibitor UPF 648 in order to compare reduction rate constants with the free enzyme. 
The concentration dependence of kobs was analysed by fitting to equation 6 to obtain 
values for the apparent dissociation constant (Kd) for the enzyme-substrate complex:  
 
                                                                                                                   (6) 
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where kobs is the observed rate constant at each NADPH concentration and kmax is the 
maximum rate constant as [NADPH] approaches infinity. 
 
 
The oxidative half-reaction of KMO was studied by mixing the reduced enzyme-
substrate complex or free enzyme with molecular oxygen in the stopped-flow 
spectrophotometer. 20 M anaerobic enzyme in 20 mM potassium phosphate buffer pH 
8.0, 50 mM NaCl and 7 mM-mercaptoethanol was reduced by titration with a solution 
of anaerobic sodium dithionite. One syringe was then filled with the reduced enzyme in 
complex with saturating concentrations of L-kynurenine and the other syringe with air-
saturated buffer and the oxidative half-reaction was monitored at 450 nm. The 
dependence of the oxidation rate on O2 concentration was determined by mixing the 
reduced KMO sample  with 20 mM potassium phosphate buffer pH 8.0, 50 mM NaCl and 
7 mM-mercaptoethanol containing varying concentrations of O2 (0-1.3 mM from a 1.3 
mM O2-saturated stock solution) in the stopped-flow instrument. The oxygen-saturated 
buffer was prepared by bubbling dioxygen gas through the buffer solution for 10 
minutes.All measurements were repeated at least 3 times, and transients were analysed by 
fitting to a standard single or double-exponential functions to generate apparent rate 
constants (kobs).  
 
 
2.2.12. Thermofluor Assay 
 
A variety of buffers and additives were investigated using the Thermofluor Assay 
technique in order to maximise protein stability and assist in the protein crystallisation. 
Experiments were performed using a Bio-Rad CFX96 real-time system C100 thermal 
cycler (BioRad Laboratories). Measurements were performed using excitation and 
emission wavelengths of 490 and 575 nm, respectively. Unfolding curves were generated 
using a temperature gradient from 15 to 95°C, by performing a fluorescence measurement 
every 0.2°C. Fluorescence was measured and plotted against temperature in order to 
determine the melting temperature (Tm), which is calculated in the Thermofluor software 
Tm based on the minimum inverted first derivative curve. 
Solutions of 7.5 l of 300 X Sypro Orange (Molecular Probes), 12.5 l of 2 X test 
compound buffer (Jena Bioscience) – see Table 2.4A for components of JBS solubility 
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kit) and 2.5 l of 10 mg/ml protein were  mixed directly into the wells of a 96-well thin-
wall PCR plate (Bio-Rad Laboratories). Control samples were run alongside. The optimal 
buffer conditions were selected based on the Tm calculated and used for further screening 
using the additive kit from JBS solubility kit, shown in Table 2.4B. 
 
Table 2.4. JBS Solubility Kit. A - Buffer kit (100 mM), B: Additive kit. 
A                                                                            B 
 
                      
 
 
                    
                                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nº Buffer pH 
1 Glycine 3.0 
2 Citric Acid 3.2 
3 PIPPS 3.7 
4 Citric Acid 4.0 
5 Sodium Acetate 4.5 
6 Sodium/ Potassium 
Phosphate 
5.0 
7 Sodium Citrate 5.5 
8 Sodium/Potassium 
Phosphate 
6.0 
9 Bis-Tris 6.0 
10 MES 6.2 
11 ADA 6.5 
12 Bis-Tris Propane 6.5 
13 Ammonium Acetate 7.0 
14 MOPS 7.0 
15 Sodium/Potassium 
Phosphate 
7.0 
16 HEPES 7.5 
17 Tris 7.5 
18 EPPS 8.0 
19 Imidazole 8.0 
20 Bicine 8.5 
21 Tris 8.5 
22 CHES 9.0 
23 CHES 9.5 
24 CAPS 10 
Nº Additive Concentration of 
stock solution 
1 Sodium Chloride 80 mM 
2 Sodium Chloride 200 mM 
3 Sodium Chloride 400 mM 
4 Glycerol 20% 
5 Glycerol 40% 
6 CHAPS 8mM 
7 Octyl Glucopyranoside 0.4% 
8 Octyl Glucopyranoside 4% 
9 Dodecyl Gluocoside 0.4% 
10 Dodecyl Gluocoside 4% 
11 BME 40 mM 
12 DTT 4 mM 
13 DTT 20 mM 
14 TCEP 120 mM 
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2.2.13. MultiAngle Laser Light Scattering (MALLS) 
 
Pure samples of KMO (250 L of 2 mg/mL) in 20 mM potassium phosphate 
buffer pH 7.5 300 mM NaCl, 7 mM -mercaptoethanol were applied to a Superdex 200 
gel filtration column (GE Healthcare) at a flow rate of 0.71 mL/min. Eluted samples were 
passed through a DAWN-EOS MALLS spectrometer (Wyatt Technology corp.) detector 
with an Optilab rEX refractometer (Wyatt Technologies) and a quasi-elastic light 
scattering (QELS) detector (Wyatt) to measure the refractive index and the hydrodynamic 
radius (Rh) values, respectively. Data were collected at a 1 second interval rate using a K5 
cell type and a laser wavelength of 690 nm. The average molecular weight (Mr) of the 
sample was calculated using the software ASTRA v5.21 (Wyatt Technology Corporation) 
based on the light scattering intensity and eluant refractive index. MALLS experiments 
were performed by Mrs. Marjorie Howard at the Biomolecular Interactions Facility in 
University of Manchester. 
 
 
2.2.14. Structure Determination 
 
 
2.2.14.1. Crystallisation 
 
Initial crystallisation trials were conducted using the commercial screens JCSGI and 
II (Qiagen), Clear Strategy I and II, PACT Premier and Morpheus (Molecular 
Dimensions) using 96-well crystallography trays. Pure proteins for crystallogenesis were 
passed through a Superdex 200 10/300 GL (GE Healthcare) gel filtration column to 
exchange the protein to the optimal buffer according to the conditions obtained in the 
Thermofluor Assays.  The protein was concentrated and made up to 10-15 mg/mL.  
200nL KMO protein or protein-ligand samples were added 1:1 to mother liquor from 
screens using a Phenix Crystal protein dispenser (Art robbins Instrument) to form sitting 
drops. Prior to setting the trays the protein was pre-incubated with ligands for ~30 
minutes. Ligand concentrations equal to the protein concentration plus an amount equal to 
10 x the dissociation constant were used to assure saturation. Protein conditions that were 
conducive for crystal growth were selected for further optimisation and potentially 
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successful buffer conditions were reproduced in 96-well manual trays with minimal 
variations so that optimal conditions for crystal growth could be achieved. 
The trays were covered with crystal clear tape (Manco® Inc.) and stored in a 
vibration-protecting refrigerator at 277 K over a period of ~72 h. Crystals and co-crystals 
were harvested with PEG 200 as a cryoprotectant and immediately flash frozen in liquid 
nitrogen and transported to the Diamond Synchrotron (Harwell, UK) for X-ray diffraction 
analysis.  
 
 
2.2.14.2. Diffraction data processing, Structure determination and 
refinement 
 
Diffraction data were collected from single cryofrozen crystals at Diamond, Harwell, 
UK and processed by  Dr. Colin Levy and Professor David Leys (University of 
Manchester). The data were scaled and integrated using XDS[225]. The Single-
wavelength Anomalous Dispersion (SAD) technique utilizing the anomalous signal from 
SeMet was employed for initial phase determination.  
Expression of selenomethione labelled protein was achieved by inhibiting the 
methionine biosynthesis shortly before induction of KMO expression by adding high 
concentrations of isoleucine, leucine, phenylalanine, lysine and threonine to the cell 
culture. Transformed E. coli cells containing the Saccharomyces cerevisiae KMO 
expression plasmid were grown in LB media at 37ºC to late exponential phase, harvested 
and then re-suspended in M9 minimal media and grown until mid-log phase. At that point 
lysine, phenylalanine, threonine (100 mg/L each), and selenomethionine, isoleucine, 
leucine, and valine (50 mg/L each) were added to the culture and induced 15 min after 
addition of amino acids with 0.1 mM IPTG. The culture was grown for 12-16 hours. 
Purification of selenomethionine incorporated Saccharomyces cerevisiae KMO was as 
described for conventional Saccharomyces cerevisiae KMO using degassed buffers. 
Initial phases were obtained from a single SAD data set collected at the selenium 
edge. Selenium sites were located using Phenix AutoSol[226] yielding an electron density 
map that could be auto traced using Phenix AutoBuild[227]. The resulting model was 
completed through iterative rounds of rebuilding in Coot[228] and refinement in Phenix 
[229]. All subsequent structures were solved by molecular replacement in Phaser [230] 
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using this initial SeMet derived structure as the template. Structure validation with 
Molprobity [231] was integrated as part of the iterative rebuild and refinement procedure. 
 
 
2.2.14.3. KMO-Kynureine modelling 
 
NAMD software [232] was used to carry out all molecular dynamics (MD) 
simulations of the Kynurenine-KMO complex, performed by Dr. Pierre Lafite (University 
of Orleans). Topology and parameters files for substrate and FAD were obtained using 
Antechamber program [233] using AM1-BCC charges [234]. The complex model was 
then immersed in a periodic water box (TIP3) and neutralized by adding Na+ ions. 
Several cycles of minimisations (steepest descent, 10 000 steps) and MD simulations (50 
K, 20 ps) were performed to equilibrate the model (backbone protein atoms were kept 
fixed). Then MD simulations were performed (310 K, 1 ns) at a time step of 2 ps, with the 
protein backbone restrained on the X-ray structure conformation. Individual snapshots 
were extracted and minimised to assess the KMO-kynurenine interactions. 
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CHAPTER 3 
 
 
BIOCHEMICAL AND BIOPHYSICAL 
CHARACTERISATION OF HUMAN 
KYNURENINE 3-MONOOXYGENASE
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3. BIOCHEMICAL AND BIOPHYSICAL 
CHARACTERISATION OF HUMAN 
KYNURENINE 3-MONOOXYGENASE 
 
 
3.1. INTRODUCTION 
 
KMO is a NADPH dependent flavoprotein monooxygenase that hydroxylates the 
aromatic substrate L-KYN and contains a tightly bound FAD cofactor. This 
hydroxylation at the third position of L-KYN produces 3-HK with the consumption of 
one molecule of NADPH and O2 per turnover [9, 197]. A number of studies have been 
published on the characterisation of the activity of KMO from different organisms, in 
terms of substrate, coenzyme and cofactor specificity, as well as strategies for expression 
and purification of KMO from higher organisms, including recombinant human KMO 
(HsKMO) [208, 207, 235]. However, as this enzyme is localised to the outer membrane 
of mitochondria [199, 200] it has proven to be extremely difficult to obtain sufficient 
quantities of KMO for structural studies and therefore, there is currently no structural 
information available for this enzyme. Additionally, the molecular basis of KMO 
inhibition by available lead compounds has remained hitherto unknown. The main goal of 
this chapter was to gain biochemical and structural information of human KMO for the 
development of novel and improved KMO inhibitors that may ultimately expedite clinical 
application of these compounds. 
The handling of membrane-associated proteins is significantly more challenging 
compared to soluble proteins, specifically in terms of protein expression, purification and 
crystallisation. Two different approaches were used in an attempt to obtain the crystal 
structure of HsKMO and are described in the current chapter. The first approach involved 
the production of truncated forms of HsKMO by deleting the transmembrane regions in 
order to prevent membrane association, insolubility or potential incorrect folding as a 
result of aggregation of the C-terminal region. The second approach involved the use of 
different overexpression systems, such as Pichia pastoris and insect cells/baculovirus 
system, both of which were previously used successfully to express other membrane 
proteins. Consequently, the chapter is divided into two main sections: the first is focused 
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on the biochemical and biophysical characterisation of truncated forms of HsKMO that 
has been expressed in P. pastoris and the second part describes the characterisation of 
full-length HsKMO expressed in insect cell using the baculovirus system. 
With the aim of gaining a better understanding of the biochemistry of HsKMO, 
the enzyme has been characterised using a variety of spectroscopic techniques. The 
activity and kinetic parameters are compared with published data, specifically on the 
native protein. Activity assays were conducted with full-length HsKMO and C-terminal 
deletion mutants to address the influence of this region on the activity of the enzyme. 
Kinetic and inhibition assays with potential KMO drugs have also been carried out to 
compare kinetic and inhibitor constants between recombinant KMO and KMO purified 
from mitochondrial preparations. 
 
 
3.2. CHARACTERISATION OF HSKMO USING PICHIA 
PASTORIS AS A HOST SYSTEM 
 
 
3.2.1. Generation of multiple expression constructs for  HsKMO  
 
 Analysis of the HsKMO primary sequence, together with predicted secondary 
structures software tools and reported data [200] suggests the presence of two 
transmembrane helices at the C-terminus of KMO between residues 384-403 and 425-447 
(Figure 3.1). From the multiple sequence alignment of HsKMO with p-hydroxybenzoate 
hydroxylase (PHBH) and other flavoproteins for which there are crystal structures 
available (Figure 1.7), we could also identify motifs that might be involved in enzyme 
catalysis and ligand binding. The NADP(H) and FAD binding motifs, characteristic of 
flavin monooxygenases, are located throughout the protein up to residue 318, whereas the 
transmembrane helices in the C-terminal region are suggested to serve as a membrane 
anchor [10]. Together, this information supported the hypothesis that the C-terminal 
region would be not expected to be crucial for the activity of the HsKMO enzyme. 
Consequently, in order to improve protein instability and insolubility, and to increase the 
likelihood of obtaining a crystal structure of HsKMO, C-terminal deletion mutants were 
engineered. 
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Figure 3.1. Prediction of membrane helices in HsKMO – Panel A: The plot shows the location of the 
predicted transmembrane helices (between residues 384-403 and 425-447) and the most probable 
orientation of transmembrane helices in the sequence (by THMM [236]). Panel B: Prediction of secondary 
structures based on HsKMO primary sequence. The letters coloured in black represent predicted loops, α-
helices are in red and β-sheets are in blue. The letters underlined represent predicted disordered regions and 
residues highlighted in green are the predicted transmembrane regions (by XtalPred [237]).  
 
 
The first truncated HsKMO variant was created by deleting one putative 
transmembrane region, after Asp-423 (KMO423) and the second truncated form was 
designed in order to delete both transmembrane regions (KMO383) after Glu-383 
(Figure 3.1). Full-length and deletion mutants were cloned into the pPICZ-B vector 
(Invitrogen) for expression of recombinant HsKMO proteins in Pichia pastoris. The C-
terminal plasmid-encoded polyhistidine (6 x His) tag, essential for downstream detection 
and purification, was retained in all constructs by typical cloning techniques using 
appropriate restriction enzymes, as the simple and direct insertion of a stop codon by site 
directed mutagenesis on the specific truncated sites could not be applied (see Section 
2.2.1. for more details). Full-length and deletion HsKMO mutants were confirmed post 
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minipreparation by DNA sequencing using the forward 5’ AOX1 and reverse 3’ AOX1 
primers (Section 2.2.1.1). Transformations into Pichia pastoris strain SMD1168H 
(protease deficient strain) were conducted by electroporation and two integrants from 
each different construct were isolated on media containing 2 mg/mL Zeocin and selected 
for expression trials. 
 
 
3.2.2. Expression and Purification of HsKMO variants 
 
Expression trials were carried out with both full-length and deletion mutants to 
select optimal growth conditions. Western blot analysis of whole cell extracts and soluble 
lysate of the HsKMO variants demonstrated that neither the full-length nor the 
KMO423 (with one predicted transmembrane region) were expressed in the Pichia 
pastoris strain SMD1168H (Figure 3.2). Several detergents such as Triton X-100, n-
dodecyl β-D- maltopyranoside (DDM) and lauryldimethylamine-oxide (LDAO) were also 
used in the extraction of these variants, but without success.  Additional P. patoris strains 
were also tested, such as X-33 and KM71H, but none were able to express these forms of 
HsKMO. In contrast, the expression of KMO383 (without any predicted transmembrane 
regions) resulted in soluble protein. These results appear to confirm the presence of 
transmembrane helices in the HsKMO enzyme between residues 383 and 460. 
 In order to analyse the expression levels and the optimal time post-induction 
before harvesting cells, different time courses were tested. Cultures were supplemented 
with absolute methanol every 24 hours to a final concentration of 0.5 % (v/v) and 
induction maintained for a total period of 72 hours. It was found that KMO383 
production decreased with prolonged induction times and a maximal expression level was 
achieved after an induction period of 24 hours (Figure 3.2). As temperature may also 
affect recombinant protein production at high cell densities, the effect of this parameter 
was also assessed, ranging from 20ºC to 30ºC. Although the usual optimum temperature 
for protein production in P. pastoris is at 30°C, it was found that for KMO383 the 
optimal expression levels occurred at 25ºC, possibly due to an improvement in the protein 
folding and solubility. The experiments shown henceforth will just refer to this form of 
the HsKMO protein. 
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Figure 3.2. Expression trials of HsKMO proteins.  Western blot analysis of whole cells and soluble lysate 
of the three HsKMO variants with anti-KMO antibody at different induction periods. The cultures were 
grown at 25ºC and supplemented with methanol to 0.5% (v/v) every 24 hours for a total incubation period 
of 72 hours. 
 
As purification strategies have not previously been established or optimised for 
recombinant HsKMO expressed in P. pastoris, numerous purification methodologies 
have been tested throughout this project, including anion (Mono Q  and DE-52 columns), 
cation exchange (Mono S), affinity (nickel and Blue Sepharose) and size exclusion (gel 
filtration columns) chromatography techniques. The optimal protocol to obtain pure 
KMO383 is described in Section 2.2.4.1. Briefly, KMO383 was purified using a three 
step purification protocol that involves nickel affinity, Blue Sepharose and size exclusion 
chromatography. Ni-affinity chromatography is the logical choice as a first purification 
step as the expression vector contained a hexa-His tag at the C- terminus. The Blue 
Sepharose contains a synthetic polycyclic dye called Cibacron Blue F3G-A, which is 
structurally similar to cofactors, such as NAD+ and therefore, certain enzymes that require 
adenylyl-containing cofactors tend to bind strongly to this resin. The protein is highly 
pure after these two steps and hence, the last step was mainly used to exchange the 
protein into an optimal buffer for crystallogenesis (optimal buffers are described in 
Section 3.2.5). Figure 3.3 shows an SDS-PAGE gel of the purity of KMO383 after each 
purification step. The apparent molecular mass of KMO383 is ~47 kDa, consistent with 
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the predicted mass from the amino acid sequence of 45 kDa, including the C-terminal 
hexa-histidine tag region.  
 
 
 
 
 
 
 
 
Figure 3.3. SDS-PAGE analysis of KMO383 purity after each purification step. Lane 1: Protein 
Marker, Lane 2: post Nickel, Lane 3: post Blue Sepharose. 
 
 
KMO383 loses part of the FAD cofactor during purification suggesting that it 
might not be covalently-bound, as previously reported for other flavin monooxygenases 
[238]. Additionally, previous studies on the PHBH enzyme suggest it adopts different 
configurations during the catalytic reaction, and in one of these configurations the flavin 
is significantly more solvent exposed and therefore susceptible to escape from the active 
site [190]. Further details on this hypothesis will be discussed in Chapter 5.  Free FAD 
(approximately 10 M) was included in the purification buffers in order to retain the 
flavin in the enzyme throughout protein purification. 
Despite the optimisation conditions, in terms of strains, time after induction and 
temperature, the expression yields were rather low (2-3 mg/L of culture). For future 
studies it might be useful to consider heterologous secretion of the recombinant protein in 
P. pastoris instead of intracellular expression. The vectors pPICZ and C contain 
the α-factor secretion signal for directing secreted expression of the recombinant protein, 
and this may be more efficient in terms of protein extraction and purification as there are 
fewer protein contaminants and less protease activity. Another possible explanation for 
the low expression yields is that the KMO gene used in the current experiments was 
codon optimised for expression in higher eukaryotic cells, which have a different codon 
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usage when compared to P. pastoris, specifically in the G + C content level, which is 
lower (42.73%) compared to mammalian codons (52.27%) [239]. The Kasuza database 
provides more information regarding codon usage frequencies in different organisms 
[239]. The use of fermenters instead of shaker-flasks might increase the expression yields 
as they optimise nutrient feeding and oxygen supplementation [240, 241]. 
 
 
3.2.3. Spectral Features of KMO383 
 
The spectrum of KMO383 is typical of a flavoprotein with absorbance maxima 
at 375 and 450 nm (Figure 3.4).  Although the spectrum is very similar to that of free 
flavin in aqueous solution there is a resolved shoulder at ~460 nm, which indicates a 
perturbation in flavin cofactor (FAD) absorbance properties through binding in the 
protein environment. Direct reduction of the non-covalently bound FAD cofactor with 
sodium dithionite from the fully oxidised KMO383, is demonstrated in Figure 3.5, as 
shown by the decrease in the visible absorption peaks. 
 
 
Figure 3.4. UV-visible absorbance spectrum of purified recombinant human KMO383 and 
anaerobic reductive titration of KMO383 with sodium dithionite. Panel A: The UV/visible absorption 
spectra were recorded at room temperature using a solution of 45 M KMO383 in buffer containing 20 
mM phosphate buffer pH 7.5, 10 % glycerol, 7 mM -mercaptoethanol. Panel B: The UV/visible 
absorption spectra were recorded at room temperature using a solution of 30 M KMO383. Titration of 
sodium dithionite was performed until the enzyme was fully reduced.  
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3.2.4. Kinetic and Ligand Binding studies 
 
The initial catalytic assays were performed by measuring the oxidation of NADPH 
at 340 nm by varying the concentration of the enzyme with excess of L-KYN. In these 
assays the rate of NADPH oxidation would be expected to increase with increasing 
concentrations of the purified HsKMO enzyme. However, it is clear that KMO383 did 
not show significant activity at any of the enzyme concentrations used (Figure 3.5). There 
was also no enzyme activity when various concentrations of the substrate L-kynurenine 
and NADPH were used. The lack of catalytic activity suggests that the segment from 
position 383 to 486 is necessary for the enzymatic activity. However, due to the lack of 
expression of the full-length and single transmembrane deletion mutant, we were unable 
to identify the exact region of the C-terminus responsible for the loss of the HsKMO 
activity. Hypotheses relating to the absence of activity will be discussed in Section 3.2.8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. NADPH oxidation rate vs KMO383 concentration. The KMO-catalysed reaction was 
monitored by measuring the oxidation of NADPH at 340 nm. 0.2-2 M of pure enzyme was added to 200 
l reaction buffer (20 mM potassium phosphate, 7 mM -mercaptoethanol) containing 0.15 mM NADPH 
and 0.15 mM L-Kyn (in black). A negative control was carried out without the substrate L-Kyn (in grey).  
 
 
Additional spectroscopic studies to investigate the interactions of substrates and 
inhibitors were used to check whether the integrity of the ligand binding site was 
compromised as a result of the truncation of the transmembrane helices in the C-terminus. 
85 
 
As a typical class A flavoprotein monooxygenase, KMO contains one molecule of FAD 
per active site and therefore, the optical properties of this cofactor allow spectroscopic 
studies of the binding of substrates or inhibitors to yield dissociations constants for these 
interactions. In the visible region, FAD has absorbance maxima at 375 nm and 450 nm 
and a fluorescence maximum at approximately 525 nm. Certain ligands are able to 
quench or enhance the FAD fluorescence emission upon binding to the protein as they 
perturb the FAD binding pocket in the active site. Consequently, the perturbation in FAD 
fluorescence emission was monitored at 525 nm when titrating KMO383 with L-KYN 
and the Ro 61-8048 KMO inhibitor (Figure 3.6). 
 
 
Figure 3.6. Measurement of binding constant for L-Kyn and Ro 61-8048 by ligand 
perturbation of flavin fluorescence emission. Titration of ligands to 5 M KMO was administered 
under atmospheric conditions at 25 ºC. The perturbation in fluorescence emission was followed at 525 nm 
using an excitation wavelength of 450 nm (A) Titration of L-KYN (0-70 M from bottom to top) to KMO 
led to an increase in the FAD fluorescence Inset: Fluorescence changes at 525 nm as a function of L-KYN 
concentration. The data were fitted to the Morrison equation to yield an observed Kd= 50.93 ± 5.3 M. (B) 
Titration of Ro 61-8048 (0-70 M from top to bottom) to KMO383 led to a decrease in the FAD 
fluorescence. Inset: Fluorescence changes at 525 nm as a function of Ro 61-8048 concentration. The data 
were fitted to the Morrison equation to yield an observed Kd= 3.54± 0.4 M. The structure of both ligands 
are shown in the respective plots. 
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Table 3.1. Dissociation constants (Kd)  for binding of L-KYN  substrate and Ro 61-
8048  inhibitor to KMO383 
 
 
 
 
Both ligands bind to the KMO383 enzyme but give different effects on the FAD 
fluorescence, which is likely to reflect differences in the mode of binding. An 
enhancement in fluorescence was observed upon binding the physiological substrate L-
KYN, which suggests that conformational changes in the protein upon ligand binding 
expose the flavin isoalloxazine ring to the solvent, thereby increasing its fluorescence 
(Figure 3.6A). The observed Kd of 50.9 ± 5.3 M is comparable with Km values for 
mammalian forms of KMO, which range from 13 M in Homo sapiens [207] to 25 M in 
Rattus novergicus [9] (see Table 1.3 for dissociation constants from KMO in different 
organisms). In contrast to the enhancement in FAD fluorescence observed with the L-
KYN substrate, the Ro 61-8048 KMO inhibitor caused a quenching of FAD fluorescence 
(Figure 3.6B), suggesting that KMO undergoes different conformational changes/binding 
modes upon binding to this inhibitor. The observed Kd is 3.5 ± 0.4 M, which is 
significantly higher than the IC50 value of 37 nM previously reported for this inhibitor in 
KMO from rat kidney mitochondria preparations [173]. Ro 61-8048 is claimed to be a 
competitive inhibitor and therefore, it should compete with L-KYN for the same binding 
pocket [242]. However, both ligands are structurally very distinct and the KMO inhibitor 
has a much more complex structure (Figure 3.6). Further enzymatic studies will be 
required in the future to validate Ro 61-8048 as a competitor KMO inhibitor. 
 
 
3.2.5. Thermofluor assay 
 
In order to obtain well-diffracting quality crystals for structure determination it is 
necessary to identify conditions that provide homogeneous, stable and soluble protein. 
The crystallisation of proteins can be strongly influenced by a number of factors, such as 
pH, ionic strength, additives, precipitants, protein concentration and temperature. 
Ligand Dissociation constant (Kd) 
L-KYN 50.9 ± 5.3 M 
Ro 61-8048 3.5 ± 0.4 M 
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Recently, the Thermofluor assay has been used in structural biology as an important tool 
to identify buffer conditions that minimise protein aggregation and improve protein 
stability [243, 244]. Briefly, Thermofluor is a fluorescence‐based thermal stability assay 
in which the fluorescence of certain dyes, such as SYPRO Orange, increase when 
exposed to hydrophobic regions of the protein compared to aqueous solution. This assay 
has been useful in helping to distinguish between folded and unfolded states of proteins. 
The transition to the unfolded state of a protein is accompanied by a corresponding 
increase in the dye fluorescence and can be monitored as a function of temperature using 
a standard real time PCR instrument by performing a high- throughput screening of buffer 
conditions in 96-well plates. The resulting curve usually shows a sharp transition between 
folded and unfolded states and the melting temperature (Tm) is precisely the midpoint of 
temperature of this unfolded transition. The Tm is consequently a parameter of protein 
stability and any buffer and additive conditions that increase this temperature may 
enhance the probability of protein crystallisation. The optimal buffer conditions that were 
found using this technique are used during the last purification step as the buffer to 
exchange the protein into prior to protein crystallisation. These conditions may allow the 
protein to be concentrated up to a high level suitable for crystallography by minimising 
the likelihood of precipitation. 
KMO383 was subjected to the JBS Solubility Kit buffer screen (Section 2.2.12. 
Material and Methods) consisting of 24 buffer solutions at different pH values, ranging 
from 4.5 to 9.0, with concentrations of 50 mM. Among the 24 buffers tested, there were 
some buffers that appeared to be more favourable for KMO383 stabilisation compared 
to the standard potassium phosphate buffer pH 7.5 buffer previously used (sample 
control), particularly Bis-Tris propane pH 6.5 (Tm= 50.6 ºC), ammonium acetate pH 7.0 
(Tm= 49.8 ºC) and sodium phosphate pH 7.0 (Tm= 50.3ºC). Table 3.2 shows all the 
averaged Tm values. The optimal buffers mentioned above were subsequently used for 
further assays that involved the addition of additives to improve the protein stability.  
Table 3.3 gives the Tm values of the additive screen assay using one of the optimal 
buffers, Bis-Tris Propane pH 6.5, identified in the previous assays. None of the additives 
tested using the JBS additive screen were found to yield significant improvements in the 
stabilisation of the protein. The addition of 200 mM NaCl and 4 mM DTT improved the 
thermal stability of the protein by 1.3ºC and 0.4 ºC respectively, when compared to 
KMO383 in Bis-Tris Propane pH 6.5 without any additive (sample control). 
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Subsequently, all KMO393 crystallisation samples were made up in this buffer 
supplemented with 150 mM NaCl and 4 mM DTT. 
 
 
Table 3.2. Melting temperatures of buffer screen of KMO383 
 
Buffer pH Tm (°C) 
Citric Acid 4.0 37.3 
Sodium/potassium 
phosphate 5.0 36.8 
Sodium citrate 5.5 42.6 
Sodium/potassium 
phosphate 6.0 46.1 
Bis-Tris 6.0 45.4 
ADA 6.5 49.1 
Bis-Tris  propane 6.5 50.6 
Ammonium Acetate 7.0 49.8 
MOPS 7.0 48.3 
Sodium/potassium 
phosphate 7.0 50.3 
Tris 7.5 47.2 
Imidazole 8.0 47.5 
Bicine 8.5 46.4 
CAPS 10.0 40.2 
Control (Potassium 
phosphate) 7.5 44.8 
   
Buffers shown are from the JBS Solubility Kit part A. Buffers which did not produce a Tm are not shown. 
Final concentrations for all buffers were 50 mM diluted from 100 mM stocks.  Sample control is in 20 mM 
phosphate buffer pH 7.5. 
 
 
Table 3.3. Melting temperatures of additive screen of KMO383 
 
Addtive 
Concentration 
Tm (°C) 
NaCl  200 mM 50.1 
NaCl  400 mM 48.8 
Glycerol  20% 45.5 
Glycerol  40% 47.3 
CHAPS  8mM 43.2 
TCEP  120mM 46.2 
BME  40mM 46.9 
DTT  4mM 48.4 
DTT  20mM 53.9 
Sample control1 - 48.6 
Additives shown are from the JBS Solubility Kit part B. Additives which did not produce a Tm are not 
shown. 
1 Sample control is in 50 mM bis-tris propane pH 6.5. 
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3.2.6. Multi Angle Laser Light Scattering (MALLS) 
 
KMO383 was analysed using MALLS coupled to a QELS detector and an extra 
gel filtration column. Essentially, this technique is able to report accurately on the 
average molecular weight of proteins, their radius of gyration and molecular 
conformation based on the hydrodynamic radius. Additionally, it also provides 
information regarding the stability and homogeneity of the sample in terms of 
aggregation or oligomeric states that are highly correlated with crystalisability. If the 
standard deviation (S.D.) of the RH is between 15-20 % it is classified as narrow 
monomodal dispersity and it is an optimal starting point for setting up crystallisation 
trials. As a general rule, proteins with monomodal distributions have a high probability 
(70-80%) of producing crystals as the presence of aggregation dramatically reduces the 
chances of obtaining crystals. S.D. less than 30 % is still considered reasonably 
monodispersed [245]. The S.D. of the RH for KMO383 is 25 % across the three axes, 
indicating that the enzyme is a globular monomeric protein in solution, consistent with 
the plot from the Molecular mass (Mr) values, in which the molecular weight values 
remains constant over the duration of the elution peak. The average Mr is 44.8 kDa, 
which is very close to the predicted value of 45 kDa based on the primary sequence 
analysis. The protein gave a single light scattering peak that eluted after approximately 15 
mL (Figure 3.7 - Black spectra), concurrent with a single refractive index peak (Figure 
3.7 - Grey spectra). 
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Figure 3.7.  Multi-Angle Laser Light Scattering spectra of KMO383. The black line represents light 
scattering data, the grey line represents the refractive index of the protein. Inset - The MALLS spectra 
shows a single peak with an average molecular weight of 44.8 kDa. B: The average molecular weight of 
KMO383 (blue dots) spanning across the only peak. Polydispersity index is 1.0 which reflects protein 
stability.   
 
The lack of information in the literature regarding the oligomerisation state of 
KMO from Homo sapiens did not allow a direct comparison with our results. The only 
study reporting information about the molecular weight and aggregation state was carried 
out in Rattus norvegicus KMO [210]. It was suggested, based on the elution pattern of 
native enzyme on size exclusion chromatography and results from SDS-PAGE, that the 
molecular weight of the enzyme from this species is 200 kDa and exists as a dimer in 
solution.  It is important to emphasise that the experiments performed in this previous 
study were done in the presence of 1 % Triton X-100 for solubilisation of the enzyme 
from the outer membrane of mitochondria and therefore, the presence of detergent 
micelles may have contributed significantly to the overall molecular weight predicted, 
based on the elution peak from the gel filtration column. The fact that our HsKMO 
variant lacks the C-terminal region did not allow a direct comparison with the results 
reported for Rattus norvegicus KMO since the transmembrane region can possibly 
interfere with the oligomeric state of the protein. The MALLS data collected for 
KMO383 suggests that the protein has been isolated in a form that is suitable for 
crystallographic studies, although it is not in the narrow monomodal dispersity range. 
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3.2.7. Crystallisation of KMO383  
 
Extensive crystallisation trials of KMO383 were performed across a range of 
conditions in 96-well plates using the sitting drop method. A range of protein 
concentrations from 5-20 mg/mL were tested with the commercially available 
crystallisation screens from Molecular Dimensions available in the laboratory (Details are 
described in Section 2.2.14.1). Co-crystallisation experiments were also performed in 
order to improve the chances of obtaining crystals, with L-KYN and Ro 61-8048, with a 
concentration of ligand that was 10-fold greater than the protein concentration to ensure 
ligand saturation. The crystallisation trials revealed that truncated HsKMO aggregated 
over short timescales under the majority of crystallisation conditions. Despite efforts to 
optimise buffer and additive conditions to stabilise the protein, no crystals were obtained 
with the crystallisation kits available in the lab, including Silver bullet kits from Hampton 
research that are usually used when traditional screens are not successful. The protein 
precipitated over a short period of time in more than 60 % of the conditions. 
 
 
3.2.8. Discussion and new approaches 
 
Recent studies have provided strong indications that the C-terminal region of 
HsKMO is important for its catalytic activity, although the exact role is not currently 
known [246]. Hirai et al. (2010) have reported the functional expression of full-length pig 
KMO in COS-7 cells together with several deletion mutants in the C-terminus. 
Accordingly, it was discovered that a segment of 20 amino acid residues close to the C-
terminus is necessary for enzymatic activity (Figure 3.8). From the sequence alignment of 
pig and human KMO, this segment is part of the putative transmembrane hydrophobic 
domain starting from residue 421 to 441 in HsKMO. It was also shown that the 
intracellular localisation of the deletion mutants shifted from the mitochondria to the 
cytosol. Taken together, it was hypothesised that the C-terminal region of KMO plays a 
dual role in mitochondrial anchoring and in enzymatic activity [246]. Interestingly, 
another study conducted on soluble full-length KMO from P. fluorescens obtained high 
levels of fully active enzyme, which was not associated with the outer membrane of the 
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mitochondria, suggesting that this KMO protein does not need to be attached to the 
membrane to catalyse the enzymatic reaction [206]. 
 
 
Figure 3.8. Sequence alignment of pig liver KMO with HsKMO. The amino acid sequences were 
aligned by the CLUSTAL method. A putative transmembrane hydrophobic domain in KMO from pig liver 
and H. sapiens is boxed. A previous study suggests the C-terminal domain of KMO is involved in enzyme 
activity [246]. 
 
Although the results from the current project demonstrate that the C-terminal 
truncation variant is not able to catalyse the hydroxylation of the substrate L-KYN, it is 
still able to bind the substrate. Therefore, it is tempting to speculate that the truncation in 
the C-terminus might affect the co-enzyme NADPH binding site rather than the substrate 
binding site as no NADPH oxidation could be observed during catalytic assays. This 
hypothesis will be discussed further in Chapter 5 after elucidation of the crystal structure 
of ScKMO. 
As it proved impossible to crystallise KMO383 subsequent efforts focused on the 
biochemical characterisation of full-length HsKMO. Previous attempts to express full-
length HsKMO in P. pastoris were not successful and therefore, an alternative expression 
system was pursued, involving the insect cells/baculovirus system.  
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3.3. CHARACTERISATION OF FULL-LENGTH HSKMO USING 
INSECT CELLS/BACULOVIRUS AS A HOST SYSTEM 
 
 
3.3.1. Expression and Purification of HsKMO 
 
As explained previously, full-length HsKMO is a membrane-associated enzyme 
with two transmembrane helices localised in the C-terminus. In order to circumvent the 
lack of full-length HsKMO expression using Pichia pastoris, alternative expression 
systems that have previously been successful in expressing membrane proteins from other 
organisms were pursued. As the posttranslational modifications found in the majority of 
eukaryotic proteins can only occur in other higher eukaryotic cells it seemed logical that a 
higher eukaryotic host would be most suitable to produce fully functional HsKMO. Insect 
cells are easier to manipulate and scale up than mammalian systems and they also offer a 
lipid environment that is more suitable for the function of membrane proteins compared 
to yeast, Therefore, this system was selected as an alternative to the Pichia pastoris host 
system. Several host strains and baculovirus transfer vectors were initially tested, as well 
as other parameters, such as multiplicity of infection (MOI) and times of incubation. 
Expression trials were performed systematically to find the best conditions for expression 
of full-length HsKMO. A summary of the various conditions tested are shown in Table 3-
2. 
 
Table 3.4. Vectors and cell lines tested for expression of HsKMO in insect cells using 
the baculovirus system 
 
 
 
Vectors Cell line Solubility Expression levels 
pQE-TriSystem 
 
Sf9 Soluble Very low 
Hi5 Soluble Very low 
pBac2 Sf9 Soluble Low Hi5 Soluble Low 
pACGHLT Sf9 Soluble Low Hi5 Soluble Low/Medium 
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All of the vector systems tested expressed detergent solubilised HsKMO (1 % 
Triton X-100), although they differed in terms of protein expression levels. The first 
vector system to be tested was the pQE-TrisSystem, as the synthetic KMO gene from 
Invitrogen was originally in this expression vector. The expression levels obtained using 
this system both with Sf9 and Hi5 cells were very low, just noticeable by Western Blot. 
To address expression protein level issues the KMO gene was efficiently sub-cloned into 
pBAC2 baculovirus transfer vector as a Nde I - EcoR I fragment. This vector is widely 
used for expression of high levels of recombinant proteins in insect cells but no 
significant improvements in KMO expression were detected. The KMO gene was also 
sub-cloned into the pAcGHLT-A GST baculovirus transfer vector and in this case, the 
protein expression levels were higher compared to the previous vectors, particularly when 
using the Hi5 insect cells strain. This baculovirus transfer vector includes an N-terminal 
Glutathione S-transferase tag that serves as an affinity tag and plays an important role as a 
solubilisation agent. Therefore, this may explain the higher expression levels of full-
length KMO using this vector system. Test expressions were carried out with different 
MOI and times of incubation and optimal conditions were selected based on the quantity 
of soluble KMO expressed (Figure 3.10).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9. Expression trials of full-length HsKMO in Hi5 cells using the pACGHLT baculovirus 
vector.  Western Blot of total and soluble lysate of human KMO with anti-KMO antibody at varying MOIs 
and times of incubation. The cultures were grown at 28ºC for a total incubation period of 72 hours. 
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Figure 3.9 shows that the amount of total and soluble lysate is very similar and 
therefore the amount of KMO protein present in the soluble fraction can be seen as the 
total amount of KMO expressed within the cells. Optimal conditions were 72 hours of 
incubation and 20 L of stock virus. The same conditions were also verified when scaling 
up of the growth cultures was carried out using the Cellbag-10 L disposable bioreactors. 
 
 
 
 
 
 
 
 
 
Figure 3.10. SDS-PAGE analysis of full-length HsKMO purity after each purification step. Lane 1: 
Protein Markers, Lane 2: post Glutathione, Lane 3: post Gel filtration. 
 
HsKMO was purified using a two-step purification strategy that includes 
glutathione-Sepharose affinity followed by size exclusion chromatography (described in 
Section 2.2.4.2). After the first purification step just two bands were eluted, one band that 
runs at ~25 kDa was identified by MALDI-TOF peptide identification as the endogenous 
insect GST, and the higher molecular weight band, with an apparent molecular mass of ~ 
80 kDa is the HsKMO (Figure 3.10). The apparent molecular weight is consistent with 
the predicted mass from the amino acid sequence of 55 kDa including the N-terminal 
GST tag region (26 kDa). The endogenous GST was easily removed by gel filtration 
(Figure 3.11). The overall expression levels of KMO in insect cells was between 0.5-0.75 
mg/L of culture, which is rather low compared to the majority of proteins expressed using 
the baculovirus system. However, the protein could be effectively purified without 
significant losses throughout the purification procedure. 
The first attempts to purify KMO were conducted with the standard detergent 
Triton X-100, although this detergent is chemically heterogeneous and not suitable for 
structural studies. Consequently, a selection of detergents was chosen for an initial 
screening based on the previous success of these detergents in producing crystals of 
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membrane proteins (Table 2.3). There are many criteria that can determine the choice of 
detergent, ranging from micelle molecular weight, critical micelle concentration (CMC) 
or length of the alkyl chain [224]. From the selection of detergents tested, n-dodecyl β-D-
maltopyranoside (DDM) and octyl-glucoside (OG) were the detergents that were most 
efficient in solubilising KMO (Figure 3.11). These two detergents were carefully chosen 
for small scale partial purification to verify the homogeneity of the target protein and with 
both conditions KMO protein was eluted in a single sharp peak by gel filtration, 
indicating that the protein is in a stable and well-folded form. The amount of detergent in 
the selected conditions was further optimised, using concentrations of detergent above its 
CMC in order to act as an effective solubiliser. Since DDM and OG were equally 
efficient in solubilising KMO, further experiments were carried out only with DDM, as 
this detergent is less harsh compared to OG. 
 
 
 
 
 
 
 
 
 
Figure 3.11. Dot-blot analysis with human anti-KMO antibody of HsKMO soluble lysate using 
different detergents. The Dot blot technique is similar to the Western Blotting except that the protein 
samples are not separated electrophoretically but just spotted directly onto the membranes. 1- without 
detergent,   2- 0.1% Triton X-100, 3- 1% CHAPS, 4 - 2% CHAPS, 5 -  0.5% FC12, 6 – 1% FC12, 7 – 0.5% 
DDM, 8 – 1% DDM, 9 – 0.5% LDAO,  10 – 1% LDAO, 11 – 1% OG   and 12 – 2% OG.  
 
 
 During size exclusion chromatography, the protein was eluted after 7.5 minutes, 
which, according to the molecular weight standards of a typical chromatogram from 
Superdex 200 10/300, corresponds to an apparent molecular weight that is significantly 
higher than expected with a Mr ≥ 300kDa (Figure 3.12). It is important to note that in 
some cases, particularly when studying a protein-lipid complex, a protein mass estimated 
by SEC may differ greatly from the actual value, possibly due to the complex shape and 
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possible matrix binding interactions. As previously mentioned in Section 3.2.6, there is a 
lack of information regarding the molecular weight and aggregation state of KMO. 
Studies on human KMO have predicted the molecular weight of denatured protein based 
on results from SDS-PAGE gels and therefore, the results are not informative in terms of 
the oligomeric state of the native protein [208]. Studies carried out in Rattus norvegicus 
KMO [210] suggest that the molecular weight of the enzyme is 200 kDa and it exists as a 
dimer in solution, although their hypothesis is based on the elution pattern of native 
enzyme solubilised in Triton X-100 which can in fact overestimate the true molecular 
weight of the enzyme.  Therefore it is tempting to speculate that due to the similarity of 
both enzymes, HsKMO may also exist as a dimer in solution.  
 
 
 
 
 
Figure 3.12. Size exclusion chromatogram and prediction of HsKMO molecular weight. (A) 
Purification chromatogram of HsKMO after passing down a Superdex 200 10/300 GL column using 0.012 
% DDM in the buffer solution and (B) Typical chromatogram from a function test of Superdex 200 10/300 
GL. 
 
 
Although MALLS is widely used for the accurate determination of the molecular 
weight and oligomeric state of proteins it is often very difficult to use this technique to 
characterise membrane proteins because they are in a lipid-containing solvent. As the 
membrane protein-lipid complexes have different conformations and therefore, different 
adsorption characteristics to the column packing compared to globular proteins, the 
elution property of membrane and globular proteins are significantly different. Previous 
studies reporting the use of MALLS in combination with UV absorption and differential 
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refractive index (DRI) detection show that it is possible to determine the molecular 
masses of membrane associated proteins [247, 248]. Attempts were made to predict the 
molar mass of full-length HsKMO based on these studies, but without success.  
Although DDM is one of the gentler detergents and widely used in 
crystallography, the relatively large micelles (60 kDa) [223] often surround the protein 
and prevents crystal formation. Membrane proteins will generally bind substantial 
amounts of detergent and consequently, the amount of detergent in the final sample is 
usually higher than the concentration in the buffer. Ideally, only KMO fractions with the 
highest protein concentration would have been selected after size exclusion 
chromatography to avoid a further concentration step. However, due to the lower 
expression yields, more fractions were collected and therefore, they needed to be 
concentrated for further structural studies. To overcome the issue of excessive amounts of 
detergent in the final sample, an ultrafiltration membrane with a cut off higher than the 
micelle size was used.  Since the DDM micelle size is approximately 60 kDa [223] a 
membrane with a cut off of 100 kDa was used to concentrate KMO and avoid excessive 
concentration of the detergent. 
 
 
3.3.2. Crystallisation Trials of HsKMO 
 
Preliminary crystallisation screens with pure GST-KMO and cleaved protein 
using the Phoenix crystallisation robot platform were performed but no crystals were 
obtained with the crystallisation kits available in the lab (more details in Section 
2.2.14.1). Unfortunately, extensive crystallisation conditions could not be pursued due to 
the very low yield of protein expression. One of the most likely reasons for the lack of 
protein crystals is the presence of DDM. It is widely known that the use of detergents in 
crystallography is extremely challenging. This is because the properties of the protein-
detergent complex do not favour the formation of well-ordered lattices due to the flexible 
and dynamic nature of the detergent that surrounds the protein. Furthermore, despite the 
use of an ultrafiltration membrane with a cut off higher than the DDM micelle size, it 
might be possible that a large number of micelles were still present in the final sample, 
preventing the formation of the crystals. As the expression levels were rather low for 
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structural studies, further experiments were focused on the biochemical characterisation 
of full-length HsKMO. 
 
 
3.3.3. Effects of pH and Temperature on HsKMO activity 
 
KMO catalyses the NADPH-dependent hydroxylation of L-kynurenine into 3-
hydroxy-kynurenine. The activity of KMO enzyme was initially tested as described in 
Section 2.2.8 as a function of temperature and pH to find the optimal conditions for 
maximal enzyme activity. The enzymatic reaction was monitored by following the 
decrease in absorbance of NADPH at 340 nm with saturating concentrations of L-KYN 
and NADPH. Figure 3.13A shows the dependence of activity on the temperature and 
reveals that there is little activity below 10°C and at temperatures higher than 50°C. The 
temperature optimum for KMO activity lies within the range 33-38°C, which is similar to 
the temperature used for enzymatic assays with crude or purified mammalian KMOs 
(temperatures between 30-37°C) under similar conditions. Although these studies do not 
clarify the temperature choice the enzyme activity could reasonably expected to 
maximised in this temperature range [208, 210]. 
 
 
Figure 3.13. Effects of temperature and pH on Hs activity. The biochemical activity was assayed 
with 500 mM L-KYN and 1 mM NADPH. The enzymatic reaction was monitored by following the 
decrease in absorbance of NADPH at 340 nm with temperatures from 10 to 40ºC (Panel A) and pH values 
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from 6 to 10 (Panel B). The temperature profile was fitted to a Gaussian curve (Equation 2) and the pH 
profile was fit to the two macroscopic pKa value equation (Equation 3). 
 
 
The activity of full-length HsKMO was also monitored at different pH values, 
which showed an optimum at pH 8.0 with significant loss of activity at pH values below 6 
and higher than 9 (Figure 3.13 B). The pH profile of HsKMO activity gave rise to two 
apparent pKa values of 5.9 and 9.7. The pH optimum obtained in this study is comparable 
with previous reports on recombinant HsKMO and rat liver extracts where a pH optimum 
of 7.5 was measured for the KMO activity [208, 9]. Similar values are also observed in 
lower organisms, ranging from pH 7.5-8.5 [212, 207]. 
 
 
3.3.4. Kinetic analysis of HsKMO 
  
A complete kinetic analysis of HsKMO was carried out by initial-velocity 
measurements of the overall reaction, varying either the L-KYN or NADPH 
concentrations. Control assays were also performed in the absence of the substrate L-
KYN and showed that very slow rates of NADPH oxidation were observed that were 
independent of enzyme concentration. This corresponds to endogenous NADPH 
oxidation and this background rate was taken into account for the calculation of the KMO 
activity. For each assay the substrate kinetic parameters were measured in the presence of 
an excess of the other substrate. Rates were determined by fitting the decrease in 
absorbance at 340 nm to a straight line over the first 30 seconds. HsKMO activity follows 
simple Michaelis-Menten kinetics and the Km values for both substrates were determined 
by fitting the data of the rate of turnover versus the substrate concentration to the 
Michealis-Menten equation (Equation 1, Section 2.2.8).  Apparent steady-state 
parameters were measured at an optimal temperature (37ºC) and pH (pH 8.0) so that the 
values could be directly comparable with published data. 
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Figure 3.14: Overall initial-velocity measurements of HsKMO activity at varying concentrations of L-
KYN or NADPH. The enzymatic reaction was monitored by following the decrease in absorbance of 
NADPH at 340 nm. Saturation curve was calculated by fitting the data to the Michaelis-Menten equation. 
 
  
Table 3.5. Apparent steady-state parameters for HsKMO 
 
 
 
 
 
 
Figure 3.14 shows a hyperbolic dependence of the turnover rate on the 
concentration of both substrates with a Km of 52.6 ± 9 M and 22.6 ± 4 M for NADPH 
and L-KYN, respectively and a kcat of 0.89 ± 0.05 s-1. The Km value for L-KYN (22.6 ± 
4.4 M) is similar to that observed for the native protein from rat liver mitochondria 
preparations (16 M) [9] and human liver enzyme (13.0 ± 3.3 M) [10]. However, the 
value is approximately 4-fold different to previously published results on recombinant 
HsKMO expressed in COS-1 cells (100 M ± 1) [208]. No published data is available 
regarding Km values for NADPH in HsKMO, although the value obtained is a similar 
range to the Km value determined for Rattus norvegicus (Km= 23 ± 1.8 M) [9]. 
Interestingly, similar kinetic parameters are also observed among lower organisms, for 
instance Pseudomonas fluorescens and Saccharomyces cerevisiae (Table 1.3). The kcat 
Kinetic Coefficients Values 
K
M
 
NADPH
 (M) 52.6 ± 9 
K
M
 
L-KYN
 (M) 22.6 ± 4 
k
cat
 (s
-1
) 0.9 ± 0.05 
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value was also found to be similar to previous studies on recombinant HsKMO (2.18 s-1) 
[208], providing evidence that we have expressed and purified functional HsKMO. 
 
 
3.3.5. Inhibition Assays of HsKMO 
 
Inhibition assays were carried out with one of the most potent inhibitors of KMO, 
UPF 648. This tight binding inhibitor has been used in several in vivo and in vitro studies 
to test and validate the hypothesis that KMO inhibition is a viable therapeutic strategy in 
Huntington’s disease [249, 3]. The inhibition of HsKMO activity by the UPF 648 KMO 
inhibitor was investigated by following the formation of the product 3-HK at varying 
UPF 648 concentrations and at saturating concentration of the L-KYN substrate (500M). 
Figure 3.16A shows typical HPLC elution curves of the product (3-HK) and substrate (L-
KYN) at varying concentration of the UPF 648 inhibitor. At increasing concentrations of 
UPF 648, the formation of 3-HK dramatically decreases with more of the L-KYN 
substrate remaining unconverted. The initial rate of 3-HK formation was fitted to the 
Morrison’s equation, which is used for tight binding ligands or when the dissociation 
constant of the inhibitor is similar to the total concentration of enzyme in the sample 
(Figure 3.16B). It is important to emphasise that these kind of inhibitors bind so tightly to 
the target enzyme that the concentration of free inhibitor decreases significantly when the 
enzyme-inhibitor complex is formed and therefore, simple binding equations based on 
Michaelis-Menten principles are no longer valid. As a general rule, the Morrison’s 
equation should be used whenever the dissociation constant of a certain inhibitor is less 
than 1000-fold greater than the total enzyme concentration.  
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Figure 3.15. Fractional velocity of 3-HK formation as a function of UP648 concentration with 
HsKMO. 100 nM enzyme was incubated at 37ºC with 2 mM NADPH, 500 M L-kyn and different 
concentrations (0-2 M) of the UPF 468 inhibitor. The product formation was analysed by reversed-phase 
HPLC. A:  HPLC elution curves of product (3-HK) and substrate (L-KYN) at varying concentration of the 
UPF 648 inhibitor. B: The data was fitted to the Morrison equation for tight binding inhibitors.  
 
 
UPF 648 was found to be highly efficient as a KMO inhibitor, with an apparent Ki 
of 56.7 ± 8.0 nM. This value is very similar to previous reports, where the IC50 
determined in an in vivo gerbil model with this ligand was 40 nM [172], although the 
concentration of substrate used in their assays is not clear. It should be noted  that for 
tight binding inhibitors the IC50 or Kiapp values depend on the substrate concentration and 
therefore our results cannot be directly comparable to published data unless the specific 
substrate concentration used in the experiments are known. These data are the first direct 
measurement of inhibitor constants for UPF 648 with pure HsKMO and provide 
additional support that the recombinant HsKMO purified in this study behaves in the 
same way as the native protein. We can speculate that UPF 648 acts as a tight binding 
competitive inhibitor as the structure is very similar to the physiological L-KYN substrate 
with an additional cyclopropyl ring in the side chain. The potential mode of inhibition 
will be discussed further in Chapter 5.  
As previously mentioned, another KMO inhibitor, Ro 61-8048, has also been 
extensively used as a tool to study the effects of KP manipulation in several diseases 
[173, 1, 167]. This compound is highly insoluble in aqueous buffers and it was only 
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possible to solubilise in DMSO. As the inhibition assays were carried out for long 
incubation periods, HsKMO precipitated even with nM concentrations of Ro 61-8048 and 
therefore, it was not possible to calculate the apparent Ki of this compound. 
 
 
3.4. CONCLUDING REMARKS 
 
In this chapter we tested two different expression systems to express and purify 
HsKMO: Pichia pastoris and insect cells/baculovirus system. A C-terminal 
transmembrane deletion mutant was expressed in P. pastoris and purified although no 
structural information was acquired despite numerous efforts to optimise conditions for 
crystallogenesis. In terms of catalytic activity, there was no evidence of NADPH 
oxidation during activity assays, which might be related to the truncation in the C-
terminal region. The lack of KMO383 activity is in accordance with published data 
showing that the C-terminal region of HsKMO is required for enzyme activity [246]. 
Although the role of the C-terminus of HsKMO in catalysis is not clear, we can speculate 
that it is involved in NADPH binding as there was no NADPH oxidation during catalytic 
assays. Since this truncated KMO did not allow a full biochemical characterisation of the 
HsKMO enzyme the expression of full-length HsKMO was pursued in another host 
strain. 
Full-length HsKMO was expressed in insect cells using the baculovirus system 
and purified to homogeneity. A complete biochemical characterisation of the enzyme was 
carried out and the kinetic parameters and inhibitor coefficients were shown to be very 
similar to KMO purified from mitochondria preparations, which provides strong evidence 
that we have expressed and purified fully active protein. Consequently, we now have a 
robust system to use as a future screening methodology for testing the efficacy of possible 
KMO inhibitors. An activity profile of various C-terminal deletions mutants may provide 
valuable information regarding the role of this region in HsKMO activity.  
In terms of structural studies none of the systems provided protein that led to 
crystals. Extensive crystallisation conditions were performed with KMO383 although 
the protein aggregated in the majority of the conditions. Due to the uncertainty of using 
the truncated HsKMO as a good model for the study of full-length HsKMO, this strategy 
was not pursued further. As regards full-length KMO, there were also several issues 
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during the course of this project that prevented further crystallisation trials of HsKMO. 
One of the major reasons was the very low yield of protein expression, which was 
sufficient for a biochemical characterisation but not for detailed crystallogenesis trials.  
As the expressed KMO from insect cells contained a GST-tag, which is rather large for 
crystallography purposes, attempts were made to cleave it with thrombin. However, this 
process was ineffective and together with the low expression yield made it very difficult 
to obtain reasonable amounts of HsKMO suitable for crystallography.   
In conclusion, although it was not possible to structurally characterise HsKMO, 
the new strategies developed in this project to express, purify and kinetically study 
HsKMO are extremely useful in a future high throughput platform for screening of 
inhibition compounds that are able to decrease the activity of the KMO enzyme.  
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CHARACTERISATION OF 
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4. BIOCHEMICAL AND BIOPHYSICAL 
CHARACTERISATION OF SACCHAROMYCES 
CEREVISIAE KYNURENINE 3-
MONOOXYGENASE 
 
 
4.1. INTRODUCTION 
 
In chapter 3, although further elucidation of the enzyme catalytic mechanism was 
not possible due to the very low expression levels, I provided a detailed biochemical 
characterisation of human KMO (HsKMO). Furthermore, the structural studies conducted 
on human KMO did not provide suitable results in terms of conditions to obtain crystals 
despite numerous attempts to crystallise both full length and truncated forms of KMO. 
Due to the difficulties encountered with the structural and biochemical studies on 
HsKMO, an alternative strategy was pursued. Several KMO enzymes from different 
organisms were analysed in order to find a suitable homology model for the study of 
HsKMO. The choice of KMO homologues were based on the sequence similarity and 
probability of crystallisation of the respective protein based on software tools for protein 
crystallisability prediction. KMO homologues from higher eukaryotes were excluded due 
to the high sequence identity (See Figure 1.9) and therefore the hydrophobic residues that 
could function as transmembrane regions were still present.  
  Of particular interest is the KMO from yeast Saccharomyces cerevisiae 
(ScKMO). Although the analysis of the ScKMO primary sequence, based on predicted 
secondary structures, suggested the presence of a hydrophobic amino acid stretch in the 
C-terminus of KMO between residues 425-455 (Figure 4.1), the probability of obtaining 
diffraction quality crystals was significantly higher compared with the predicted 
transmembrane regions for HsKMO. Additionally, predictive crystallisation software 
tools suggested that there was an increased likelihood of crystallising the ScKMO 
compared to HsKMO.  
A persuasive argument for the study of ScKMO as a good homology model for 
HsKMO came from a genome-wide screen in yeast that identified the yeast orthologue of 
KMO  (BNA4) as a suppressor of mutant htt toxicity, suggesting that the mechanism of 
polyQ tract toxicity is preserved - at least in part -  in yeast and humans [2]. Moreover, in 
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addition to the KMO enzyme, all of the other enzymes involved in the kynurenine 
pathway were shown to be conserved in yeast, supporting the hypothesis of a conserved 
mechanism of this pathway in lower organisms.   
In order to gain a better understanding of the reaction mechanism of KMO, 
ScKMO has now been heterologously expressed in E. coli, purified and characterised 
using a variety of spectroscopic techniques, including UV/Visible and fluorescence 
spectroscopy. Elucidation of the reductive and oxidative half reactions was performed 
using kinetic and stopped flow techniques. Ligand binding and inhibition studies with 
KMO inhibitors were undertaken and compared to the dissociation constants obtained in 
Chapter 3 to validate ScKMO as a good homology model for the study HsKMO. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Prediction of membrane helices and secondary structures in ScKMO – Panel A: The plot 
shows the location of the predicted hydrophobic regions ( between residues 1-27 and 425-455) (by 
THMM[236]). Panel B: Prediction of secondary structures based on KMO primary sequence The letters 
coloured in black represent predicted loops, in red helices and blue s trands. The software XtalPred did not 
predict any transmembrane region (by XtalPred[237]).  
 
 Figure 4.2 shows the sequence alignment of KMO from H. sapiens and S. 
saccharomyces. They share 34.1 % identity and 51.4 % similarity. Although these values 
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are not significantly high, the dinucleotide binding motif characteristics of flavin 
monooxygenases that require NADP(H) and FAD as coenzymes (Figure 4.2 -first boxed 
fragment) is conserved as well as putative consensus domains for both FAD and 
NAD(P)H binding ( Figure 4.2 - second and third boxed fragments). 
 
Figure 4.2. Multiple alignment of the amino acid sequence of KMO from H. sapiens and S. cerevisiae. 
Blue coloured residues denote sites of conserved amino acids. Sequence alignment was generated by 
ClustalOmega and drawn by Jalview software. Boxed areas are sequences associated with NADP(H) and 
FAD binding that are conserved in human and yeast KMO. 
 
 
4.2. EXPRESSION AND PURIFICATION OF  SCKMO 
 
Synthetic ScKMO gene was codon optimised for overexpression in E. coli 
(Section 2.2.1.3). The choice of this bacterial system lies in the fact that it is the most 
widely used host system for protein amplification and there is an extensive choice of 
cloning vectors compared to other host organisms. Furthermore, due to the fact that it is 
the simplest and easiest system to grow in high yields, it was our first choice in 
attempting to express ScKMO.   
ScKMO was cloned into pET15b and pET24b vectors in order to compare the 
expression levels of the recombinant protein with N- and C-terminal His6-tags, 
respectively. The resulting constructs were confirmed post-miniprep by DNA sequencing 
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using the forward T7 and reverse T7 term primers. The plasmids were then transformed  
into E. coli BL21(DE3) cells. 
Expression trials were carried out with both constructs to select optimal growth 
conditions.  Figure 4.3 shows a Western Blot of soluble lysates of the different KMO 
constructs at varying growth temperatures and IPTG concentrations. Both the pET24b-
KMO and pET15b-KMO plamids yielded overexpressed KMO protein in the soluble 
fraction of BL21(DE3) cells. The maximum expression levels were achieved with 0.1 M 
IPTG and at 25ºC for both constructs. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3:  Expression trials of Sc KMO variants. Panel A - Western Blot of soluble lysate of pET15b-
KMO and pET24b-KMO variants with anti-His antibody. Panel B - Western Blot of soluble lysate of 
pET15b-KMO with anti-KMO antibody at different temperatures and IPTG concentrations.  
 
 
As purification strategies have not previously been reported for ScKMO, the first 
approach was to follow the purification steps used for human truncated KMO expressed 
in P. pastoris (Section 3.1.2.).  As both pET vectors contained His-tags, the first 
purification step involved using Ni2+ affinity chromatography as described in the 
Materials and Methods section. The protein from this step was purified further using a 
Blue Sepharose Chromatography column. Finally, size exclusion chromatography was 
used to further polish the final sample or simply to exchange buffer into optimal 
conditions for crystallography. This procedure could be used to purify N-terminally His-
tagged KMO (Figure 4.4) but did not result in pure KMO when the His-tag was attached 
MW (kDa) 
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to the C-terminus. The results with this protein suggest that the C-terminal His tag might 
not be solvent exposed as the protein did not bind to the nickel resin. Several attempts to 
optimise the purification protocol were carried out using anion (DE-52) and cation (Mono 
S) exchange chromatography techniques, as well as hydrophobic interaction 
chromatography, but without success. As a result, the pET15b-KMO construct was used 
to produce N-terminally His-tagged KMO for further biochemical and biophysical 
studies. Typical expression levels obtained for pET15b-KMO were 4 mg/L of culture, 
which was sufficient to progress for further characterisation of the enzyme. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. SDS-PAGE analysis of ScKMO purity after each purification step. Lane 1: Protein Marker, 
Lane 2: post nickel sepharose column, Lane 3: post Blue Sepharose column, Lane 4: post size exclusion 
chromatography. 
 
Western Blot (Figure 4.3) and SDS-PAGE gel analyses of purified ScKMO 
(Figure 4.4) showed a band migrating at ~48 kDa which is lower than the expected 
molecular weight of 57 kDa, calculated from the amino acid sequence. The difference in 
the apparent molecular weight might be due to cleavage in the C-terminal region by 
exoproteolysis during protein expression, as the N-terminus is intact and was recognised 
by antibodies to the His-tag. Interestingly, from the Western Blot (Figure 4.3) it is 
possible to visualise a subtle difference in the molecular weight of both KMO variants, 
where the C-terminally His-tagged KMO presents a higher molecular weight. In this case 
the C-terminal region is preserved and was recognised by antibodies to the His-tag. We 
hypothesise that the His-tag in the C-terminus might prevent the exposure of some 
residues where proteolysis is more likely, although analysis of the primary sequence did 
MW (kDa) 
 1         2           3           4           
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not suggest any characteristic proteolysis site in the KMO C-terminal region. Protein 
instability could also be caused by loosely structured peripheral regions such as the C-
terminal end and therefore allowing a number of degradation processes to occur. The 
exact molecular weight of pure ScKMO was confirmed by Electrospray Ionisation Mass 
Spectrometry (EL-MS) (Figure 4.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5. The electrospray ionization liquid chromatography-mass spectrometry of semi purified 
ScKMO. Deconvoluted Mass spectrum shows an exact molecular weight of 47.107kDa. 
 
 
According to the molecular weight obtained from EI-MS, 47.1 kDa, and protein 
sequence analysis, the protein was cleaved after Phenylalanine 396. Initial 
crystallographic structure of ScKMO was solved as described in Section 5.3. However, in 
order to prevent ambiguities in the definition of the C-terminal region and to prevent 
future problems with further cleavage, an engineered truncated form was generated, 
KMO394, by site directed mutagenesis to delete the residues 395 to 460.  
KMO394 was expressed and purified following the same steps carried out for 
ScKMO. The protein yield obtained was significantly higher for this truncated form (15 
mg/L of culture) when compared to the cleaved ScKMO, which supports the hypothesis 
that the hydrophobic residues in the C-terminus were preventing the efficient expression 
of soluble KMO. 
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4.3. PH AND TEMPERATURE DEPENDENCE ON KMO394 
ACTIVITY 
 
The activity of the ScKMO enzyme was initially tested at a range of different 
temperatures and pHs to find the optimal conditions for maximal enzyme activity. Assays 
were conducted as described in section 2.2.8 and the enzymatic reaction was monitored 
spectroscopically by following the decrease in absorbance of NADPH at 340 nm at 
saturating concentrations of L-KYN and NADPH.  
Initial measurements revealed that cleaved ScKMO and KMO394 were 
kinetically identical, as expected, and therefore, all subsequent the kinetic 
characterisations were carried out exclusively with KMO394. 
 
Figure 4.6. Effects of temperature and pH on KMO394 activity. The biochemical activity was assayed 
with 500 M KMO394, 200 M L-KYN and 200 M NADPH. The enzymatic reaction was monitored by 
following the decrease in absorbance of NADPH at 340 nm with temperatures ranging from 10 to 40ºC 
(Panel A) and pH ranging from 6 to 10 (Panel B). The temperature profile was fit to a hyperbola and the pH 
profile was fit to two pKa’s equation. 
 
 
The temperature has a major effect on the activity of KMO394, with the highest 
activity achieved at temperatures between 30-35°C and a rapid decrease on either side of 
this interval (Figure 4.6A). The activity was also found to be stable when assays were 
performed with enzyme that had been pre-incubated at the same temperature over a 
period of at least 20 minutes. However, the enzyme started to precipitate upon prolonged 
incubation at temperatures higher than 35°C and consequently, further steady state and 
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inhibition assays were carried out at 30°C. The optimal temperature range for the activity 
of yeast KMO is in the same range as described in section 3.2.3 for recombinant human 
KMO (Topt= 33-38°C) and is similar to reported results carried out in crude or partially 
purified mammalian KMOs under similar conditions [208, 210]. No published data is 
available regarding the optimal temperature for yeast KMO. 
 An activity pH-profile was also obtained for the ScKMO enzyme (Figure 4.6B). 
KMO394 was most active between pH 7.5 and pH 9 with an optimum pH at 8.5. 
Analysis of the pH profile using the two pKa’s equation (Equation 2) gave a first pKa of 
7.2 and a second pKa of 9.5. On either side of these values the enzyme activity decreases 
significantly. 
The pH optimum obtained for KMO394 is comparable with previous reports on 
mitochondrial preparations of ScKMO where maximal KMO activity was observed at a 
pH of 8.0[250]. The value obtained is also in the same range for recombinant HsKMO 
described in section 3.2.3 where the optimum pH was 8.0. 
 
 
4.4. KINETIC ASSAYS OF KMO394 
 
As mentioned in the previous section, KMO activity can be monitored by 
following the decrease in absorbance of NADPH at 340 nm. A complete kinetic analysis 
of KMO394 was carried out by using initial-velocity measurements of the overall 
reaction at varying L-KYN or NADPH concentrations as described in Section 3.2.4. 
Apparent steady-state parameters were measured at an optimal temperature (30ºC) and 
pH (pH 8.5) for KMO394 so that the values could be directly comparable to published 
data.  
The initial kinetic analysis of KMO394 was carried out with NADPH 
concentrations ranging from 0-200 M based on the Km values reported in the literature 
[250]. However, using this range of concentrations the enzyme activity did not saturate. 
The extinction coefficient of NADPH (6.22 mM cm-1) limited the use of concentrations 
higher than 200 M in a standard cuvette due to the high absorbance and therefore an 
accurate Km for NADPH was not determined in this way. Consequently, the kinetic 
analysis was performed by following the formation of the product 3-HK by HPLC, as 
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described in section 2.2.9. 3-HK was quantified by comparison with a 3-
hydroxykynurenine calibration curve. 
Figure 4.7 shows the initial-velocity measurements of KMO394 activity at 
varying concentrations of L-KYN and NADPH. The Km values for both substrates were 
determined by fitting the rate of turnover to the Michaelis Menten equation (Equation 1). 
 
 
Figure 4.7. Overall initial-velocity measurements of KMO394 activity at varying concentration of L-
KYN (Panel A) and NADPH (Panel B). Km values were calculated by fitting the data to the Michaelis-
Menten equation. 
 
 
Table 4.1. Apparent steady-state parameters for KMO394 
 
 
 
 
 
 
 
The kinetic analysis of recombinant KMO394 shows a hyperbolic dependence 
on the concentration of L-KYN with an experimental Km value (17.98 ± 2.5 M) that is 
similar to those observed for native protein in Saccharomyces cerevisiae mitochondria 
preparations (Km = 40 M) [250]. In contrast, Km for NADPH (Km = 155.7 ± 26 M) is 
approximately 10-fold higher than Km values previously reported in the literature for 
Kinetic Coefficients Values 
Km NADPH (M) 155.7 ± 26 
Km L-KYN (M) 17.9 ± 2.5 
kcat (s
-1
) 0.02 ± 0.003 
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native Saccharomyces cerevisiae (Km = 16 M) [250], as well as for higher organisms 
such as Rattus norvegicus (Km = 23 M) [9]. 
   Although there is no published data regarding the rate of turnover for ScKMO, the 
k
cat of approximately 0.02 s
-1 is significantly slower than the rate obtained in the previous 
chapter for recombinant HsKMO (k
cat = 0.89 s
-1). The turnover number is also 
significantly lower than those obtained for KMO from other organisms [207, 251]. 
Although we were not able to purify full length ScKMO with a C-terminal His-tag, the 
expression levels were sufficient to carry out enzyme activity assays using the soluble 
lysate fraction. The concentration of the enzyme was estimated by Western Blot and 
compared with pure KMO394 of known concentration.  The activity of both enzymes 
was compared by following the formation of the product 3 hydroxykynurenine by C18 
reversed-phase HPLC. The full length ScKMO was estimated to give a k
cat = 0.13± 0.02 s
-
1 which is approximately 6 times higher than KMO394. 
It is possible that the lower turnover number in the truncated protein could be 
engineered result of the C-terminal deletion of the protein. As previously explained in 
Chapter 3, there is evidence that the C-terminal region might be involved in the catalytic 
activity of the enzyme, although its role is not completely clear. From the results obtained 
for human truncated KMO (Chapter 3), we hypothesise that it might be related to 
NADPH binding. This hypothesis has now been further explored by studying individually 
the reductive half reaction of the catalytic cycle (see below). 
 
 
4.5. KINETICS OF THE REDUCTIVE HALF REACTION  
 
The rate of reduction of the flavin cofactor by NADPH was measured 
spectrophotometrically using stopped-flow methods. Studies of reaction processes by 
stopped-flow methods enable analysis of reaction rates on the millisecond timescale and 
can be used to directly determine the rate constants for the reductive half-reaction of 
KMO. KMO394 was mixed anaerobically with high concentrations of NADPH (10 
mM) and in the presence and absence of 500 M L-KYN or inhibitor (UPF 648). The rate 
of flavin reduction was monitored at 450 nm and the transients obtained were fitted to a 
single exponential (Figure 4.8). The reduction rates obtained are similar to the kcat value 
(0.02s-1) calculated using steady-state experiments, suggesting that reduction by NADPH 
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is the rate-determining step of the reaction. The limiting rate constant obtained for the 
free enzyme is similar to the rate of reduction in the presence of the L-KYN substrate but 
is approximately two-fold lower in the presence of the UPF 648 inhibitor. These results 
are not in accordance with reports from several class A flavoprotein monooxygenases, in 
which flavin reduction by NADPH is strongly stimulated by formation of the enzyme-
substrate complex [188]. Results from Pseudomonas fluorescens KMO had shown that 
reduction of complex KMO-L-KYN is 2500 faster compared to the free enzyme [206]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4.8: Reductive half reaction of KMO394 in the presence and absence of ligands. Anaerobic 
mixtures of 20 μM KMO (Black trace) and saturating concentrations of L-KYN (Dark grey trace) and UPF 
648 (Light grey trace) were mixed against anaerobic NADPH (10 mM) on a stopped-flow 
spectrophotometer at 10 °C. The decrease in flavin absorbance was observed at 450 nm. The insect depicts 
the same reaction but performed with Dithionite instead of NADPH. Traces obtained were fit to a single 
exponential. 
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Table 4.2. Rate constants for KMO394 upon reduction with NADPH and 
Dithionite 
 
 
 
 
 
 
 
 
 
The reductive half reaction of KMO394 was also measured by substituting 
NADPH with sodium dithionite as an electron donor, in order to infer the possible 
involvement of NADPH in the low activity of the enzyme (Figure 4.8 Inset and Table 
4.2). Interestingly, the rate constants for flavin reduction of KMO394 with sodium 
dithionite are much higher compared to reduction with the NADPH cofactor. However, 
they are now similar to the reduction rates observed for Pseudomonas fluorescens KMO-
L-KYN complex by NADPH (kobs= 4.9 ± 0.3 s-1) [206], providing further evidence that 
binding of NADPH may be limiting the catalytic efficiency of KMO394. It is likely that 
the NADPH binding site of KMO394 may be less accessible or structurally modified by 
the C-terminal deletion in this protein. This hypothesis will be discussed further 
throughout Chapter 5.  
 
As the reductive half reaction with NADPH occurs on the minutes timescale, the 
dependence of the observed rate constant for reduction of KMO394 on the concentration 
of NADPH was carried out anaerobically using a standard spectrophotometer rather than 
a stopped-flow instrument. This was achieved by mixing KMO394 with different 
concentrations of NADPH in the presence of an excess of L-KYN substrate and by fitting 
the flavin absorbance changes at 450 nm to a single exponential equation to obtain an 
apparent rate constant.  
Representative absorbance changes for the reduction of KMO394 are shown in 
Figure 4.9 at different concentrations of NADPH. The dependence of the rate of reduction 
on NADPH concentration yielded an apparent Km for NADPH of 1.08 ± 0.3 mM (Figure 
4.10). This value is approximately 6-fold higher than the Km value obtained from the 
 NADPH Sodium Dithionite 
KMO394 0.009 ± 9x10-4 s- 1.9 ± 0.04 s-1 
KMO394L-KYN 0.012 ± 1x10-4 s-1 1.4 ± 7x10-4 s-1 
KMO394UPF 648 0.02 ± 3 x10-4 s-1 1.5 ± 0.03 s-1 
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steady state measurements (see above) and at this stage it is unclear why such a 
discrepancy should exist.  
 
Figure 4.9. Absorbance changes due to the reduction of KMO394 with different concentrations of 
NADPH. Anaerobic mixtures of 20 μM KMO394 were titrated with 70 M (Panel A) and 20 mM 
NADPH (Panel B) and the reaction was monitored for 10 minutes in cycle mode to compare the reduction 
rate. The insets of both panels show the absorbance changes at 450 nm over 25 minutes. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10. Dependence of the observed reduction rate constant of KMO394-L-KYN on the 
concentration of NADPH. Anaerobic mixtures of 20 μM KMO394 in the presence of an excess of L-
KYN were titrated with different concentrations of NADPH (0-20mM) and the flavin absorbance changes 
at 450 nm were measured and fitted to a single exponential equation to obtain an apparent rate constant. 
The dependence of the apparent rate constants on the concentration of NADPH was fitted to a one site 
binding equation. 
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4.6. KINETIC ANALYSIS OF THE OXIDATIVE HALF 
REACTION 
 
 In order to study the mechanism of the oxidative half reaction of KMO394, 
the anaerobically reduced KMO-L-KYN complex was mixed with oxygenated buffer 
using a stopped-flow spectrometer (Figure 4.11).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11. Oxidation of KMO394 in the stopped-flow instrument. A) Raw data Spectral changes 
recorded after mixing equal volumes of the fully reduced L-KYN-KMO complex and oxygenated buffer 
The spectrum corresponds to the fully reduced enzyme, and the oxidized enzyme (λmax of 450 nm), 
respectively. The arrow indicated the formation of the oxidized enzyme. B) Pure deconvoluted intermediate 
spectra observed in the reoxidation of the KMO-Lkyn complex resulted from global analysis, indicating a 
two-step process of oxidation. Inset: Relative concentration of species over time 
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The raw data shows that in the presence of molecular oxygen the KMO-L-KYN 
complex fully oxidises with the formation of a peak at 450 nm characteristic of FAD 
molecule (Figure 4.11A). The data were analysed using global analysis where the spectral 
changes were fitted to a sequential model of A → B → C (Figure 4.11B).  In the 
deconvoluted spectrum of species B the intermediate that accumulates after mixing with 
dioxygen is similar to the spectrum of the oxidised enzyme and may arise after 
hydroxylation of L-KYN. It is possible that this species is the C4a-hydroperoxyflavin 
intermediate, which is the hydroxylating species that is typically formed in this class of 
flavoproteins. However, it was difficult to confirm the identity of the species as this 
intermediate would typically be expected to absorb in the 370 – 380 nm region and is 
complicated by the overlapping spectra of the L-KYN substrate, 3-HK product and the 
NADPH cofactor in this same wavelength region. In subsequent stopped-flow 
experiments on the oxidative half reaction the reaction was followed by measuring the 
increase in absorbance at 450 nm. Biphasic absorbance transients were observed for 
KMO in the presence and absence of L-KYN upon mixing with oxygen (Figure 4.12). 
The observed rate constant for the first phase revealed a hyperbolic dependence on the 
concentration of molecular oxygen with rate constants of k1 = 2.1 s-1 in the absence of L-
KYN and k1 = 1.8 s-1 in the presence of L-KYN. It was possible to calculate an apparent 
Km for oxygen of 341.8 ± 54 M, However, at low oxygen concentrations it should be 
noted that the rate of the first phase is similar to that of the second phase (Figure 4.12 
Inset), which makes an accurate determination of the first rate constant more difficult. In 
previous studies the rate of the first phase has shown a linear dependence on oxygen 
concentration and it has been suggested that it is likely to represent the binding of 
molecular oxygen to the enzyme followed by the formation of the C(4a)-hydroperoxide 
species. However, the apparent hyperbolic dependence on oxygen concentration in the 
current study suggests that the reaction may be more complicated and it is likely that 
additional experiments will be required to confirm the identity of this intermediate. 
Additional studies were also carried out in the presence of the UPF 648 inhibitor in order 
to compare the oxidative rate constants relative to the physiological substrate L-KYN 
(Table 4.3). Interestingly, the fact that the inhibitor complex gets fully oxidised supports 
the hypothesis that the oxidative half reaction is not dependent on the binding of the 
substrate with an activated ring but can undertake the subsequent steps with a different 
ligand. The observed spectral changes are similar to those observed in the presence of the 
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native substrate L-KYN, although the first rate constant for the KMO-UPF 648 complex 
is slightly decreased (k1=1.3 s-1), suggesting that the oxygen binding site might be 
occupied or structurally disturbed in the presence of the KMO inhibitor.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12. Oxidative half reaction of KMO394 in the presence of oxygen. Absorbance traces for 
KMO in the presence (in black) and absence of L-KYN (in light grey) and in the presence of UPF 648 (dark 
grey) showing the oxidation of the flavin cofactor with saturating O2. Inset: dependence of the observed rate 
constants, k1 and k2 on the concentration of dioxygen for KMO-L-KYN. 
 
 
The rate of the second phase showed little or no dependence on the concentration of 
oxygen with rate constants of k2 = 0.3 s-1 in the absence of L-KYN and k2 = 0.4 s-1 in the 
presence of L-KYN. Similar results were also reported for the oxidative half reaction of 
Pseudomonas fluorescens KMO[198]. Consequently, this phase has been attributed to the 
hydroxylation step where the distal oxygen reacts in an electrophilic attack with the L-
KYN substrate to form the hydroxylated product, water and the  flavin C(4a)-hydroxide 
which is then hydrated to the oxidised enzyme. There is no evidence of the hydroxyflavin 
species as a second intermediate possibly because this species is formed instantly after the 
hydroxylation of the aromatic substrate. According to their results, the second 
intermediate C4(a)-hydroxyflavin was not observed and therefore they suggested that the 
dehydration of  hydroxyflavin does not depend on the release of the product and takes 
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place instantly after the hydroxylation of the aromatic substrate. The rate of the second 
phase is also reduced in the presence of the UPF 648 inhibitor, suggesting that a bound 
ligand may also affect this process.  
 
 
Table 4.3. Rate constants for the oxidative half reaction for KMO394 
 
 k1 (s-1) k2 (s-1) 
KMO394  2.1 ± 0.3 0.5 ± 0.04 
KMO394L-KYN 1.8 ± 0.4 0.4 0 ± 0.03 
KMO394UPF 648 1.3 ± 0.2 0.2 ± 0.04 
 
 
 
4.7. INHIBITION ASSAYS OF KMO394 
 
The inhibition of KMO394 activity by the KMO inhibitor UPF 648 was 
investigated by following the formation of the product 3-HK by reversed phase HPLC at 
saturating L-KYN conditions (500M) and at varying UPF 648 concentrations. As 
previous results on the recombinant HsKMO have already showed the efficacy of UPF 
648 (Section 3.3.5) the main purpose of these measurements was to compare the 
inhibition constants of both enzymes in order to verify that the yeast enzyme is a good 
model for studying inhibitor binding in HsKMO. UPF 648 is a tight binding inhibitor and 
therefore the data from the inhibition studies was fitted to the Morrison equation.   
Additional explanations on tight binding inhibitors and the use of the Morrison’s equation 
are described in Section 3.3.5. 
As with the HsKMO, UPF 648 also shows tight binding inhibition for yeast 
KMO394 with an apparent Ki of 73.96 ± 14.3 nM (Figure 4.13). This value is in the 
same range to previous studies carried out in gerbil models with an IC50 = 40 nM [172], 
providing further evidence that UPF 648 is a very attractive ligand to use in future co-
crystallization studies. Comparisons with HsKMO will be discussed further in Section 
4.9. 
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Figure 4.13. Fractional velocity of 3-HK formation as a function of UP648 concentration with S. 
cerevisiae KMO. 100 nM enzyme was incubated with 2 mM NADPH, 500 M L-kyn and different 
concentrations (0-M) of the inhibitor UPF 468. The product formation was analysed by reversed-phase 
HPLC. The data were fitted to the Morrison equation for tight binding inhibitors and yielded an apparent Ki 
= 73.96 ± 14.3 nM. 
 
 
4.8. LIGAND BINDING ASSAYS OF KMO394 
 
Binding assays, based on changes in the fluorescence emission spectra of FAD, 
were conducted to determine the binding affinity (Kd) of substrates or KMO inhibitors to 
KMO394. As explained in Section 3.2.4., certain substrates and analogues are able to 
quench or enhance the fluorescence of the FAD depending on any conformation changes 
in the active site. The fluorescence of the FAD cofactor, which was recorded after 
excitation at 450 nm, has been measured at different ligand concentration after titration of 
the ligand the enzyme solution.  Fluorescence spectra of KMO394 in the absence and 
presence of different ligands are shown in Figure 4.14. The binding isotherm of the 
interactions between each compound and KMO394 is also shown in the respective inset 
panels.  
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Figure 4.14. Measurements of the 
binding constants for L-KYN, 
UPF 648 and Ro 61-8048 by 
ligand perturbation of flavin 
fluorescence emission. Titration of 
ligands into 5 M KMO was 
carried out under aerobic conditions 
at 25 ºC. The perturbation in 
fluorescence emission was followed 
at 520 nm using an excitation 
wavelength of 450 nm. (A) Titration 
of L-KYN (0-30M from top to 
bottom) to KMO394 led to an 
increase in the FAD fluorescence. 
Inset: Fluorescence changes at 520 
nm as a function of L-KYN 
concentration. Fitting of the data to 
the Morrison equation yields an 
observed Kd of 14.53 ± 1.6 M. (B) 
Titration of UPF 648 (0-10 M 
from bottom to top) to KMO394 
led to an increase in the FAD 
fluorescence Inset: Fluorescence 
changes at 520 nm as function of 
UPF 648 concentration. Fitting of 
the data to the Morrison equation 
yields an observed Kd of 137.7 ± 8.3 
nM. (C) Titration of Ro 61-8048 (0-
17 M from top to bottom) to 
KMO394 led to a decrease in the 
FAD fluorescence Inset: 
Fluorescence changes at 520 nm as 
a function of the Ro 61-8048 
concentration. Fitting of data to the 
Morrison equation yields an 
observed Kd of 750.3 ± 132.4 nM. 
 
 
 
A 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
C 
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Table 4.4. Dissociation constants for the binding of selected KMO drugs and 
substrate to KMO394 
 
 
 
 
 
 
 
Binding of the L-KYN substrate led to an increase in the fluorescence of the FAD 
cofactor at 520 nm in a dose-dependent manner giving a dissociation constant of 14.5 ± 2 
M (Figure 4.14A). The dissociation constant obtained for the physiological substrate is 
within a factor of 4 of the Kd calculated for the truncated form of HsKMO (See section 
3.2.4) and in both cases an enhancement of the FAD fluorescence was observed upon 
titration with L-KYN, suggesting that the binding mode of the substrate is conserved in 
yeast and human KMO. As previously mentioned in Section 3.2.4, the enhancement in 
the fluorescence suggests that conformation changes in KMO394 upon ligand binding 
expose the flavin isoalloxazine ring to the solvent, which leads to the increase in the 
fluorescence signal. 
An enhancement in the flavin fluorescence was also observed in the titration of 
KMO394 with the UPF 648 inhibitor (Figure 4.14B). The observed Kd was 138 ± 8 nM, 
which indicates a tight binding of the ligand to the KMO394, as expected from the 
apparent Ki of 74 ± 14.3 nM previously obtained during inhibition assays (Section 4.7). In 
addition, the fluorescence changes upon ligand binding are similar to those of the natural 
substrate, suggesting a similar mode of binding, which may well be expected as the UPF 
648 inhibitor is a substrate analogue. 
The KMO inhibitor Ro 61 80-48 was also tested to explore the conformation 
changes induced in the active site upon ligand binding (Figure 4.14C). Interestingly, 
while the previous ligands enhanced the FAD fluorescence, Ro 61-8048 quenched the 
fluorescence with an observed Kd= 750.3 ± 132 nM. This suggests that binding of this 
ligand may cause a conformational rearrangement of the surrounding protein that ensures 
that the FAD is less solvent exposed. The same behaviour was also observed for truncated 
HsKMO, suggesting a similar mode of binding to both enzymes (Section 3.2.4). In 
combination, these results suggest that KMO394 might undergo different 
Substrate/Inhibitor Kd 
L-KYN 14.5 ± 1.6 M 
UPF 648 137.7 ± 8.3 nM 
Ro 61-8048 750.3 ± 132.4 nM 
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conformational changes and binding modes compared to the physiological substrate, 
possibly binding in a second binding pocket re-side of FAD. However, importantly both 
human and yeast KMO enzymes show a comparable mechanism in the binding mode of 
Ro 61-8048. The dissociation constant is 20 times higher compared with the  IC50 value 
of 37 nM that was previously reported for this inhibitor in KMO from rat kidney 
mitochondria preparations [173] but is within a factor of 3 when compared to 
recombinant truncated HsKMO (Section 3.2.4).  
 
 
4.9. CONCLUDING REMARKS 
 
Initial experiments to elucidate the catalytic mechanism of HsKMO (Chapter 3) 
using spectroscopic, kinetics and crystallographic methods were not possible due to the 
poor stability and low expression yield of this protein. Given the difficulties in expression 
of high quantities of HsKMO suitable for further biochemical and biophysical assays we 
turned our attention to ScKMO, which is closely related to HsKMO (38 % identity and 51 
% similarity). This chapter has presented a quantitative biochemical characterisation of 
ScKMO. Expression of full-length ScKMO in E. coli yielded a protein fragment with a 
lower molecular weight than anticipated and electrospray ionisation mass spectrometry 
indicated proteolytic cleavage at residue 394. Consequently, a truncated KMO394 
(deleted in residues 395 to 460) version of the enzyme was engineered by site-directed 
mutagenesis to define the exact cleavage point and to prevent further cleavage. The 
biochemical characterisation of KMO394 was carried out by using a combination of 
UV/Visible absorbance spectroscopy, fluorescence spectroscopy, HPLC-based assays and 
stopped-flow analyses and revealed important kinetic and ligand binding properties of 
this enzyme. The purified KMO394 enzyme was active as a flavin-dependent 
monooxygenase and therefore, facilitates structural characterisation of KMO, which will 
be discussed in more detail in Chapter 5. 
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Figure 4.15. Kinetic comparison between HsKMO and ScKMO. (A) Initial velocity measurements of 
HsKMO (grey trace) and ScKMO (black trace) activity varying the concentration of the substrate L-
kynurenine. The data was fitted with Michaelis Menten equation yields a Km= 24.35± 4.1 and Km= 18.24± 
2.58 for ScKMO. (B) Fractional velocity of 3-HK formation as a function of UP648 concentration with 
HsKMO (grey trace) and ScKMO (black trace). 100nM enzyme was incubated with 2mM NADPH, 500M 
L-kyn and different concentrations (0-M) of the inhibitor UPF 468. The product formation was analysed 
by reversed-phase HPLC. The data was fitted with Morrison equation for tight binding inhibitors yields an 
apparent Ki = 56.74 ± 8.02 nM for HsKMO and Ki = 73.96 ± 14.3 for ScKMO 
 
 
Table 4.5- Apparent kinetic constants for HsKMO and ScKMO 
 
 



KMO394 generated 3-HK in multiple turnover measurements and was inhibited 
by UPF 648 (Ki 74 nM) with a similar potency to that with HsKMO (Figure 4.15 and 
Table 4.5). Figure 4.14 and Table 4.5 illustrate HsKMO and ScKMO present similar 
kinetic and inhibitor constants, which confirm that the mechanism of the KMO enzyme is 
remarkably well conserved between yeast and humans. As UPF 648 is a substrate 
analogue of L-KYN and both ligands bind with the same selectivity in human and yeast 
KMO, it is tempting to speculate that the active site of KMO is preserved among both 
enzymes, providing support that ScKMO is a good homology model for the study of 
HsKMO. 
 
Enzyme Km L-KYN (M) Ki appUPF648 (nM) 
HsKMO 24.4 ± 4.1 56.7 ± 8.0 
ScKMO 18.2 ± 2.6 73.9 ± 14.3 
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  However, a comparison of the rate of turnover between KMO394 and full length 
yeast and human KMO revealed that the activity of KMO394 is significantly slower (6 
and 44 fold lower respectively). The simplest and most likely explanation for this 
difference is that the truncation of the C-terminal region of the protein plays an important 
role in the activity of the protein. As previously explained in Chapter 3, studies conducted 
on full length pig KMO and C-terminal deletion mutants revealed that a segment of 20 
amino acid residues close to the C-terminus is necessary for the enzymatic activity 
although its exact role remains elusive [246].  
Moreover, the results from the reductive half reaction studies suggest that the 
truncation of the protein may influence the NADPH binding properties of the enzyme. 
The reduction of flavin by NADPH is the rate-limiting step in the activity of KMO394 
and we have shown that the rate of flavin reduction with sodium dithionite is 
considerably higher. In addition, the dissociation constant obtained for NADPH (1.08 ± 
0.3 mM) is significantly higher than previously published data where Kd values are 
typically in the M range [250, 9]. 
An alternative explanations for the lower turnover might be related to the the 
expression of a eukaryotic protein in a prokaryotic system. It is known that  native KMO 
from Saccharomyces cerevisiae is localised in the membranes of mitochondria and 
promitochondria [212, 250]. Consequently, the overexpression of full length soluble 
KMO in E. coli, without the C-terminal membrane anchoring region, may lead to a 
decrease in the catalytic activity of the enzyme. In addition, it is known that KMO protein 
that is expressed in E. coli will not contain any of the native post-translational 
modifications or glycosylation. Although there are relatively few studies reporting such 
changes it is possible that the catalytic activity of an enzyme could be modulated by post-
translational modifications [252]. As protein phosphorylation is the most frequent type of 
post-translational modification in Saccharomyces cerevisiae [252] phosphorylation 
modification prediction software has been used to estimate any probable phosphorylation 
sites in the ScKMO protein sequence (Figure 4.16). The attachment of a phosphoryl 
group is hypothesised to affect the energy landscape of the modified protein, but in the 
majority of cases the tertiary structure of the enzyme is not affected [253]. The main 
advantage of avoiding post-translational modifications by using E. coli as a host 
expression system is that such modifications have been linked to intrinsically disordered 
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protein regions and therefore the possibility of crystallising ScKMO would be 
significantly lower. 
 
 
 
 
 
 
 
 
 
 
Figure 4.16. Prediction of phosphorylation sites in ScKMO using the online tool NetPhosYeast 1.0 
Server [254]. 
 
Stopped-flow measurements were also used to study the mechanism of the 
oxidative half reaction. The rates constants that were determined for this step are in the 
same range to KMO from P. fluorescens [198] and are comparable to other flavoprotein 
monooxygenases [255]. The biphasic traces and analysis of deconvoluted spectra 
suggests the formation of only one intermediate during the oxidation step, which is 
hypothesised to be the C(4a)-hydroperoxide species. The second intermediate that is 
typically characteristic of the oxidation step in flavoportein monooxygenases was not 
observed. Many other studies have shown similar results, suggesting that the dehydration 
of the hydroxyflavin does not depend on the release of the product and takes place 
instantly after the hydroxylation of the aromatic substrate. Further details on the 
mechanism of KMO and a comparison with other flavoproteins monooxygenases will be 
discussed in the next chapter, which describes the structural characterisation of ScKMO 
and KMO394 and complements the results from this chapter. 
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STRUCTURAL CHARACTERISATION OF 
SACCHAROMYCES CEREVISIAE 
KYNURENINE 3-MONOOXYGENASE
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5. STRUCTURAL CHARACTERISATION OF 
SACCHAROMYCES CEREVISIAE 
KYNURENINE 3-MONOOXYGENASE 
 
 
5.1. INTRODUCTION 
 
Inhibition of KMO is an attractive therapeutic strategy for several acute and 
chronic neurological diseases, particularly HD. Despite major interest in therapeutically 
targeting KMO only a few potent inhibitors are currently available [178, 8]. In order to 
rationally design novel KMO inhibitory compounds through structure-based drug design 
it is vital to obtain structural information for this protein, both native and bound to 
existing drugs. This will permit docking screens using virtual libraries of compounds, 
which may ultimately identify novel inhibitor scaffolds that possess the selectivity and 
affinity necessary to open novel opportunities for therapeutic intervention in HD and 
other brain disorders. 
However, since HsKMO is membrane associated, it has proven to be extremely 
difficult to obtain sufficient quantities of this enzyme for structural studies and therefore 
there is no structural knowledge of this enzyme. It is widely known that the crystallisation 
of membrane-associated proteins is a very challenging process that often ends in the 
failure to obtain diffraction quality crystals. This fact is consistent with the rarity of such 
structures solved by X-ray crystallography. To date, the investigation of the binding 
modes of possible KMO inhibitors has been carried out using structure and ligand-based 
computer-aided design tools based on structurally and functionally related enzymes [180, 
181]. 
Chapter 3 reports attempts to crystallise HsKMO and despite extensive efforts this 
study failed to yield crystals. In Chapter 4 we provide strong evidence that ScKMO is 
functionally similar to HsKMO and therefore it can be used as a model to develop new 
therapeutic inhibitors of the highly related (38 % identity and 51% similarity) HsKMO. 
The current chapter reports on the biophysical and structural studies of ScKMO, 
both the initial proteolytic soluble form of ScKMO and KMO394 (deleted in residues 
394 to 460). The elucidation of the ScKMO structure in complex with inhibitor UPF 648 
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will also be reported as well as the modelling of the physiologic substrate L-KYN. The 
residues involved in ligand binding will be verified by site directed mutagenesis and 
validated by inhibitor binding and kinetic assays.  
 
 
5.2. BIOPHYSICAL CHARACTERISATION OF SCKMO 
 
ScKMO was successfully isolated, expressed and purified, as described in Chapter 
4. A sufficient quantity of soluble protein was obtained to carry out further biophysical 
and structural studies. Prior to structural analysis, ScKMO was subjected to Thermofluor 
and MALLS analysis to determine their suitability for crystallography. 
 
 
5.2.1. Thermofluor Assay 
 
The Thermofluor assay is used to determine optimal buffer and additive 
conditions to further maximize the protein stability and increase the chances of protein 
crystallisation. Optimal buffers are necessary to allow proteins to be concentrated to the 
high levels often used in crystallography (5-30 mg/mL).  
The JBS Solubility Kit buffer screen (Section 2.2.12 Material and Methods) 
consisting of 24 buffer solutions at different pH values, ranging from 4.5 to 9.0, with 
concentrations of 50 mM was used to screen ScKMO. Among the 24 buffers tested, there 
were some buffers that appeared to be more favourable for ScKMO stabilisation, 
particularly ammonium acetate pH 7.0, HEPES pH 7.5, and potassium/sodium phosphate 
pH 7.0 with Tm of 54.5ºC, 50.2ºC and 47.8ºC respectively (Table 5.1). The ammonium 
acetate pH 7.0 and HEPES pH 7.5 buffers were subsequently used for further assays 
including the addition of additives capable of improving protein stability (Table 5.2).  
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Table 5.1. Melting temperatures of buffer screen of ScKMO 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
            
 
Table 5.2. Melting temperatures of additive screen of ScKMO 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Buffer pH Tm (°C) 
Citric acid 4.0 34.2 
Sodium/potassium  
phosphate 5.0 43.2 
Sodium citrate 5.0 42.8 
Sodium/potassium 
phosphate 6.0 45.7 
Bis-Tris 6.0 46.4 
Bis-Tris  propane 6.5 45.3 
Ammonium acetate 7.0 54.5 
Sodium/potassium 
phosphate 7.0 47.8 
HEPES 7.5  50.2 
Imidazole 8.0 42.8 
Tris 8.5 39.3 
Control 7.5 47.1 
Addtive Buffer Tm (°C) Buffer Tm (°C) 
NaCl 200 mM   1 1 56.2 22 47.4 
NaCl 400 mM 1 54.1 2 46.2 
Glycerol 20% 1 55.3 2 44.3 
CHAPS 8mM 1 53.3 2 40.2 
Dodecyl Maltoside 
0.4% 1 53.8 2 45.9 
BME 40mM 1 55.7 2 47.3 
DTT 4mM 1 54.2 2 44.6 
DTT 20mM 1 53.9 2 43.1 
Sample control 1 54.8 2 47.6 
Buffers shown are from the JBS Solubility Kit part A. Buffers which did not produce a 
Tm are not shown. Final concentrations for all buffers were 50 mM diluted from 100 
mM stocks. . Sample control is in 20 mM phosphate buffer pH 7.5. 
 
Additives shown are from the JBS Solubility Kit part B. Additives which did not produce 
a Tm are not shown. 
1 Buffer 1 correspond to Ammonium Acetate pH 7.0 
2 Buffer 2 corresponds to HEPES pH 7.0 
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Enhanced thermal stability of ScKMO was observed following the addition of 200 
mM Sodium Chloride, 40 mM BME and 4mM DTT in ammonium acetate pH 7.0 buffer 
(Table 5.2). These results are consistent with previous reports of KMO protein from 
Pseudomonas fluorescens in which the enzyme is more stable with moderate 
concentrations of NaCl and increases its activity in the presence of reducing agents [207]. 
Although the addition of 20% Glycerol improved the thermal stability of ScKMO by 
0.5ºC, this component was not included in the final buffer. High concentrations of this 
additive tend to be avoided in crystallography as it inhibits nucleation. Non-enhanced 
thermal stability was observed with the addition of additives when in MOPS pH 7.0.  
Following Thermofluor analysis ScKMO crystallisation samples were initially 
made up in Ammonium Acetate pH 7.0 with the addition of 150 mM NaCl and 7 mM 
BME.  
 
 
5.2.2. MultiAngle Laser Light Scattering(MALLS) 
 
Prior to crystallogenesis, MALLS was conducted on ScKMO to provide 
information about the polydispersity and aggregation state of the sample.  
Traces from the light scattering and refractive index for ScKMO were monitored 
and are shown in Figure 5.1. The traces show a single peak eluted after approximately 15 
mL with average molecular weight of 47.8 kDa. The standard deviation (S.D.) of the RH  
is 20.6% across the three axes,  indicating that ScKMO is a globular monomeric protein 
in solution, consistent with the plot from the Mr values, in which the molecular weight 
values remains constant over the duration of the elution peak (Figure 5.1 Inset). The 
single light scattering peak is concurrent with the refractive index peak. 
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Figure 5.1. MALLS analysis of ScKMO. Trace from a MALLS run of a sample of ScKMO. Light 
scattering is indicated as a voltage and refractive index is a relative scale. A single peak elutes at 
approximately 15 mL indicating only one species of ScKMO. Inset -  Plot of the molecular masses against 
the elution volume.  
 
 
Based on the primary sequence analysis, and according to the results obtained 
from EL-MS (Section 4.2), the molecular weight of the ScKMO is approximately 47kDa, 
taking into account that the protein was cleaved by exoproteolysis at residue 396. This is 
consistent with the Mr determined by MALLS and provides further evidence that ScKMO 
exists as a monomer in solution and has been isolated in a form highly suitable for 
crystallographic studies. The lack of information in the literature regarding the 
oligomerisation state of KMO from Saccharomyces cerevisiae and other species of yeast 
did not allow a direct comparison with our results. As previously described in Section 
3.2.6, the only study predicting the molecular weight and aggregation state of KMO was 
conducted in Rattus norvegicus KMO [210], suggesting a molecular weight of 200 kDa 
based on the elution pattern on size exclusion chromatography and results from SDS-
PAGE. They have also concluded that native R. novergicus exists as dimer in solution 
[210], which differs from the results obtained in ScKMO.  
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5.3. STRUCTURAL CHARACTERISATION OF SCKMO  
 
 
5.3.1. Crystallisation trials of ScKMO  
 
           Crystallogenesis trials of highly purified ScKMO were performed using the sitting 
drop vapour diffusion technique as described in Section 2.2.14.1. Initial screening 
involved the use of five commercially available crystallisation screens from Molecular 
Dimensions (Newmarket, UK) (JCSG +, PACT, Clear Strategy I + II, Morpheus). A 
broad range of protein concentrations (7-16 mg/mL) were also tested to improve the 
chance of obtaining crystals. Co-crystallisation experiments were performed with L-
KYN, UPF 648, Ro 80-6048 and NADPH in order to facilitate the formation of crystals. 
Proteins may be stabilised when they are complexed with a substrate through enhanced 
thermal stability and reduced flexibility [256, 257]. Furthermore, the complex structure 
with ligands would be also extremely useful to understand the mechanism of catalysis and 
the key residues involved in ligand binding. Ligand concentrations were calculated to be 
approximately 10 times the Kd plus protein concentration. 
Very few of the initially screened conditions gave rise to protein crystals either 
with or without ligands. ScKMO crystals were obtained from JCSG + E12 (0.1M 
Imidazole 7.8, 11% w/v PEG 8K) and Clear Strategy II B7 (0.1M Sodium Acetate 5.5, 
35% propanol). In both conditions the protein was screened at a concentration of ~14 
mg/mL, with crystals forming over a period of ~72 h at 277K.  
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Figure 5.2. Crystallogenesis of ScKMO and KMO394. Crystals obtained from crystallisation trials of 
ScKMO and KMO394. (A) ScKMO crystals obtained from B7 (0.1M Sodium Acetate 5.5, 35% propanol) 
CSS2 crystallisation screen, (B) ScKMO crystals obtained from E12 (0.1M Imidazole 7.8, 11% w/v PEG 
8K) JCSG crystallisation screen.   
          Two distinct crystal morphologies were observed (Figure 5.2). Condition B7 from 
Clear Strategy II gave rise to needles, whilst E12 from JCSG + produced crystals with a 
more plate like appearance. The presence of ligands during crystallogenesis did not 
produce any further variation in the observed morphology. 
        Both crystals display a yellow colour, indicating that the FAD cofactor was bound to 
the protein. Initial hit conditions were refined; through the use of grid screening 
variations were made in the pH, percentage of propanol and weight of PEG. Numerous 
ScKMO crystals were obtained, particularly with the propanol conditions, the majority of 
them producing large isolated crystals. The colour and morphologies of crystals remained 
unchanged. Given the possibility that the crystals obtained by co-crystallisation with 
ligands would not retain those compounds, protein crystals were additionally soaked with 
saturated solutions of ligands solubilised in the mother liquor. Crystals with appropriate 
size were flash frozen in liquid N2 and analysed at the Diamond Synchrotron (Didcot, 
Oxfordshire).  
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5.3.2. Data Collection and Phase problem 
 
            The data collection from the X-ray diffraction was analysed by Dr Colin Levy 
(University of Manchester). A complete data set was collected to 2.6 (Figure 5.3) Å 
resolution from a single crystal and belonged to space group P21. X-ray diffraction data 
were integrated and scaled using the program XDS as described in Section 2.2.14.2. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3. Representative X-ray diffraction pattern for ScKMO. The X-ray diffraction pattern shows a 
resolution of 2.6 Å. Diffraction data from ScKMO crystals were collected from single cryofrozen samples 
at the Diamond Light Source, Harwell, UK, with a wavelength of 0.9795 Å 
 
 
           Initial attempts to solve the structure of ScKMO were made by molecular 
replacement (MR) using the PHBH structure (1Q5E) as a search model. However, these 
enzymes share only approximately 18% identity and no solution was found. Further 
studies carried out by Dr. Colin Levy using combined algorithms for protein structure 
modelling with those developed for crystallographic structure determination (Rosetta 
MR) [258] were also conducted but again these attempts proved fruitless. The results 
were not unexpected since MR is usually used efficiently for homologues with a sequence 
identity of 30% or higher [258].  
               Heavy atom soaks were carried out in an attempt to provide a multiple 
isomorphous replacement (MIR) [259, 260]. A variety of heavy atom reagents were 
screened but the majority of crystals were damaged after the soaking. Those crystals that 
were able to withstand the soaking procedure failed to yield any suitable derivatives. 
2.6 Å 
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               The Single-wavelength Anomalous Dispersion (SAD) technique utilising the 
anomalous signal from Selenomethionine (SeMet) was also employed for phase 
determination. SeMet has been widely used as a phasing tool due to the relative ease with 
which this intrinsic anomalous scatter can be introduced into the target of choice. This 
technique avoids the problems associated with non isomorphism that often plague more 
traditional MIR [261]. Furthermore, in the majority of cases, the crystallisation of SeMet 
proteins tends to occur in similar conditions when compared to the wild type protein. 
There are several methods for prokaryotic expression of SeMet-labelled proteins which 
include the use of a methionine auxotroph strain of E. coli, the inhibition of methionine 
biosynthesis shortly before induction, growing the culture directly in LeMaster media 
supplemented with SeMet and the use of auto-inducing media with a non-auxotrophic 
strain [261]. The first attempts to produce ScKMO-SeMet using the defined LeMaster 
medium resulted in a very low yield. Subsequently, a methionine inhibition method was 
applied. This technique supplements the minimal media with high concentrations of 
isoleucine, leucine, phenylalanine, lysine and threonine, efficiently shutting down 
methionine biosynthesis [261]. This repression is instigated immediately prior to 
induction and the introduction of SeMet into the media (Details of the method are 
described in Section 2.2.14.2).  
               The expression levels obtained using this method were comparable to that of the 
wild type ScKMO providing evidence that the SeMet was not toxic to the cells. 
Purification of selenomethionine incorporated ScKMO (ScKMOSeMet) was conducted as 
described for conventional ScKMO (Section 2.2.4.3) with the exception that all the 
buffers were degassed to avoid oxidation of SeMet.  Crystals with similar shape to those 
for native ScKMO were obtained in propanol conditions (0.1 M sodium acetate, pH 5.5, 
and 35 % isopropanol). 
        Initial phases were obtained from a single SAD data set collected at the selenium 
edge. Selenium sites were located using Phenix AutoSol [226] yielding an electron 
density map that could be auto traced using Phenix AutoBuild [227]. 
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5.3.3. Structure Determination and Refinement 
 
As mentioned in the previous section, single-wavelength anomalous dispersion 
(SAD) data set at the selenium edge was used for initial phase determination. The 
resulting model was completed through iterative rounds of rebuilding in COOT [228] and 
refinement in Phenix [229]. Structure validation with MOLPROBITY [231] was 
integrated as part of the iterative rebuild and refinement procedure. Subsequent structures 
were solved by molecular replacement in PHASER [230] using this initial SeMet derived 
structure as the template. Data collection and refinement statistics for ScKMO, ScKMO-
SeMet are presented in Table 5.3. 
 
Table 5.3. X-ray data collection and refinement statistics for ScKMOSeMet 
andScKMO 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ScKMOSeMet ScKMO 
Data collection   
Space group P21 P21 
Cell dimensions   
a, b, c (Å) 59.1, 99.4, 85.3 58.9, 98.7, 85.9 
 () 90, 105.6, 90 90, 105.1, 90 
Resolution (Å) 2.6(2.71-2.6) 2.4(2.5-2.4) 
Rmeas 9.3(75.5) 9.1(68.4) 
I/I 12.0(2.1) 15.0(2.5) 
Completeness (%) 99.3(98.4) 98.3(95.3) 
Redundancy 3.9(3.9) 2.6(2.6) 
Refinement   
Resolution (Å) 2.6 2.4 
No. reflections 29686 36692 
Rwork/ Rfree 19.8 / 25.6 19.9 / 24.4 
No. atoms   
Protein 6035 5892 
Ligand/ion 106 106 
Water 107 243 
B-factors   
Protein 26.6 33.6 
Ligand/ion   
Water 17.5 29.4 
R.m.s deviations   
Bond lengths (Å) 0.009 0.002 
Bond angles (º) 1.3 0.6 
141 
 
The final model of ScKMO contains residues 1-97 and 101-390 and the bound 
FAD cofactor (Figure 5.4). The missing residues have no clear electron density. The 
crystal form contains a putative KMO dimer in the asymmetric unit (Figure 5.5A). PISA 
analysis (Protein Interfaces, Surfaces and Assemblies) [262] of the crystallographic dimer 
indicates that this is likely an artifact of crystallization and is not reflected in the solution 
state. This interpretation is further supported by the results obtained from the Electrospray 
Ionisation Mass Spectrometry and MALLS revealing a molecular weight consistent with 
a monomer in solution.  
The overall fold of ScKMO is similar to the flavin-dependent hydroxylase family 
[255] and the highest structural similarity, based on a search of the Protein Data Bank 
with the program DALI [263] is obtained with 2-methyl-3-hydroxypyridine-5-carboxylic 
acid oxygenase [264], an enzyme from the vitamin B6 catabolic pathway (rmsd of 2.3 Å 
over 310 C, overall sequence identity 16%, Q score 0.43, Z score 15.0). 
ScKMO forms a complex of three discernible domains (Figure 5.4B). There is the 
FAD-binding domain that exhibits the typical dinucleotide-binding fold, including 5 -
sheets and 4 -helices, and this domain is responsible for the interactions between the 
protein and FAD in an extended conformation (blue domain).  
 
 
 
 
 
 
 
 
 
Figure 5.4. Structural features of ScKMO. (A) A depiction of the ScKMO dimer displayed in ribbon 
format with transparent surface. FAD is represented as sticks and coloured by all atom type. (B) ScKMO 
monomer represented in ribbon format coloured according to the different domains; In salmon is the head 
domain, in light green the lateral domain and in light blue the FAD binding domain.  
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The large FAD binding domain (residues 1-76, 97-192 and 293-390) contains the 
three main FAD sequence motifs. The first sequence (residues 9-14) contains the 
Rossmann fold motif GxGxxG [193], commonly found in FAD- and NAD(P)H-
dependent monooxygenases and is generally found at the N-terminal part of the protein 
sequence. The second sequence (residues 313-314) contains the GD sequence in 
hydroxylases and forms part of a helix and the following loop. The third conserved motif 
is a part of a loop (residues 168-169) and contains the DG short amino acid sequence 
motif commonly shared for this group of enzymes. 
The functions of the other two domains (salmon and green domains) were not 
clear based on the apo structure of ScKMO, although subsequent structures will show that 
they are involved in ligand binding (Section 5.7). 
The re-face of the FAD is connected to the solvent by a narrow water-filled cavity 
that runs perpendicular to the active site cleft (Figure 5.5A). The isoalloxazine ring 
moiety is located at one end of the large cleft that runs through the protein interior, with a 
large part of FAD being exposed to the solvent region. The residues involved in FAD 
binding are shown in Figure 5.5B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5. ScKMO FAD-binding site (A) Surface cavity of FAD-binding site. (B) Residues around the 
FAD-binding site are shown as stick models and labelled. 
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The C-terminal -helix becomes increasingly disordered from residue 380 
onwards with residues 390 and above not visible in the electron density map. Subsequent 
structural characterisation of ScKMO was conducted on the engineered truncated form 
KMO394 to prevent ambiguities in the definition of the C-terminal region and to 
prevent future problems with further cleavage. Additionally, the protein yield obtained 
was significantly higher for this truncated form (15 mg/L of culture) when compared to 
the cleaved ScKMO (4mg/L of culture) which facilitates further structural work. 
 
 
5.4. STRUCTURAL CHARACTERISATION OF KMO394 
 
 
5.4.1. Crystallisation and structural determination of 
KMO394 
 
       Highly purified KMO394 was subjected to crystal trials across the same range of 
conditions tested for ScKMO. KMO394 diffraction quality crystals were grown in 
condition E12 (0.1M Imidazole 7.8, 11% w/v PEG 8K) from JCSG + crystallisation 
screen, in trays containing 14mg/mL of KMO394, with crystals forming over a period 
of ~24 h at 277K.  
 
 
 
 
 
 
 
 
Figure 5.6. Crystallogenesis of KMO394. KMO394 crystals obtained from B7 (0.1M Sodium Acetate 
5.5, 35% propanol) CSS2 crystallisation screen. 

KMO394 crystals are significantly larger compared to ScKMO crystals and 
present a variety of shapes (Figure 5.6A / B ). They also display a yellow colour 
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indicative of FAD bound to the protein.  KMO394 crystals were reproduced in a variety 
of PEG conditions with the colour of the crystals remaining yellow and the morphology 
identical. KMO394 structures were solved by molecular replacement in PHASER [230] 
using this initial ScKMOSeMet derived structure as the template (Table 5.4). 
The final model of KMO394, obtained at a resolution of 1.8 Å, was isostructural 
with ScKMO. KMO394 did give rise to a more readily reproducible crystal form and 
therefore this engineered truncated form was used for all further crystallisation trials in 
order to obtain structure complexes with ligands. 
 
Table 5.4. X-ray data collection and refinement statistics for KMO394, 
KMO394UPF and KMO394His-           
 
          
 KMO394 KMO394UPF KMO394His- 
Data collection    
Space group P21 P21 P21 
Cell dimensions    
a, b, c (Å) 58.4, 98.7, 85.4 73.0, 89.8, 82.8 59.1, 98.8, 86.3 
 () 105.3 90, 110.6, 90 90, 105.8, 90 
Resolution (Å) 1.8(1.9-1.8) 2.1(2.2-2.1) 2.0(2.1-2.0) 
Rmeas 7.1(141.2) 6.1(80.8) 7.6(60.6) 
I/I 16.5(2.4) 14.7(2.6) 10.4(2.7) 
Completeness (%) 99.6(99.7) 99.2(99.0) 98.6(99.3) 
Redundancy 3.4(3.5) 3.3(3.4) 3.4(3.5) 
Refinement    
Resolution (Å) 1.8 2.1 2.0 
No. reflections 83287 55578 60714 
Rwork/ Rfree 18.7 / 22.2 19.6 / 23.5 20.1 / 24.1 
No. atoms    
Protein 6046 5776 6106 
Ligand/ion 106 122 106 
Water 584 358 414 
B-factors    
Protein 21.8 13.8 42.8 
Ligand/ion  13.6  
Water 28.8 14.7 44.6 
R.m.s deviations    
Bond lengths (Å) 0.007 0.003 0.008 
Bond angles (º) 1.1 0.8 1.2 
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         An overlay of the individual KMO394 ligand free monomers reveals significant 
variation in two different positions (Figure 5.7A). The first disordered region is the C-
terminal -helix, with most monomers showing disorder beyond residue 380. The high 
flexibility of C-terminal -helix does not seem to be involved in the catalysis of KMO 
and is hypothesised to be related to the truncation of the region of the peptide chain after 
residue 394, resulting in a flexible region being able to move away from the remainder of 
the protein. This flexibility could possibly disrupt some interactions within the protein 
and therefore could explain in part the slow turnover rate obtained for KMO394. The 
linker region immediately following the second strand of the antiparallel -sheet is also 
disordered with large variations occurring in the position of residues 96-97 and 101-104. 
The relative position of the FAD-binding domain and the six-stranded antiparallel 
sheet domain is also subject to minor variation, reminiscent of domain motion coupled 
to substrate binding documented for other members of this family [255]. 
The inherent flexibility in the relative position of both domains flanking the KMO 
active site in the absence of substrate is reflected in the distinct conformations observed 
for amino acids lining the active site (Figure 5.7B) 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7. Detailed view of the KMO394 structural changes. (A) Overlay of the 5 ligand-free KMO 
monomers displayed in ribbon format. The C-terminal region (residue 348 onwards) is coloured red, the 
flexible linker region (residue 96-104) is depicted in green.(B). Overlay of the free KMO394 structures 
obtained from various crystal forms. 
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5.4.2. Structure of UPF 648 bound to KMO394 
 
We were able to co-crystallise KMO394 with UPF 648 inhibitor, a tight-binding 
substrate-like inhibitor, in the same condition E12 (0.1M Imidazole 7.8, 11% w/v PEG 
8K) from JCSG + crystallisation screen used for crystallisation of the apo-enzyme (Table 
5.4). The electron density of the inhibitor was clearly observed in a pocket adjacent to the 
FAD re-face (Figure 5.8). The UPF 648 carboxylate group is bound by conserved 
residues Arg-83 and Tyr-97 while the aromatic dichlorobenzene moiety is flanked by 
several hydrophobic residues, including Leu-221, Met-230, Ile-232, Leu-234, Phe-246, 
Pro-321, and Phe-322 (Figure 5.8B). The binding of UPF 648 induced several structural 
changes in the enzyme, most notably the reorientation of the 321-325 loop flanking the 
re-side of the FAD (indicated by the arrow in Figure 5.8A). In addition, a minor 
reorientation in the position of the six-stranded antiparallel -sheet domain with respect to 
the flavin binding domain is also evident (Figure 5.8B). Both of these changes result in 
increased disorder of the C-terminal alpha-helix, which is only visible up to Arg-359. The 
reorientation of the 321-325 loop is a direct consequence of adaptation of the active site 
to the presence of the vicinal chloride substituents of UPF 648, neither of which have a 
counterpart in the kynurenine substrate. To provide sufficient space for both chlorides, 
Phe-322 moves away from the active site, effectively occupying the position previously 
occupied by Tyr-323. In turn, the P321-Q325 loop reorients to compensate for the altered 
Phe-322 position.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8. A depiction of changes induced by binding of the KMO inhibitor UPF 648. An overlay of 
KMO394 and KMO394UPF is presented, the unbound monomer coloured in grey. The UPF-
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bound monomer is coloured in blue. The UPF ligand and the FAD are shown as atom coloured spheres. The 
arrow indicate the changes induced by binding of UPF 648. There is also a rearrangement of six-stranded 
antiparallel -sheet domain. 
 
 
5.4.3. Model of L-KYN bound to KMO394 
 
Attempts to obtain a complex with the physiological substrate kynurenine proved 
unsuccessful. Both co-crystallisation and soaking strategies were employed but failed to 
yield a suitable complex. One of the reasons that could explain the failure of achieving a 
complex with kynurenine or with any other ligand through soaking might lie in the 
presence of the N-terminal his-tag within the active site. Although this region was weakly 
defined in the electron density because of flexibility, within the confines of the crystal 
lattice it is clear that a proportion of his-tags encroach into the active site pocket. Whilst 
this might not be a problem for solution studies, it is likely to have a deleterious impact 
upon soaking studies. Hence, the N-terminal His-tag was efficiently cleaved (-
HIS-) by overnight incubation with Thrombin as described in Section 2.2.4.3. -
HIS- was subsequently crystallised in the same conditions as Table 
However, despite extensive soaking experiments with different concentrations of 
kynurenine and several additional KMO inhibitors, no complex was produced.  
The similarity between UPF 648 and the kynurenine substrate allows modelling of 
the latter in the KMO active site using the position of UPF 648 as a starting point (see 
Section 2.2.14.3). This suggests that the substrate is bound in a similar manner, but 
without any effect on the P321-Q325 loop. The aromatic substrate moiety is located in the 
conserved hydrophobic pocket (made by residues Leu-221, Met-230, Ile-232, Leu-234, 
Phe-246, Pro-321, and Phe-322) on the re-face of the flavin (Figure 5.9). In this case, 
additional polar contacts between the conserved Gln-235 and the kynurenine ketone 
group, and between the substrate aniline nitrogen and the FAD O4, are observed. While 
the amino acid carboxylate is bound by the Arg-83 and Tyr-97 motif, the amino group is 
devoid of direct interactions with the protein in this model. It is possible that an additional 
salt bridge is made between the kynurenine amine and the side chain of Glu-102, which is 
located on a highly flexible region of the KMO structure. However, the latter amino acid 
is often conservatively replaced by a Gln in other KMOs, indicating such an interaction is 
less critical to enzyme activity (Figure 5.9). 
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Figure 5.9.  Detailed view of the KMO394 active site. Model for the KMO:kynurenine complex.  
 
 
Multiple sequence alignment was performed with several KMOs, ranging from 
bacterial to human enzymes, to confirm that the key residues in the active of ScKMO 
were conserved among different KMOs (Figure 5.10). Interestingly, all residues implied 
by the KMO:kynurenine model to be involved in kynurenine binding are preserved across 
KMOs, which shows a conserved mechanism in the KMO catalysis. 
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Figure 5.10. Multiple alignment of amino acid sequences of KMO from diverse organisms. Homo 
sapiens KMO (Accession number NP_003670), Rattus norvegicus KMO (Accession number NP_067604), 
Drosophila melanogaster KMO (Accession number A1Z746), Xanthomonas oryzae KMO (Accession 
number B2SIT6), Saccharomyces cereviseae KMO (Accession number P38169), Pseudomonas fluorescens 
(Accession number Q84HF5). Residues involved in ligand binding are conserved and highlighted in red. 
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5.4.4. Active site mutants of KMO394 
 
Based on the KMO:kynurenine model, the carboxylate moiety of the substrate 
forms a salt bridge with  the side chains of Arg-83 and Tyr-97 and these interactions are 
critical to enzyme activity. Therefore the perturbation of these interactions is 
hypothesised to affect dramatically the binding of the substrate. The validation of this 
model was conducted by targeting the active site residue Arg-83. Two distinctive 
mutations were performed by site direct mutagenesis (see Section 2.2.1.3), by replacing 
the Arginine residue 83 to an Alanine and a Methionine. The choice of these mutations 
lies in the fact that the Alanine substitution could preserve the chemical bonds with the 
substrate but the smaller bulk would possibly interfere with the ligand binding, and 
Methionine, with an overall size similar to Arginine, it is not able to form chemical 
interactions with carboxy moiety of the substrate.  
Both mutants were expressed and purified as described for wild type (Section 
2.2.4.3) and the enzyme activity was compared to the wild type by following formation of 
the product 3-hydroxykynurenine by C18 reversed-phase HPLC with excess of NADPH 
(2mM) and kynurenine (500 M).  
The enzyme activity was significantly compromised following mutations with 
25% and 3% of wild-type activity for Ala-83 and Met-83 KMOs respectively (Figure 
5.11), consistent with the model for kynurenine binding. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11.  Enzymatic activity comparison between wild type KMO and R83 mutants. Enzyme 
activity is significantly reduced following mutation (< 25% and < 3% of wild-type activity for Ala-83 and 
Met-83 KMOs). 
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Additional kinetic assays to calculate the inhibition efficiency of UPF648 (Kiapp) 
for KMO mutants could not be carried out since the enzymatic activity was significantly 
compromised following mutations. Alternatively, fluorescence emission measurements 
were performed to determine dissociation constants (Kd) of the KMO inhibitor by ligand 
perturbation of flavin fluorescence (Figure 5.12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 5.12. Measurement of binding constant for KMO inhibitor UPF 648 by ligand perturbation of 
flavin fluorescence emission. Titration of UPF 648 to 5 M wild type KMO (closed squares), R83M 
(closed triangles) and R83A (closed circles) mutants resulted in perturbation of 520 nm fluorescence 
emission. Fluorescence changes at 520 nm as function of UPF 648 concentration were fitted to Morrison 
equation yields an observed Kd= 137.8 ± 8 nM for wild type KMO, Kd= 3.1± 0.2 M for R83M and Kd= 3.2 
± 0.2 M for R83A. 
 
 
The affinity of R83A and R83M for binding of KMO inhibitor UPF 648 is 
extremely similar with Kd= 3.1± 0.2 M and Kd= 3.2±0.2 M respectively (Table 5.5) 
and these values are approximately 23 fold lower than that of native KMO consistent with 
the structure which implicates Arg-83 in inhibitor binding. 
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Table 5.5: Dissociation constants (Kd) for binding of native and active-site mutants 
to UPF 648 
 
 
 
 
 
5.4.5. Prediction of NADPH binding mode 
 
Although many attempts were performed at either co-crystallising or soaking with 
NADPH, we were unable to obtain a structure in complex with the cofactor. The binding 
mode of NADPH in many NAPH-dependent flavoproteins such as Class B flavoprotein 
monooxygenases is relatively easy to predict due to the presence of two dinucleotide 
binding domains for binding FAD and NADPH, respectively [187]. However, the binding 
mode of NADPH in flavin monooxygenases belonging to Class A is not fully understood 
yet, because they do not present a well-defined domain for NADPH binding. In the 
absence of a NADPH-KMO crystal complex, the NADPH-binding site can be inferred 
from the comparison with the structures of the NADPH complexes of flavoenzymes with 
similar folding topology. With this aim, we have exploited the structure of human p-
hydroxybenzoate hydroxylase (PHBH).  
As pointed out in Section 1.4.2.1, p-Hydroxybenzoate hydroxylase (PHBH) is the 
most extensively studied flavoprotein monooxygenase and it is representative of Class A 
monooxygenases. This enzyme has been studied in detail since its first crystal structure 
was published in 1979 [189], nevertheless the binding mode of NADPH remains elusive. 
In 2002, Wang et al performed some studies in the mutant R220Q of PHBH enzyme, 
because this mutant had lower affinity for the substrate and previous efforts to crystallise 
the apo-enzyme were not successfully [190]. They have obtained the structure of this 
mutant in complex with NADPH and shown that the coenzyme binds at the surface of the 
protein in a channel that crosses the binding site of FAD [190] (Figure 5.14). Although 
the adenosyl moiety was well-defined by the electron density, the nicotinamide moiety 
was less defined, possibly indicating a high mobility. According to their model, in one 
side of the channel the Tyr-38, Arg-42 and Arg-44 are implicated in the binding of the 
adenosyl moiety of NADPH and this pocket is also lined by the pyrophosphate and 
 Native R83A mutant R83M mutant 
K
d
 UPF648 (M) 0.14 ± 0.008 3.1  ± 0.2 3.2  ±  0.2 
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adenosyl moieties of FAD, and on the other side of the channel His-162 and Arg-269 
were the key residues involved in binding the pyrophosphate moiety (Figure 5.13). 
 
 
 
 
 
Figure 5.13. Crystal structure of p-hydroxybenzoate and proposed interdomain binding of NADPH. 
This enzyme does not present a recognizable domain to bind NADPH as the majority of flavin 
monooxygenases. Interestingly NADPH binds in an extended conformation at the surface of the protein in a 
channel that crosses the binding site of FAD (Adapted from [190]).The inset is the Stereo view of the 
NADPH binding site with the key residues involved in NADPH binding 
 
Even though ScKMO and PHBH from Pseudomonas aeruginosa do not present a 
significant high primary sequence identity (16%) and similarity (28%), the structural 
alignment revealed that both enzymes share the same topology and overall fold (Figure 
5.14). 
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Figure 5.14. Structural alignment of KMO and PHBH structures. KMO394 protein is shown in grey 
and PHBH in blue. The two different orientations highlight the conserved topology of both proteins. 
 
 
Both have a large domain that has the characteristics of a Rossman fold, 
responsible for the interaction of FAD with the active site of the protein and a head 
domain responsible for the binding of the aromatic substrate in the active site. The active 
site of both enzymes forms a channel inside the structures running through the interior 
and large part of the FAD molecule is exposed to the solvent. As it happens for KMO, 
PHBH does not have a clear recognisable domain for binding of NADPH. 
     
 
 
 
 
 
 
 
 
Figure 5.15. Prediction of NADPH binding mode in ScKMO based on the PHBH homology model.  
NADPH is predicted to bind in an extended conformation on the surface of the NADPH-binding domain. 
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Based on the similarity with these two enzymes, it is postulated that NADPH may 
bind in a manner similar to that observed for PHBH (Figure 5.15), however further 
studies would need to be performed to provide structural evidence to this effect. 
It is important to emphasize that the NADPH binding mode of Class A 
flavoprotein monooxygenases remains to be elucidated. Several attempts were carried out 
with many Class A flavoprotein mononooxygenases without success and therefore it is 
not yet known if the NADPH binding mode of PHBH is representative of this class of 
enzymes. The complex structure of NADPH-PHBH was obtained by soaking crystals in 
the absence of the substrate pOHB with a very high concentration of NADPH (50mM) 
[190]. Furthermore, the isoalloxazine ring of FAD and the dihydronicotinamide moiety of 
NADPH were not in a position to react and consequently it remains uncertain that the 
NADPH binding mode obtained in this report represents the real reactive complex. 
Although this model has been supported by earlier studies using mutagenesis and 
chemical modification in the same key residues [265, 266] there are also proposed 
NADPH binding modes significantly different from the one based on the Arg 220 PHBH 
mutant NADPH structure. Eppink et al. (1998) had shown by mutagenesis that the 
adenosine 2’-phosphate moiety of NADPH interacts with the residues of Arg33, Tyr38 
and Arg42, part of Helix H2 in PHBH, which is a highly conserved region among 
NADPH-specific PHBH enzymes but differs from the only PHBH enzyme that has higher 
affinity towards NADH, PHBH from Pseudomonas sp. CBS3 [267]. 
Therefore, we cannot rule out the possibility that the NADPH binding mode in 
ScKMO is not consistent with this model. 
 
 
5.4.6. Proposed Mechanism for KMO catalysis 
 
The proposed mechanism for KMO hydroxylation of kynurenine is based on the 
ScKMO:kynurenine model. The aromatic substrate moiety is located in the conserved 
hydrophobic pocket on the re-face of the flavin with polar contacts between Gln-325 and 
the kynurenine ketone group and between the substrate aniline nitrogen and the FAD O4 
(Figure 5.9).  
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Figure 5.16. The proposed mechanism for kynurenine hydroxylation by KMO based on the 
ScKMO:kynurenine model. The 3 arrows present a concerted mechanism in which the aromatic group 
attacks the flavin peroxide breaking the O-O bond and pick up a proton from the substrate NH2 group. The 
electrons are released at the NH2 group by removal of a proton to the flavin peroxide flow into the aromatic 
group. Following hydroxylation, the intermediate rearranges to form the 3-hydroxyl kynurenine product. 
 
 
The orientation of the substrate in the KMO:kynurenine model places the C3 atom 
directly adjacent to the flavin C4a, in a position poised for nucleophilic attack on the 
flavin C4a peroxide adduct and hydroxylate of the substrate. The substrate hydroxylation 
must produce the C4a-hydroxyflavin and the elimination of one water molecule will 
enable the reoxidation of the isoalloxazine. Following hydroxylation, the intermediate 
rearranges to form the 3-hydroxyl kynurenine product (Figure 5.16). 
Interestingly, a structural water molecule is located directly above the FAD C4a, 
mimicking the position of the C4a-peroxide adduct formed upon reaction with oxygen. 
The dimethylbenzene moiety of the isoalloxazine ring is protected from solvent by Lys 48 
and the conserved residue Tyr 195 (Figure 5.17), suggesting that a “waving flavin” 
motion as part of the flavin reduction process, as demonstrated in other FAD-dependent 
mono-oxygenases [268], is unlikely to occur in the absence of large protein 
rearrangements. 
This flavin motion, mostly described for PHBH enzyme [268], involves the 
movement of the FAD from an in-position for hydroxylation of p-hydroxybenzoate 
(pOHB) substrate, to an out-position for reduction of the flavin by NADPH. However, 
unlike KMO, PHBH does not have any restrains nearby the isoalloxazine ring and 
therefore is can move to a solvent-accessible position. Since the structural data obtained 
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for ScKMO in the current project showed clearly an in conformation in which the flavin 
is proximal to the substrate to achieve hydroxylation, it is difficult to hypothesise further 
conformations in the active site unless new crystallographic data is available.  
 
 
 
Figure 5.17. Solvent access channel to the FAD isoalloxazine moiety. The re-face of the FAD is 
connected to the solvent by a narrow water filled cavity that runs perpendicular to the active site cleft. The 
structural water molecule located directly above the FAD C4a, mimicking the position of the C4a-peroxide 
adduct formed upon reaction with oxygen, is shown in green. Other water molecules in the channel are 
depicted as red spheres. The dimethylbenzene moiety of the isoalloxazine ring is protected from solvent by 
Lys 48 and the conserved residue Tyr 195, both depicted in atom coloured spheres. The solvent accessible 
KMO surface is shown as a transparent grey surface. 
 
 
5.4.7. Homology model of HsKMO  
 
Throughout Chapter 4 we have shown that ScKMO is highly related to HsKMO 
(38 % identity and 51 % similarity) and we provide further evidence that the mechanism 
of action of KMO is remarkably well conserved between yeast and humans with similar 
kinetic and inhibition constants. 
From the structural point of view, although there is no information regarding the 
crystal structure of HsKMO, the multiple sequence alignment with other KMOs together 
with the crystal structure of ScKMO provide further information regarding conserved 
residues and confirm that the key residues implied by the KMO:kynurenine model to be 
involved in kynurenine and FAD binding are preserved in HsKMO, suggesting a 
conserved mechanism of KMO catalysis. 
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A homology model of HsKMO was built with the I-TASSER server [269], using 
the structure of ScKMO as a template (Figure 5.18A). The core structures of both 
enzymes are remarkably conserved with decreasing similarity towards the C-terminus of 
HsKMO which is predicted to be the transmembrane region. As this part of the homology 
model was built without template, since ScKMO does not share the C-terminal region 
with HsKMO, it is probable that the predicted region is not reliable 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.18. HsKMO homology model (A) Structural alignment of Homo sapiens and Saccharomyces 
cerevisiae KMO. HsKMO homology model was generated by I-TASSER using KMO394 as template. 
The HsKMO protein (blue) and KMO394 (white) are shown in cartoon with transparent surface. (B) 
Conserved residues are shown in red. KMO surface is shown as a transparent grey surface. Ribbon with 
surface transparent (and conserved residues in red) 
 
 
The conserved residues are shown in Figure 5.18B and it is evident that the region 
in the vicinity of the active site is highly conserved, demonstrating again that the active 
site of KMO is preserved among both enzymes. 
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5.5. DISCUSSION 
 
This chapter reports on the structural studies of ScKMO and complements the 
biochemical results from Chapter 4.We solved the crystal structures of the initial 
proteolytic soluble form (2.6 Å) and KMO394 (1.8 Å) version of the enzyme and both 
structures are identical as expected. The KMO overall fold is similar to other class A 
flavin monooxygenases [190] with one large domain that includes the Rossman fold with 
5 -sheets and 4 -helices responsible for the interactions between the protein and FAD. 
A structural alignment of the various KMO constructs reveals greatest variation in the C-
terminal -helix. Flexibility in this region of the structure might interfere with the activity 
of the protein, not because the C-terminal -helix plays any crucial role in the catalytic 
activity, but perhaps the high flexibility observed induces structural perturbations that 
have a negative impact on the core structure of the enzyme. Such changes may obstruct or 
alter important ligand or cofactor binding pockets. This hypothesis remains elusive and 
further experiments need to be conducted to validate the present concept. 
The crystal structure of KMO394 in complex with the KMO inhibitor UPF 648 
revealed structural changes in the enzyme, particularly in a pocket facing the re-side of 
the FAD. Due to the similarity of UPF 648 and L-KYN, the latter was modelled in the 
KMO active site and all residues involved in L-KYN binding were found to be conserved 
across KMOs, ranging from bacterial to human enzymes providing evidence that the 
KMO catalytic mechanism is preserved. We further validated this model by targeting the 
active site residue Arg-83 (to Ala-83 and Met-83) and performed inhibitor binding and 
kinetic assays, confirming that mutations led to a significant decrease in enzyme activity 
and ligand binding affinity. 
 During this project numerous attempts were made to obtain additional structure 
complexes with a variety of ligands, however these attempts failed to yield the desired 
complexes. The determination of cofactor- and product-bound structures of KMO would 
be of great assistance in elucidating the catalytic mechanism of KMO. Ligand binding 
assays were performed prior to co-crystallisation and long incubation periods with ligands 
were also conducted to confirm ligand binding, but none of them resulted in a complex 
structure. To aid these efforts, crystallisation of the ligand-free protein with subsequent 
soaking with ligands was also carried out unsuccessfully. One of the hypotheses 
suggested to explain why we never achieved any complex through soaking might lie in 
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the presence of the N-terminal his-tag within the active site. As explained in Section 5.8, 
while this might not be problem for solution studies, it could have possibly affected our 
attempts for soaking anything. Although we have tried the His-tag cleaved version of 
KMO394, due to time constraints of this PhD project, further studies with this KMO 
variant were curtailed. Hence, if we are to continue with this project, extensive 
crystallisation screens should be proceeded with KMO394HIS- in order to solve 
structure complexes with ligands of interest. 
Since we were unable to obtain a structure complex with NADPH, the binding site 
of this cofactor remains indefinable. KMO, as many class A flavoprotein 
monooxygenases, does not have a clear recognizable domain for binding of NADPH and 
there is a lack of published structures in complex with this factor, which complicates the 
prediction of NADPH binding mode. The hypotheses suggested for NADPH binding in 
KMO is based in on the structure of PHBH in complex with NADPH and based on the 
similarity with these two enzymes, NADPH is predicted to bind in an extended 
conformation at the surface of the protein. 
It has been proposed throughout Chapter 3 and 4 that the KMO C-terminal 
deletion might have interfered with the catalytic activity of the enzyme both in human and 
yeast KMO. One of the hypotheses suggested to explain the low turnover number based 
on kinetic assays was that the NADPH binding pocket could have been structurally 
affected by the C-terminal deletion, affecting the cofactor affinity. With the structural 
information of ScKMO together with the assumption that KMO shares the same NADPH 
binding mode as PHBH enzyme, the residues forming the binding pocket are not in the 
vicinity of the C-terminal region and therefore is unlikely that structural changes might 
have occurred in the NADPH binding domain.  
Regarding the proposed mechanism of KMO, the structural information obtained 
in this Chapter complemented with the studies conducted spectroscopically on the 
reductive and oxidative half reaction (Chapter 4) indicate that the catalytic mechanism is 
similar to other flavin monooxygenases, with an electrophilic attack to the aromatic ring 
carried out by the reactive species C(4a) hydroperoxyflavin and the distal oxygen is 
inserted at the ortho position of the activated ring forming the hydroxilated product, C4a-
hydroxyflavin and one water molecule with the reoxidation of the isoalloxazine. 
Following hydroxylation, the intermediate rearranges to form the 3-hydroxyl kynurenine 
product. Interestingly, the “waving flavin” motion as part of the flavin reduction process, 
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as demonstrated in other FAD-dependent monooxygenases, is improbable as the 
dimethylbenzene moiety of the isoalloxazine ring is protected from solvent. To infer the 
possible movement of the flavin during the catalytic process more crystallographic 
studies need to be conducted with ScKMO, preferentially with a variety of ligands, to 
assess the possible positions of the flavin prosthetic group within the enzyme. The 
crystallographic studies should also be complemented with spectroscopic studies to study 
the dynamic events involved in catalysis. 
A homology model of HsKMO was built using the structure of ScKMO as 
template, and the active site topology of both enzymes bears significant resemblance, 
particularly the regions of ligand and FAD binding, showing a conserved mechanism in 
the KMO catalysis and validating ScKMO as a good candidate for the development of 
novel inhibitors for HsKMO. 
In conclusion, we were able to perform for the first time, the structural 
characterisation of ScKMO. We determined the crystal structure of ScKMO complexed 
with UPF 648 and established that this enzyme-inhibitor structure can be used for the 
future design of novel KMO inhibitors with the affinity and specificity necessary and for 
optimization of brain penetrance that could ultimately have major therapeutic value. 
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6. CONCLUSIONS AND OUTLOOK 
 
 
6.1 SUMMARY AND FUTURE WORK 
 
Metabolites of the kynurenine pathway (KP), which arise from the degradation of 
tryptophan, have been studied in detail for over a century and garnered the interest of the 
neuroscience community in the late 1970s and early 1980s with work uncovering the 
neuromodulatory potential of this pathway [135, 136, 98]. Much research in the following 
decades found that perturbations in the levels of KP metabolites likely contribute to the 
pathogenesis of several neurodegenerative diseases. More recently, it has become 
apparent that targeting KP enzymes, in particular kynurenine 3-monoxygenase (KMO), 
may hold substantial therapeutic potential for these disorders. The most compelling 
evidence supporting a role for KP metabolites in neurodegenerative disease comes from 
studies in Huntington’s disease (HD), using cell and animal models [159, 158, 4]. 
To date several KMO inhibitors have been developed and characterised, however, 
none of them appears to appreciably cross the BBB [172, 174, 270, 173, 178]. Although 
pharmacological inhibition of KMO in the blood has proven to be sufficient to ameliorate 
disease phenotypes in mouse models of AD and HD [3], the development of KMO 
inhibitors able to cross the BBB is essential to ensure efficient delivery directly to the 
brain, to reduce the levels of neurotoxic metabolites, and to increase the levels of 
neuroprotective KYNA [174, 179].  
The approaches used for drug design have changed over time, from experimental 
techniques to the development of more sophisticated computational software with the aim 
of reducing the number of possible ligands, enhancing the accuracy of analysis and 
reducing the cost and time spend in the drug discovery process [271]. Structure-based 
drug design has been gaining more credit within the pharmaceutical industry exactly 
because the amount of time, cost and work spent is comparatively low particularly in ‘hit 
identification’ and ‘hit-to-lead’ phases [272]. 
A number of studies characterised the activity of KMO from different organisms 
in terms of substrate, coenzyme and cofactor specificity, as well as strategies for 
expression and purification of KMO from higher organisms including recombinant 
HsKMO [208, 207, 235]. However, as this enzyme is membrane associated, it has proven 
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to be extremely difficult to obtain sufficient quantities of HsKMO for structural studies 
and therefore, until now there was no structural knowledge of this enzyme [208, 273]. 
Such information – both with native KMO and ligand-bound enzyme - would aid in the 
rational design of novel KMO inhibitory compounds. In order to partially address this 
issue, the investigation of the binding modes of possible KMO inhibitors has been carried 
out using structure and ligand-based computer-aided design tools based on structurally 
and functionally related enzymes [180, 181]. Nonetheless, obtaining the crystal structure 
of KMO is necessary to truly inform rational design of novel inhibitors with the affinity 
and specificity necessary for clinical trials and which may also be optimised for brain 
penetrance.   
 
The work conducted in this thesis has presented a complete biochemical and 
structural characterisation of the KMO enzyme, elucidating the mechanisms of ligand 
binding and providing insights into the structure of the active site of KMO that are 
essential for the future development of novel inhibitor scaffolds. During this project, we 
described efficient strategies to express and purify recombinant HsKMO. We have 
initially explored truncated forms of HsKMO by deleting the transmembrane regions in 
order to prevent insolubility. The spectral features of KMO383 (without transmembrane 
helices) were characteristic of a flavoprotein with maximum absorbance peaks at 375 and 
450 nm, and the enzyme was shown to bind the physiological substrate L-KYN and KMO 
inhibitor Ro 61-8046. However, this truncation variant was not able to catalyse the 
hydroxylation of the substrate. In addition, crystallisation screens did not retrieve positive 
hits despite intensive efforts. We thus turned our attention to the expression of full-length 
HsKMO using the insect cell baculovirus system, which yielded small quantities (~0.5 
mg/L of culture) of detergent solubilised active HsKMO. The recombinant form exhibited 
similar kinetic constants to native KMO isolated from pig liver mitochondrial 
preparations [216]. The inhibitor UPF 648 was found to bind recombinant HsKMO 
tightly with an apparent Ki of 56.7 nM. These data are the first direct measurements of a 
binding/inhibitor constant for KMO inhibitor with pure recombinant HsKMO and this 
strategy can also be used as a valuable tool for high throughput drug screening 
methodologies. 
However, the very low yield, together with the challenges associated with 
working with membrane proteins, meant that progression with structural studies ceased. It 
165 
 
was decided that a great deal of time would be required in order to simply produce 
enough quantities of full length KMO in a suitable form for further crystallographic 
studies. Furthermore, the fact that initial crystallisation screens did not retrieve any 
positive hits prevented additional efforts to crystallise HsKMO. 
An alternative approach was adopted and focused on ScKMO, which is closely 
related to HsKMO (38 % identity and 51 % similarity). Expression and purification of 
ScKMO revealed that this enzyme was active as a flavin-dependent monooxygenase, 
generated authentic 3HK in HPLC-based assays and was inhibited by UPF 648 (Ki 74 
nM) with potency similar to that observed with HsKMO, thus supporting the hypothesis 
that ScKMO would be a good homology model for the study of HsKMO. Attempts to 
express full length ScKMO resulted in proteolytic clipping of the enzyme. This was 
corroborated by electrospray mass spectrometry and Multi Angle Laser Light Scattering 
analysis, which identified a protein with a molecular weight of 47 kDa, consistent with a 
truncation of KMO at residue 396. The proteolysis might have been caused by several 
factors, such as the instability of the full-length protein or the flexibility of the C-terminal 
region, which might have exposed susceptible residues to proteolysis during expression. 
Regardless of the truncated version of ScKMO, the engineered truncated form of ScKMO 
(394KMO) has been shown to interact with L-KYN, NADPH and KMO inhibitors, 
although the rate observed is likely to be much lower than the true catalytic rate.  
In this thesis I described the first crystal structure of KMO from Saccharomyces 
cerevisiae in complex with the tight-binding inhibitor UPF 648. The overall structure of 
KMO is reminiscent of the flavin-dependent hydroxylase family [255], sharing the classic 
Rossman fold with five -sheets and four -helices in the large domain responsible for 
interactions with FAD. The potentially most important accomplishment to come from the 
studies of ScKMO was the identification of key residues involved in substrate binding, 
confirmed by functional assays and active site mutagenesis, and the confirmation that 
those residues are conserved among KMOs from different organisms. Structural 
comparison of ScKMO and HsKMO has shown that the active site is essentially identical, 
validating the yeast KMO:UPF 648 structure as a template for structure-based drug 
design and the future development of novel inhibitors. To further support these studies, 
the same residues can also be mutated in HsKMO by sequence and structural comparison 
with ScKMO and validated with functional assays. 
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As the structure of full-length KMO remains elusive, both from S. cerevisiae and 
H. sapiens, the role of the C-terminal -helix in the enzymatic activity remains unclear. 
Hypotheses were made throughout the project, supported by evidence from previous 
studies, showing that the C-terminus of KMO is important for its catalytic activity [246]. 
As the binding affinity of the truncated ScKMO enzyme for the physiological substrate 
and analogues are similar with results from the literature, the most likely explanation for 
the role of the C-terminal region is its involvement in NADPH binding. The structure of 
ScKMO and the structural alignment with PHBH gave some insight into the possible 
mechanism of NADPH binding, although the binding mode of this cofactor in external 
flavoproteins remains elusive. NADPH is predicted to bind in an extended conformation 
on the surface of the NADPH-binding domain. If this mechanism represents the true 
mechanism for NADPH binding in KMO enzymes, the truncation in the C-terminus 
should not interfere with the catalytic activity since the predicted binding pocket is 
structurally distant from the C-terminal -helix. The flexibility of the C-terminal region, 
shown by comparison of free enzyme monomers corroborate the hypothesis that 
proteolytically cleaved distal C-terminal residues might have been caused by excess of -
helix movement and thereby exposing such residues to exoproteolysis. Such flexibility 
could also be responsible for breaking interactions of the -helix with remaining core 
structure, explaining the lower catalytic rate when compared to full-length HsKMO. 
In the future, the elucidation of the role of the C-terminal region in the catalytic 
activity of KMO might be achieved through a number of different approaches. A possible 
strategy could be the development of a variety of C-terminal KMO deletion mutants and 
their comparison in terms of enzymatic activity with the full-length KMO by monitoring 
the formation of the product 3-HK using the HPLC-based assays described in this thesis. 
This would allow the identification of the exact region of the C-terminus responsible for 
the loss of the KMO activity. This approach could be carried out for both human and 
yeast KMO. In the first case, the recombinant expression could be conducted using the 
baculovirus system as described for expression of detergent solubilised full length 
HsKMO (Chapter 3). In the latter case, the recombinant expression of C-terminal deletion 
mutants of ScKMO could follow the same approach used for expression of the proteolytic 
version of N-terminal His-tagged ScKMO and KMO394 in E. coli, with the requirement 
that mutation(s) in the proteolysis site must be carried out to prevent cleavage after Asp 
396. An alternative approach would be to explore C-terminally His-tagged ScKMO. We 
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established that it is possible to express full length C-terminally His-tagged ScKMO using 
the pET-24b vector, although the yield obtained did not allow us to further explore 
alternative purification strategies. It appears that the His-tag at the C-terminal of KMO 
somehow prevented proteolysis at susceptible cleavage sites and therefore, it might be a 
viable approach to explore alternative vectors such as pET45b or pET51b (Novagen). In 
case these approaches fail, one could also develop the C-terminal deletion mutants fused 
to a larger tag than the His6-tag, to stabilise and protect the recombinant fused protein 
from proteolysis, as appears to occur during expression trials. These tags may include 
GST- or thioredoxin. 
In addition to standard activity assays, further studies can also be carried out using 
stopped-flow assays with emphasis on the reductive half-reaction. By mixing 
anaerobically saturating concentrations of NADPH (with and without the presence of L-
KYN) with KMO variants and monitoring the FAD reduction at 450 nm, it is possible to 
calculate the limiting rate constants and compare these values across the different 
mutants. In case this parameter varies according to the size of the C-terminal truncated, it 
will confirm the hypothesis that the C-terminus is in fact affecting the NADPH binding 
pocket. The dependence of the rate of reduction on NADPH concentration can also be 
performed and the comparison of the apparent Km for NADPH can determine if the C-
terminal deletion is responsible for weakening NADPH affinity. 
Further structural analysis of the respective mutants might also be critical for the 
elucidation of C-terminal flexibility and its relation to enzyme catalytic activity. The 
extensive co-crystallisation and soaking methodologies with different concentrations of 
NADPH should also be pursued with the intention of understanding the molecular 
mechanism of NADPH binding. To obtain the structure of the complex of NADPH-
KMO, perhaps crystallisation in anaerobic conditions could possibly stabilise the protein 
and facilitate the crystallisation process, since the enzyme would be permanently in the 
reduced state and would not be oxidised by the presence of molecular oxygen. The 
reduction of FAD can be monitored spectroscopically at 450 nm prior to crystallisation to 
assure the efficient binding of NADPH. 
Biophysical characterisation by circular dichroism (CD) analysis can be a valuable 
tool to compare C-terminal deletion mutants, in order to confirm the secondary structural 
integrity of mutants and assessing the structural relationships between wild type and 
mutant proteins. The overall structural features can also be deduced by CD and 
conformational changes caused by ligand binding may also be inferred. This technique 
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can be of particular interest when analysing the UV and visible regions since relatively 
small structural differences can be detected. In addition, analysis of the flavin 
environment can also be studied. 
Previous FAD-dependent monooxygenase structural studies [268] have suggested 
that a “waving flavin” motion is part of the flavin reduction process in order to make 
contact with the nicotinamide ring at the protein surface. Although the structure of 
ScKMO suggests that this movement is unlikely to take place in the absence of large 
protein rearrangements, CD analysis as well as FTIR and NMR can be alternative 
approaches to explore the conformational dynamics upon NADPH binding in KMO 
enzyme. These studies can be also complemented with structural data and conformational 
dynamics, which can be indicative of the catalytic mechanism of KMO enzyme. Ideally, a 
whole set of crystal structures of ScKMO, ranging from native, NADPH bound, substrate 
and product bound must be solved to provide key insights into the catalytic mechanism of 
this enzyme.  Alternatively, CD spectroscopy together with kinetic data could also give 
valuable information into the binding and recognition modes of ligands and cofactors 
providing a structural basis for the catalytic mechanism of KMO. 
 
 
6.2 CONCLUSIONS 
 
Despite great interest in the therapeutic potential of KMO inhibitors, to date none 
have been tested in clinical trials. The work presented in this thesis elucidates for the first 
time the crystal structure of ligand-bound KMO. This is a major breakthrough that will 
permit docking screens using virtual libraries of compounds, which may ultimately 
identify novel inhibitor scaffolds. Fragment-based screening or modelling could also 
potentially be employed to design and refine competitive inhibitor molecules that possess 
the selectivity and affinity necessary to open novel opportunities for therapeutic 
intervention in a variety of brain disorders, and other conditions. Critically, such 
approaches may also inform development of brain-penetrant KMO inhibitors. 
Biophysical analysis of positive hits can be performed using the techniques carried out in 
this project, such as fluorescence spectroscopy and HPLC-based assays to calculate 
dissociation constants and compare inhibitor efficiency and affinity. HPLC assays are 
particularly efficient to carry out high throughput screening experiments. 
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Overall, the main objectives of this research, which were the elucidation of the 
crystal structure of KMO for future development of KMO inhibitors and the 
understanding of the catalytic mechanism of KMO, have been met. Results from this 
thesis are important to understand the nature of ligand binding in KMO and have 
exploited a multifaceted approach using biochemical, biophysical and structural data to 
obtain a comprehensive understanding of the mechanism and function of this enzyme. 
The prospect of elucidating the catalytic mechanism of KMO, using spectroscopic, 
kinetic and crystallographic methods, are much greater for the soluble ScKMO enzyme 
by comparison to using detergent-solubilised HsKMO, given the difficulties in expression 
and isolation of high quantities of HsKMO. This work has also raised a number of 
questions about the catalytic mechanism of KMO, and future studies will surely uncover 
a deeper understanding that will contribute to additional knowledge of class A 
flavoprotein monooxygenases. Crystallographic methods combined with stopped-flow 
assays would appear to be the most prosperous way forward. In terms of drug discovery, 
both enzymes studied in this thesis, ScKMO and HsKMO, can efficiently be incorporated 
in high throughput drug screening experiments.  
The understanding of the mode of KMO inhibition will help the future 
development of inhibitors able to cross the BBB and will no doubt increase enormously 
their therapeutic effectiveness. Future analysis of the efficacy of new KMO inhibitors can 
be complemented in various HD models that ultimately would aid in the development of 
new effective therapies for HD and other neurodegenerative diseases that despite 
affecting millions have no cure or treatments. 
 
“In the excitement of the abnormal gene identification in 1993, many of us in HD 
families imagined that a cure – or at least an effective treatment – was close at hand. 
That dream has not yet been realized. But if the history of Huntington’s can provide clues 
for the future, it suggests that change does not always happen gradually. Change can 
also happen swiftly. And that, I believe, is a great source of hope….For families and 
individuals struggling daily with HD, effective therapies cannot come soon enough. But 
while major discoveries in the lab have not yet been matched by similar advances in 
treatment, the volume of research has increased tremendously in the past decade. 
Disease-altering interventions are now moving closer to the clinic”[274] 
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 Although aware that the future development of KMO inhibitors and its validation 
in clinical trials will take several years or decades, I am honoured that this thesis can 
possibly contribute to the future development of a therapeutic intervention against HD 
and other neurodegenerative diseases that are on the fast rise in developed countries 
where the ageing population is growing without stop.  
 
“Please don’t give up, keep fighting with us” 
 
This sentence was said by a patient with HD in my first Hereditary Disease 
Foundation Conference in 2010 that I will never forget and will always follow me in my 
future projects. 
---- 
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8. SUPPLEMENTARY SECTION 
 
 
8.1. SUPPLEMENTARY FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 1. Thermofluor assay of KMO383 buffer and additive screen. Negative first 
derivatives of the melting curves produced by KMO383 are shown in a range of different buffers (A) and 
additives (B) from the JBS Solubility Kit. The minimum value represents the midpoint of the unfolding 
transition, providing a quick and robust method for determining the Tm of samples in individual wells. 
Only the buffers from which a Tm could be derived are shown. dF/dT represents fluorescence change at 
different temperatures. Sample control is in 20 mM phosphate buffer pH 7.5 (B) Representative curves of 
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the additive screen using Bis-Tris Propane pH 6.5 as the standard buffer. Sample control is in Bis-Tris 
Propane pH  6.5 without additives. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 2. Thermofluor assay of ScKMO buffer and additive screen. (A) Negative first 
derivatives of the melting curves produced by ScKMO are shown in a range of different buffers from the 
JBS Solubility Kit. The resulted curve usually shows a sharp transition between folded and unfolded states 
and the melting temperature (Tm) is precisely the midpoint of temperature of this unfolded transition. Only 
the buffers from which a Tm could be derived are shown. dF/dT represents fluorescence change at different 
temperatures. Sample control is in 20 mM phosphate buffer pH 7.5. (B)  Negative first derivatives are 
shown of the Representative melt curves produced by ScKMO supplemented with additives from the JBS 
Solubility Kit screen using Ammonium Acetate pH 7.0 and Sodium phosphate pH 7.0 as the standard 
buffers. 
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